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CHAPTER 1 
GENERAL INTRODUCTION 
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Chapter 1 
Septic shock with purpura is a rapidly evolving clinical picture characterized by sepsis 
(tachycardia, tachypnea, fever), shock (hypotension or signs of end-organ failure) and a 
spectrum of coagulation disorders (ranging from petechiae, purpura to ecchymoses). It is 
mainly (80 %) caused by N. meningitidis (group A, B or C). However, occasionally other 
micro-organisms such as Haemophilus influenzae, Haemophilus aegyptius, 
Streptococcus group A, group B streptococcus, streptococcus pneumoniae, 
Staphylococcus aureus, Pseudomonas species and Capnocytophagus canimorsus can 
be detected as a causative agent. Even viruses can under certain conditions cause a 
comparable clinical picture. Approximately 80 % of the patients is below the age of 18 
years, and 50 % below the age of 5 years. The development of the disease in older patients 
is partly due to the presence of a deficiency in the immune system (complement deficiency, 
spleen extirpation, diabetes mellitus). The occurrence in children is related to the absence 
of antibodies, although it is assumed that these children are healthy except for an age-
related immaturity oftheir immune system. The mortality ranges from 15 - 40 %, depending 
on the selection of the patients. 
It is difficult to extrapolate the pathophysiology, clinical findings and therapeutic outcome 
in adults with sepsis to those in children. In most studies in adults a variety of micro-
organisms and underlying diseases has been observed. In contrast, children with 
meningococcal sepsis form a relatively homogeneous group in which age-related 
developmental processes in the first years of life probably provide an explanation for the 
very high mortality in this young age group. The frequent occurrence of this awe-inspiring 
life threatening clinical picture in the Netherlands encouraged us to perform the studies 
described in this thesis. To this purpose we prospectively studied the pathophysiology of 
meningococcal disease, mainly focusing on the role of pro-and counter-inflammatory 
cytokines, complement activation and coagulation and fibrinolysis. We also initiated 
investigations on the role of genetic variability in immune response on the course of 
disease. A large number of the children studied were concomitantly enrolled in a 
prospective study on the efficacy of HA-1-A, a monoclonal antibody to neutralize circulating 
endotoxin. Since there were several questions which could not be answered in human 
studies, we developed a sepsis model in infant and nearly-adult pigs to analyze the 
presence of age-related differences in the course of the disease of these animals. All 
patients described in this thesis were admitted to the Pediatric Intensive Care Unit of the 
Sophia Children' s Hospital in Rotterdam. The first child was enrolled in August 1988. The 
animal experiments were carried out in the Laboratory for Experimental Cardiology, 
Erasmus University Rotterdam. 
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Chapter 1.1 
CHAPTER 1.1 
AIMS OF THE STUDIES 
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Chapler 1.1 
Chapter 1 provides a general overview of the characteristics of sepsis in children (1.2) and 
reviews the current literature on the pathophysiology of septic shock and purpura (1.3). 
Chapter 2 mainly contains studies which focus on the effects of LPS and the relation 
between LPS and cytokines. This chapter describes the binding and clearance of 
endotoxin in young and old pigs during experimental sepsis (2.1), the different levels of pro-
inflammatory mediators (TNF-a., IL-1, and IL-6) in patients with sepsis and the relation 
between these levels and standard laboratory parameters (2.2), as well as the presence 
during sepsis of IL-12, a recenlly described cytokine (2.3). This cytokine induces the 
production of interferon-y (IFN-y) by T cells and natural killer cells. Recenlly, IL-12 was 
characterized as a major cytokine in the pathogenesis of gram-negative endotoxemia in 
mice and in primates. 
Chapter 3 describes studies on disorders of coagulation and fibrinolysis in children with 
septic shock and purpura. In these studies the following questions were discussed: 
3.1: How are plasma levels of protein C and S related to presence of disseminated 
intravascular coagulation (DIC), outcome and severity of disease? This study was 
carried out in collaboration with the University Hospital of Lille, France. 
3.2: Are there age related differences in coagulation parameters between younger and 
older patients? 
3.3: What is the relationship between plasminogen activator inhibitor 1 (PAl-i) and 
serum cytokine levels in children with septic shock and purpura? 
3.4: Is the presence of a 4G/5G promotor polymorphism in the PAI-1 gene related to 
more severe coagulopathy and fatal outcome? 
In Chapter 4 experimental and clinical features of circulatory failure are discussed. 
Two major contributing factors to circulatory failure are the capillary leakage leading to a 
decrease in preload, and the development of myocardial dysfunction. The following issues 
were studied: 
4.1: What is the importance of the complement system in relation to capillary leakage, 
severity of disease and outcome? 
What is the extent of the complement activation, the possible route and regulation of 
this activation, and the relation of this activation to other inflammatory mediators? 
4.2: Since many of the invasive hemodynamic aspects of sepsis can not be assessed in 
pediatric patients, animals were used to study these items. In this chapter the 
hemodynamic effects of 2 different dosages of meningococcal toxin are studied in 
younger and older piglets. 
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4.3: The clinical and laboratory parameters from 75 patients are evaluated. With these 
data we developed a potentially useful prognostic score consisting of four simple 
laboratory parameters. 
Chapter 5 In this concluding chapter the results from the previous studies are summarized 
and put into a future perspective. 
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CHAPTER 1.2 
SEPSIS·RELATED PROBLEMS IN PEDIATRIC PATIENTS 
Jan A. Hazelzet and Ronald de Groot 
Sepsis. current perspectives in pathophysiology and therapy. 18ed. Berlin Heidelberg. 
New York; Springer Verlag. 1994: 214-27 
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1 INTRODUCTION 
The physiologic changes that constitute the process of sepsis are induced by microbial 
agents during bloodstream infection or by the toxic products of pathogens that are ret eased 
from sites of focal infection. This process involves changes generated by the immune 
system, and controlled by hormones, cytokines and enzymes. There are many host and 
microbial factors that may unfavorably influence this complex immune-response. 
Underlying diseases with immunosuppressive effects, surgery, state of nutrition, 
immunomodulatory therapy, and site of infection, increase the risk for development of 
invasive disease and determine the extent of the immune response (10,20,181) . However, 
sepsis in the pediatric population occurs very frequently in previously healthy children. 
Also, in comparison with adults, the sepsis is more overwhelming. The mortality is mainly 
confined to the first 48 hours of the disease. In children vs adults, different pathogens are 
involved and the quality and quantity of the immune-response depend on the age of the 
child. These differences are probably caused by developmental aspects of several organ 
systems and may have special consequences for management and therapy. 
2 EPIDEMIOLOGY 
The incidence of sepsis in children shows a bimodal distribution. The first peak is in the 
neonatal period (defined as infants < 1 month of age): 4.3/1000 newborns from which 60% 
in the first 5 days and an overall mortality of about 20 % (98), and a second peak around 
the age of 2 years. These periods are two milestones in the development of 
immunocompetence of the child. In children 1-4 years of age sepsis represents the 9th 
leading cause of death with an estimated annual mortality rate of 0.5/100.000 population. 
The pathogens involved in this age group are in the first 2 months mainly group B 
Streptococci (G8S) and Escherichia coli (98, 385), and later on: Neisseria meningilidis, 
Haemophilus influenzae, Streptococcus pneumoniae (all of them encapsulated micro-
organisms, which are protected against complement mediated phagocytosis and killing), 
Streptococcus pyogenes, and Staphylococcus aureus. In addition an extensive list of other 
pathogens is involved in nosocomial infections (180). Host factors predisposing to 
nosocomial infections are similar to those in adults (10, 248). 
Sepsis in young children caused by severe meningococcal disease is rapidly progressive, 
overwhelming and its mortality is high (20-60%) in the first 24-48 hours. Late mortality 
seems to be rare (44). 
There are several clinical syndromes in pediatric patients which show much resemblance 
with the clinical picture of septic shock. Their relation with toxins is either established or 
hypothesized. Examples of these syndromes are the toxic shock syndrome (16), 
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necrotizing enterocolitis (16), and the hemorrhagic shock and encephalopathy syndrome 
(67). 
Clarification of current terminology is important to understand the pathophysiology of the 
septic process. A definition for sepsis in infants and children is suggested Jafari (181), 
which is adapted from guidelines proposed for older patients (Table 1). We believe that the 
diastolic blood pressure should be included, because in the early phase of sepsis patients 
are sometimes able to maintain their systolic, but not their diastolic blood pressure. This 
results in a low mean bloodpressure and an altered organ perfusion leading to organ 
dysfunction. 
Table 1. Definition for sepsis In pediatric patients a 
Bacteremia Presence of viable bacteria in the circulating blood confirmed by culture. 
Sepsis Clinical suspicion of infection and evidence of systemic response to infection 
(tachycardia, tachypnea, hyperthermia or hypothermia).b 
Sepsis syndrome Sepsis plus evIdence of altered organ perfusion with at least one of the following: 
acute change in mental status c, oliguria d, elevated blood lactate and hypoxemia. 
Septic shock Sepsis syndrome with hypotension e requiring fluid resuscitation andlor vasopressor 
support . 
• Adapted from Jafari (181) 
bTachycardia and tachypnea> 2 standard deviations (SO) for age, hyperthermia> 38.5 coC; hypothermia 
< 36 "C. 
C A reduction by at least 3 points from baseline value in Glasgow coma score. 
d Diuresis < 0.8 mllkg/hr. 
e Systolic ill diastolic blood pressure < SO for age. 
3 RECOGNITION 
Clinical signs and symptoms of sepsis in the pediatric population depend very much of the 
age of the child. Especially in the first 6 months the symptoms are non-specific. In contrast 
to most adults or older children, a variety of thermal responses are seen in this age group. 
Apnea, leading to respiratory insufficiency, is an important sign. Extension of the 
bacteremia to the meninges is seen in 30 % of the patients with sepsis. Seizures and focal 
findings are often associated with the presence of meningitis. The hemodynamic signs in 
patients with sepsis include tachycardia, hypotension (systolic and diastolic) and cold 
extremities indicating an increased systemic vascular resistance (SVR). The early stages 
of warm septic shock in infants and older children are heralded by signs of hypo perfusion. 
The earliest signs are a change in mental state and a decreased urine output. Other signs 
include tachycardia, a widened pulse pressure with an increase in cardiac output and a 
decrease in SVR. The rapid progression of the disease and the early exhaustion are 
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characteristic. The remainder of the clinical picture in this age·group is comparable with 
that in adults. 
4 PATHOPHYSIOLOGY 
The interaction between microbial and host factors may partly explain the differences in 
immune-response between children and adults. 
4.1 Microbial factors 
Group B streptococci (GBS) are among the leading causes of overwhelming neonatal 
sepsis. Although other micro-organisms may cause similar clinical syndromes, most 
investigators have used experimental animal models of GBS infection to study the 
pulmonary and cardiac hemodynamics of neonatal septic shock. Gram-positive bacteria 
such as GBS do not have endotoxin. Two different polysaccharide toxins of GBS have 
been described (164). The polysaccharide capsule may also contribute to the organism's 
virulence through its protection from host phagocytosis. Although the presence of 
neutralizing maternal IgG antibodies to the capsular polysaccharide correlates with 
protection against disease in neonates, the age-related risk of GBS in newborns has not 
been fully explained. 
Severe meningococcal disease is the most frequent cause of sepsis in children above 3 
months of age and in teenagers without underlying disease. In several countries in Europe 
the incidence has increased during the last decade. The clinical picture includes an 
overwhelming septic shock with purpura. The mortality remains high, in spite of extensive 
research especially regarding the pathogenetic role of endotoxin (354). The reason for this 
specific clinical picture is still not completely elucidated. The endotoxin or 
lipopolysaccharides (LPS) of many non-enteric gram-negative organisms, such as 
Neisseria meningitidis and Haemophilus influenzae lack the outer polysacchardide 0-
chain and contain only the oligosaccharide and the lipid A region often referred to as lipo-
oligosaccharides (LOS). The lipid A part is considered to be the most bioactive and toxic 
part and extensive investigative efforts have been directed towards developing anti-lipid A 
antibodies. However, in animal experiments there are differences in lethality and in 
neutralization by polymyxin B between LOS and LPS from E.coli. (13) and the lipid A cores 
of gram-negative organisms are known to be heterogenous. Furthermore, the 
meningococcus contains surface components and secretes molecules and complex 
vesicle structures (blebs) that may modulate or deflect the immune system. The bacterium 
can undergo phase and antigenic variation and is able to use host factors for its own 
protection and growth (353). These blebs are shed through the body and contain LOS, and 
also other membrane parts which may also have antigenic properties. Ultracentrifugation 
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studies on plasma specimens from patients with severe meningococcal disease (SMD) 
suggest that most of the circulating LOSs are present as large fragments or· aggregates 
(44). which make recognition by the immune system probably more difficult. 
4.2 Hostfactors 
4.2.1 immune-response 
Developmental aspects of the pediatric immune response are still unknown to a large 
extent. The majority of the work has been performed in the neonate. Much less is known 
about the growing child. At birth. a child is protected against a variety of bacterial and viral 
agents by maternal antibodies and remains less susceptible for many infections untill the 
age of 6 months. The immunoglobulin-synthesis of the infants increases untill at the age of 
2 years about 75 % of adult values are reached. The IgG and IgA-synthesis produced after 
a certain antigenic stimulus is limited until the age of 2- 4 years. Polysaccharide capsules 
does not give an appropriate immune response and does not induce immunological 
memory. This is due to an immature T-cell function. These problems can be circumvented 
by covalently linking the polysaccharide antigens to proteins. the principle used in the 
production of conjugate vaccines (276. 354). There are many differences between the 
neonatal polymorphonuclear leukocyte (PMN) and the adult PMN. The response of the 
neonatal PMN to chemotactic Signals initiated by infectious agents is poor. Further 
disaggregation of PMN and migration to the infected tissues is markedly depressed. 
Depletion of circulating neutrophils with the exhaustion of the neutrophil storage pool in the 
bone marrow is more likely to occur because the storage pool is low (14 % of the adult pool) 
and the turnover rate is high (53). In comparison with adults. there are differences in the 
cytokine-production of mononuclear cells when they are stimulated in vitro (95). Several 
studies over the past 5 years have indicated the possible benefit of hematopoietic colony-
stimulating factors (CSF). These cytokines may in fact enhance neonatal myeloid 
progenitor proliferation. modulate neonatal bone marrow neutrophil storage and proliferate 
pools. and enhance neonatal host defense against overwhelming bacterial infection (52). 
The characteristics of the PMN of the growing child are not studied in detail. 
Results of studies regarding age related differences in susceptibility to and mortality of 
sepsis between infant and adult animals are controversial and probably depend the 
experimental model (284. 367). the exact age (284). and the pathogen involved (284). 
4.2.2 metabolic-response 
Sepsis may lead to pronounced metabolic alterations: elevations of plasma glucose. 
lactate. insulin. free fatty acids concentrations. and increased muscle protein breakdown 
21 
Chapter 1.2 
are well known changes during the early phase of sepsis in the adult patient. The 
differences in metabolic response to sepsis between infants and adults are not completely 
understood. Muscle protein metabolism data from experimental studies suggest that 
despite prominent differences in basal protein turnover rates between infant and adult rats 
the effect of sepsis on muscle protein metabolism is not age dependent (266, 384). The 
glucoregulatory changes in the developing human and animal are different from the adult. 
In young infants during sepsis, there is an increased glucose disappearance rate without 
hyperinsulinaemia (107, 284, 387). In an experimental sepsis model in rats, studying age 
related differences, the adult rats became hyperglycemic, while young animals were 
hypoglycemic eight hours after cecal ligation and normalized after 16 hours (266) In the 
human situation infants with a severe septic shock often have a hypoglycemia which 
necessitates correction. 
4.2.3 cardiovascular system 
Clinical stUdies in adults have shown that myocardial dysfunction begins within hours of 
sepsis and peaks in 1-2 days with survivors returning to normal function in a 7-10 days 
period. Hyperdynamic circulatory state in survivors is probably maintained by ventricular 
dilatation. Again, studies in adults present conflicting results regarding the coronary 
perfusion during sepsis. Similar studies in children are not available. However, there are 
several experimental studies, which have shown the presence of age-related differences 
between neonatal and adult animals in myocardial reserve (which increases because of an 
improving diastolic compliance), relation between contractile and non-contractile 
myocardial elements, metabolic substrates (from carbohydrates to free fatty acids), 
sensitivity for hypoxemia, maturation of the pulmonary vasculature and, sensitivity of 
sympathic receptors to catecholamines (5, 105, 173, 306) . Our group is preparing an 
experimental septic shock model in young piglets using meningococcal endotoxin to study 
the differences between young and adult pigs. Only a small number of studies have been 
published about the myocardial dysfunction during septic shock in children (38, 238, 242). 
These studies were performed in pediatric patients with meningococcal sepsis. They 
revealed hypovolemia and severe disturbances in cardiac function as indicated by left 
ventricular shortening fraction (echocardiography) and cardiac output (thermodilution). 
Myocardial dysfunction in septic shock in children reaches a maximum within hours, and is 
the main cause of early mortality. Recovery takes 1-3 days. Cardiac output (C.O) in infants 
is classically thought to be more rate- than stroke-volume-dependent, which is probably the 
reason for cardiac frequencies of sometimes over 180 b/min. It is unknown to what extent 
ventricular dilatation is useful in the maintainance of a possible hyperdynamic state. It is 
also not known whether there is a hyperdynamic state in infants (238). C.O in infants is very 
much preload-dependent. Therefore fluid resuscitation is an important step in the initial 
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management of children wilh septic shock to overcome the hypovolemia on Ihe basis of a 
diffuse capillary leak (58, 59). Altered vascular tone and flow-oxygen utilization systemic 
relationships are considered a hallmark of sepsis in children. An aile red vascular tone 
leads to decreased peripheral vascular resistance (SVR). This results in a lowered diastolic 
aorta pressure. II is this pressure in combination with the duration of the diastole which are 
the two main determinants of coronary perfusion and indeed, coronary ischemia may be 
seen in children even in the first 24 hours after admission. 
4.2.4 coagulation system 
Especially in meningococcal sepsis, but also in other forms of pediatric and neonatal 
sepsis, thrombopenia and disseminated intravascular coagulation (DIG) can be found 
leading to petecchiae and ecchymoses. At birth several clottingfactors are present at 
serumlevels much lower than in adults. This possibly explains why the balance is easily 
switched towards coagulation. During the first two years of life these serumlevels increase 
untill adult values are reached (8, 346). In meningococcal sepsis in children, there is an 
extreme depletion of anticoagulatoryfactors like protein G and S (207) as opposed to adulls 
in which a depletion of anlilhrombine III predominates. Protein G has gained interest 
because its possible role in sepsis and its protective effect in experimental sepsis (323). 
The combination of exlreme capillary vasoconstriction, caused by mediators like 
endothelin, and the increased deposition of fibrin, caused by the hypercoagulatory state 
and a decreased fibrinolysis, will lead to an increased formation of microthrombi and in this 
way to auto-infarction and gangrene. 
Therefore an important part of the volume-suppletion which is administered in our hospilal 
during the acute phase of the sepsis comprises of fresh frozen plasma (FFP), which still is 
the only balanced substitute of clotting factors in this situation. However there have been 
no conlrolled studies to prove the superiority of FFP over other colloids in Ihis situation. On 
the contrary, recently a study was published in experimental sepsis which indicated the 
presence of deleterious effects of plasma therapy (51). 
5 MANAGEMENT ASPECTS 
5.1 Cardiovascular function 
The abnormal microcirculation and a decreased aortic diastolic pressure cause a 
compromised coronary perfusion in children with septic shock. Togelher with possible 
depressing mediators this will lead to a severely depressed myocardial function with a 
decreased stroke-volume. Alfa- and beta-adrenergic support may possibly restore a 
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normal mean arterial pressure and systemic vascular resistance. To inhibit or improve 
capillary vasoconstriction, a local vasodilatator could be added. Recently Heyderman 
(169) presented findings suggesting that a deficiency of prostacyciin (PGI,) may have a 
role in the pathogenesis of meningococcal shock and that exogenous PGI, may be of 
therapeutic benefit. There is no consensus on which particular inotropic drugs are most 
useful. Especially in children the pharmacodynamics of these drugs are still not well known. 
The combination we use is noradrenaline + dobutamine + prostacyclin, with the lowest 
possible a-agonist dose to achieve a mean arterial blood pressure which enables an 
adequate urine output and no further increase in oxygen consumption. 
5.2 Respiratory function 
More than 60% of critically ill children with septic shock are intubated and ventilated within 
24 hours after admission. Indications for intubation are hypoxia, apnea, acidosis, increased 
work of breathing (W.O. B), and neuromuscular blokkade for invasive procedures. About 
40% of these patients develop ARDS. In children with heartfailure, W.O.B can require as 
much as 25% of oxygen consumption. Extrapolating a simular effect of cardiac dysfunction 
and increased W.O.B to ARDS in sepsis leads to the general recommendation to intubate 
and ventilate in an early stage and not to wait untill a disease stage in which intUbation 
becomes a dangerous procedure. Delicate handling of the nuid balance because of 
increased extravascular lungwater is necessary. 
5.3 Fluldresuscltation and Monitoring 
The importance of nuidresuscitation to overcome the hypovolemia caused by capillary leak 
has already been mentioned. Sometimes 100-200 mllkg of colloids (like FFP) are needed 
during the first day of treatment. Because of several reasons it is not daily practice to insert 
pulmonary artery catheters in every patient but central venous pressure monitoring and 
echocardiography is indicated and frequently used (38, 59, 128, 238). Lactate and several 
coagulation parameters are used as a tool to monitor the condition of the patient. 
6 PROGNOSTIC FACTORS 
Several prognostic factors have been related to non-survival: 
Increased levels of: Serum-endotoxin (44), TNF,IL-1 (362),IL-6 (159, 298, 320, 360),IL-
8 (145), lactate (159), plasminogen activator inibitor-1 (42), ICAM-1 (200), procalcitonin 
(11), elastase-a,,-proteinase inhibitor (314,326). 
decreased levels of: CRP (159, 206), fibrinogen, glucose, protein-C (207), leucocytes, 
platelets (174), as well as several scoring systems (205, 206, 208, 274). 
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The morbidity of sepsis in pediatric patients depends on the age and the causative 
pathogen. In the neonate and infant the neurologic sequelae can be more severe 
especially if meningitis is present. Chronic renal failure after a septic period is rare in 
children. In particular in SMD the morbidity is relatively low and is limited to skin lesions and 
amputations of extremities. 
7 FUTURE THERAPY 
Prevention is still superior to treatment. Progress has been made in the field of active 
immunization. In several countries in Europe immunization has been started against 
Haemophilus influenzae. It will take at least another 5 years to develop a vaccin against N. 
meningitidis group B. Passive immunization using either pooled plasma or pathogen 
specific-immunoglobulins has been used in neonates. A limited number of studies have 
been performed and they suggest a beneficial effect in GBS-infections (104). 
Administration of neutrophils to infants with significant neutropenia has been suggested as 
approach (98). The European multicenter trial using HA-1-A in pediatric patients with septic 
shock and purpura is still ongoing. More than 170 patients are included. Until this trial has 
been concluded, a recommendation for the use of HA-1-A in these patients can not be 
given. Concerning the extensive list of other possible immunomodulative therapies, it is 
important to realize that on admission of a septic child, the process is in a well advanced 
stage, so that only influencing the momentary endotoxin-level will have a limited influence 
on outcome. Trials should be directed to influence the micro-circulation. Currently, a trial 
with recombinant protein C is in preparation. 
8 CONCLUSIONS 
There is only limited epidemiological and clinical data available on children with septic 
shock. There is a need for a universal definition in children with sepsis. This definition 
may be adapted from guidelines proposed for adults. 
Septic shock in neonates and infants is more overwhelming than in adults. The highest 
mortality is in the first 48 hours and does often occur in previously healthy children. 
Specific sepsis-related differences between adults and pediatric patients are probably 
caused by developmental aspects especially in the cardiovascular and coagulation 
system, and the immune-, and metabolic response. 
Pathophysiological aspects of sepsis especially in the infant-age range should be 
subject of further research. 
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CHAPTER 1.3 
PATHOPHYSIOLOGY OF MENINGOCOCCAL SEPSIS IN CHILDREN 
Ester D. de Kleijn, Jan A. Hazelzet, Rene F. Kornelisse and Ronald de Groot 
Eur J Pediatr, in press 
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1. INTRODUCTION 
Meningococcal disease, first described by Vieusseux in 1805 as epidemic cerebrospinal 
fever, remains a major health problem in many countries (356). Clinical manifestations vary 
from self-limiting bacteremia to meningitis or fulminant sepsis (figure 1). 
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Figure 1. Clinical evolution of infections by Neisseria meningitidis. 
.... 
Resolved 
Bacteremia: presence of viable bacteria in the circulation blood confirmed by culture 
Sepsis: clinical suspicion of a severe infection and evidence of systemic response to infection (tachycar-
dia, tachypnea, hyperthemia or hypoterhmia) 
Sepsis syndrome: sepsis plus evidence of altered end-organ perfusion with at least one of the following: 
acute changes in mental status, oliguria, elevated lactate and hypoxemia 
Septic shock: sepsis syndrome with hypotention requiring fluid resuscitation and/or vasopressor support 
eNS: central nervous system. 
Meningococcal sepsis is characterized by a rapid onset of disease, fever, purpura and 
ultimately shock. Non-specific presenting symptoms such as a flu-like picture and a rash 
are commonly observed. The diagnosis of meningococcal disease becomes obvious 
when petechiae develop. Meningococcal disease is predominantly seen in children with 
a peak incidence around 2 years of age. A second peak is noted among teenagers. The 
overall mortality rate of meningococcal septic shock varies between 20% and 50%, is 
higher in infants than in older children and has not changed significantly over the past 
three decades despite improvements in management and therapy (44,121,146,158, 
250,279, 343, 380). 
The systemic inflammatory response in patients with meningococcal disease aims to 
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neutralize microorganisms and their toxic products, but it may also overreact and thus 
induce serious tissue damage to the host. Three pathways characterize the intravascular 
inflammatory response: 1) activation of cascade systems, 2) the release of intercellular 
pro- and anti-inflammatory mediators and 3) altered function of endothelial cells in the 
vascular wall. In meningococcal infection coagulation, fibrinolysis, complement and 
kallikrein-kinin systems, cytokine production, and aclivation of neutrophils and platelets, 
are all apparently upregulated by native lipopolysaccharides (LPS) in a dose-dependent 
manner (45) (figure 2). This review provides an overview of the systems involved in the 
pathophysiology of meningococcal sepsis and of possible therapeutic interventions. 
Activation ......... _ ........ LPS 
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Figure 2. Pathophysiology of meningococcal sepsis 
LPS: Lipopolysaccharide, PMN: Polymorphonuclear leukocytes, DIC: disseminated intravascular 
coagulation. 
1.1 Role of LPS in meningococcal disease 
Meningococci enter and replicate in the bloodstream, after crossing the epithelial barrier 
without causing an intense local inflammatory response. They liberate various amounts of 
endotoxin (Iipopolysaccharides)-containing outer cell wall fragments partly in the form of 
blebs (88). Blebs bind antibodies that would otherwise attach to whole bacteria and 
probably playa crucial role in the pathogenesis of this form of septic shock. High levels of 
circulating endotoxins correlate with fatal outcome and with severityofdisease(45, 47, 360, 
361) . Low levels of bactericidal antibodies and immaturity of the T-cell system may play an 
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important role in the development of meningococcal disease in young children. The 
presence of bactericidal antibodies is crucial. The levels of "natural" bactericidal antibodies 
are influenced by carriage of meningococci or colonization by nonpathogenic bacteria such 
as Neisseria lactamica (354). High density lipoproteins, complement factors, antibodies, 
albumin, transferrin and lipopolysaccharide binding protein (LBP) have the ability to 
complex with LPS. Several of these proteins appear to have a detoxifying effect (152, 234, 
327). LBP however, amplifies the effect of LPS. After complexation with LBP, LPS is 
presented to the CD14 receptor of macrophages and PMN's (Figure 3). This interaction 
leads to cellular activation at a much lower concentration of LPS than without LBP (234). 
High levels of LPS can also directly activate CD14 receptors. Bactericidal/permeability-
increasing protein (BPI) is a potent bactericidal protein produced by polymorphonuclear 
leukocytes (PMN). It is stored in the azurophilic granules and also expressed on the cell 
surface. The bactericidal activity of BPI is caused by the strong affinity of BPI for LPS (368). 
In addition to bactericidal capacity, BPI also neutralizes LPS activities in vitro and vivo 
(232). 
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Figure 3. Competition between BPI and LBP in the binding of LPS 
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LPS: lipopolysaccharides, BPI: bactericidal/permeability=increasing protein, LPB: lipopolysaccharide 
binding protein, CD14: CD14 membrane bound antigen, sCD14: soluble CD14 antigen, +: activation, _H 
neutralization. 
1.2 Pro- and counterinflammatory mediators 
Lipopolysaccharides induce a release of proinflammatory mediators in gram-negative 
sepsis. These mediators are synthesized and released by macro phages, monocytes, and 
endothelial cells. Cytokines are paracrine agents: they act locally on a variety of tissues 
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signalling information to adjacent cells. Experimental and clinical data have shown that 
tumor necrosis factor (TN F)-a and interleukin (lL)-111 are the key mediators in 
meningococcal sepsis. TNF-a and IL -111 exert their effects by different mechanisms 
including the induction of other cytokines, activation of neutrophils and leukocytes, 
enhancement of adherence of PMN and monocytes to endothelium, generation of 
prostaglandins and production of nitric oxide. The release of other mediators (IL-6, IL-8, 
UF, IL-12 and IFN-y) is triggered by LPS, TNF-a, and IL-111. These cytokines are elevated 
in meningococcal sepsis and their levels correlate with severity of disease. Interleukin (lL)-
6 is a major pyrogen, stimulates the synthesis of acute-phase proteins (159) and has the 
ability to induce proliferation and antibody production by B-cells. Interleukin (IL)-8 is a 
potent chemoattractant, activates neutrophils and is thought to be involved in neutrophil-
mediated vessel-wall injury (12, 161). Leukemia inhibitory factor (UF) has multiple actions, 
many of which are shared with TNF-a, IL-1 and IL-6 (13, 366).IL-12 is a recently described 
proinflammatory cytokine, which seems to playa key role in the differentiation of Th1 
cells and induces the production of interferon (IFN)-y by T-cells and natural killer (NK)-cells 
(65,163,182,333,334,336,381,157). The levels of IL-12 in meningococcal septic shock 
are related to outcome and severity of disease (157). Interferon-y (lFN-y) activates other 
cytokines. Plasma levels of IFN-y are increased in sepsis, although not consistently (49, 
54, 129, 157, 162, 193,360). 
The short peak of pro-inflammatory cytokines is directly followed by an increase of 
counterregulatory cytokines like IL-1 receptor antagonist (IL-1Ra), IL-10, soluble TNF 
receptors (sTNFRs) and soluble IL-6 receptor(sIL-6R). These mediators exceptslL-6Rare 
considered to be anti-inflammatory because they reduce mortality in experimental 
endotoxemia (124, 257, 347). IL-1Ra inhibits the proinflammatory actions of IL-1 by 
competitive binding to the IL-1 receptor. IL-1Ra and also sTNFRs are present in the 
circulation during early meningococcal infection (343). The role of sTNFR is complex. It is 
believed that sTNFR is released in the circulation after binding of TNF-a on the target cell. 
This shedding may protect the cell against ongoing stimulation of TNF-a (202). In contrast 
sIL-6R seems to stimulate the biologic activity of IL-6. Septic patients had significantly 
lower concentrations of sIL-6R compared to healthy volunteers (115, 116,388). Interleukin 
10 is released in massive amounts into the systemic circulation during the initial phase of 
fulminant meningococcal septic shock and high serum levels of IL-10 are related to 
outcome in children with this disease (85, 211,281). IL-10 is a potent inhibitor of cytokine 
production (177, 124, 182,363). It also suppresses the procoagulant activity induced by 
LPS at the surface of human monocytes (281). IL-10 stimulates the production of IL-1 Ra 
and induces the release of sTNFRs by monocytes (209). 
Generally, serum levels of proinflammatory cytokines are significantly increased at the 
onset of disease in patients with meningococcal sepsis and these levels are associated 
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with outcome and severity of disease (45,121,159,360,366,372). These cytokines are 
cleared from plasma rapidly. A negative correlation has been reported between the initial 
levels of cytokines and the time between first appearance of petechiae and admission (159, 
195). This shorter duration of petechiae in non-survivors suggests a shorter disease course 
and associated higher levels of cytokines. The earlier admission of non-survivors may 
indicate a higher production of LPS per time span, thus triggering mediator systems more 
intensively or may be explained by a higher responsiveness to lipopolysaccharides or to 
proinflammatory cytokines (195). Westendorp et al. found a genetically encoded anti-
inflammatory cytokine profile during the initial phase of infection, which decreased the non-
specific host response and favored growth of micro-organisms. Families from 
meningococcal disease patients characterized by low TNF production in an ex vivo whole 
blood stimulation setup, had a tenfold increased risk for fatal outcome, whereas high IL-10 
production increased the risk 20-fold. Families with both characteristics had the highest risk 
(373). However, others have studied the genotype of both surviving and non-surviving 
patients with severe sepsis and found support for the hypothesis that individuals with a 
genotype for high TNF production have a worse outcome (37, 244, 318). Their results 
showed an association between a polymorphic variation in the TNF-a gene promotor 
region and death from meningococcal disease (244). 
1.3 Endothelial damage and capillary leakage 
Endothelial cells are not merely a selective permeability barrier between blood and 
underlying tissues, but actively play an important role in maintaining homeostasis. During 
sepsis, endotoxin and several other mediators activate vascular endothelial cells and 
initiate a rapid alteration of structure and function of these cells (figure 4). Finally 
endothelial damage is leading to a severe capillary leak syndrome. Capillary leakage and 
subsequently edema are the result of: destructive changes of endothelium 
(glycosaminoglycan component (190)), active separation of tight junctions between 
endothelial cells (201) and high molecular protein leakage. 
These processes are partly induced by circulating mediators (TNF-a, IL-1, IL-8, platelet 
activating factor (PAF), leukotrienes, thromboxane A" thrombin, vascular permeability 
factor, complement factors, kinins (34,75), and the adherence of neutrophils and platelets 
(133,351,365). Activated leukocytes are primed to initiate phagocytosis and microbial 
killing by degranulation and release of proteolytic enzymes and toxic oxygen radicals, but 
in this way they also playa role in endothelial damage (31, 133, 351,365). Elastase is one 
of these degranulation products of activated neutrophils. Elastase-a i-antitrypsin 
complexes in plasma appear to be of prognostic significance: levels are higher in non-
survivors (254). Ultimately, increased vascular permeability leads to profound interstitial 
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Figure 4. Disseminated intravascular coagulation, characterized by microvascular thrombosis and bleeding 
diathesis. PAl: plasminogen actovator inhibitor; PAF: platelet activating factor. 
edema with diffuse parenchymal cell injury and persistent hypovolemia followed by organ 
dysfunction. 
1.4 Complement 
The complement system plays a key role in host defense mechanisms, resulting in lysis of 
bacteria, enhancement of phagocytosis by monocytes or polymorphonuclear leukocytes or 
neutralization of endotoxin (113, 114). This system is an essential element in the 
maintenance of homeostasis not only of several immunological functions, but also of the 
coagulation and fibrinolysis system, vascular permeability and vascular tonus. Fulminant 
meningococcal sepsis is associated with excessive complement activation (47,113). 
Complement peptides generated during activation, have pro-inflammatory effects such as 
stimulation, aggregation and degranulation of neutrophils and induction of expression of 
selectins on the endothelial surface. However, overstimulation or inadequate inhibition of 
the complement system may lead to an inappropriate reaction and ultimately to tissue 
injury (135). The complement system can be activated through the classical and the 
alternative pathway. The classic pathway requires recognition and binding of bacterial 
antigens by specific antibodies. In vitro studies indicate that lipid A and the polysaccharide 
side chain may complex with C1 q and factor B to initiate activation of the classical pathway 
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without involvement of antibodies. The alternative complement pathway can be activated 
by a variety of substances, including polysaccharides, bacterial endotoxins, cytokines and 
immune complexes (31, 296). Normally, intravascular clearance of bacteria is mediated 
through the deposition of complement components: C3b for phagocytic clearance (294); 
the membrane aUack complex or C5b-C9 for lysis (113, 114). Previous studies indicate that 
the degree of complement activation in sepsis is related to the amount of circulating native 
lipopolysaccharides (119, 220, 243). In meningococcal septic shock increased levels of 
complement factors C3, C4, C5, and terminal complement complex and decreased levels 
of prekallikrein are related to outcome (47). The presence of C4bc, C4bd and Bd point to 
activation of both the classical and alternative pathways. Brandtzaeg et al. suggest that 
complement activation is predominanlly caused by alternative pathway activation (41). In 
contrast, we could prove an important contribution of the classical pathway in the activation 
of the complement system in patients with meningococcal sepsis. This activation was 
related to outcome and severity of disease (155). Brandtzaeg and colleagues showed that 
complement activation may persist during the first 12-24 hours of disease, when production 
of other inflammatory mediators is already downregulated (47). Complement deficient 
individuals point to the importance of the complement system in meningococcal disease. 
Meningococci cause 80% of all systemic bacterial infections in these individuals, although 
in late-complement-component deficient individuals mortality is five to ten fold lower than 
in complement sufficient individuals (84). The complement and the coagulation system 
share the same protein as their inhibitor in plasma, Le. C1-esterase inhibitor (C1-INH). C1-
INH levels may increase up to two-fold during uncomplicated infections (139). During 
sepsis C1-INH levels were found to be normal or even decreased especially in non-
survivors (252). In our patients we also found decreased levels ofC1-INH (155, 156). Hack 
et al. hypothesized that increased degradation of C1-INH in sepsis may result in an 
insufficient control of the complement and coagulation systems (139). 
1.5 Coagulation and fibrinolysiS 
Coagulation disorders and abnormalities of fibrinolysis are common in patients with 
meningococcal sepsis. The most severe manifestation is disseminated intravascular 
coagulation (DIC), characterized by microvascular thrombosis and bleeding diathesis 
(table 1). Widespread microvascular thrombosis does contribute substantially to organ 
dysfunction and survival. The production of thrombin and the conversion of fibrinogen to 
fibrin, may be activated by the intrinsic pathway (through factor XII) or by the extrinsic 
pathway (through factor VII/tissue factor) activation (figure 5). Activation of the coagulation 
system in sepsis occurs predominanlly through the extrinsic route. The importance of the 
extrinsic route of coagulation was shown in an experimental model of baboons in which 
infusion of monoclonal antibodies against tissue-factor protects against lethal shock by 
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Table 1. Factors involved in the pathophysiology of DIG 
Deposition of micro-thrombi 
expression of procoagulant surface 
increased turnover of activated clotting factors 
consumption of regulatory proteins 
release of excess fibrinolytic inhibitors 
release of platelet activating factor 
-Bleeding diathesis 
increased fibrinolysis 
consumption of coagulation factors/platelets 
interference with platelet aggregation and fibrin polymerization by FOP's 
-Vascular injury and capillary leak 
direct toxic effect of endotoxin 
activation of kinins, complement and cytokines 
neutrophil adhesion and release of cytotoxic products 
loss of clotting factors by capillary leak 
(Adapted from Manco-Johnson) 
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E. coli. and attenuates coagutopathy (325). In contrast, inhibition of the intrinsic 
pathway by administration of monoclonal antibodies against factor XII has no effect on 
the coagulopathy in the same model (270). 
Endotoxin and TNF-u. induce the expression of tissue factor by monocytes, macrophages 
and endothelial cells which activate factor VII. Of interest, increased levels of tissue factor 
are present in circulating monocytes isolated from blood of patients with meningococcal 
sepsis. The highest values were found in nonsurvivors (261). Through kallikrein, activation 
of factor XII resulls in the generation of bradykinin, complement, plasmin and elastase. In 
this way, factor XII mediates inflammation, fibrinolysis, and tissue damage as well as clot 
formation. Hypotension is probably partly mediated by generation of kinins such as 
bradykinin. Factor XII levels are lowest in patients with septic shock (168,253). 
Levels of natural inhibitors of coagulation are markedly altered during meningococcal -
sepsis. Several stUdies confirmed that antithrombin III (AT-III) levels (46,110-112,207), 
protein S, and notably protein e (46, 100, 110, 112, 207, 279, 280), are decreased in 
meningococcal septic shock. The decline in protein e levels is more pronounced than the 
decrease in ATIII and protein S levels. The decrease in ATIII, protein e and protein S levels 
is associated with the presence of ole and poor outcome. The higher mortality of infants 
with meningococcal septic shock is probably related to immaturity of the protein e system 
(158,279). Elevated initial levels of the extrinsic pathway inhibitor (EPI), another inhibitor 
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Figure 5. TNF-a: tumor necrosis faxtor a; IL~1: interleuking-1 
V: coagulation factor V; X: coagulation factor X and Xa, when activated; 
tPA: tissue plasminogen actovator; PAl: plasminogen activator inhibitor. 
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The intrinsic pathway involves the activation of coagulation factor XII, and VIII. The extrinsic pathway 
involves the activation of factor VII by tissue factor. 
Natural inhibitors: 
1: antithrombin III ==:::? 
2: activated Protein C 
3: tissue factor pathway Inhibitor 
of coagulalion, were found in patients with fulminant meningococcemia (46). This is in 
contrast to the levels of ATII! and protein C. The levels of EPI were significantly higher in 
nonsurvivors in comparison to survivors. Furthermore, levels of EPI increased during the 
course of disease (46). 
The fibrinolytic system becomes activated by tissue plasminogen activator (tPA) during the 
early course of meningococcal sepsis. Subsequently, fibrinolysis is inhibited by increased 
levels of plasminogen activator inhibitor (PAI-1) (42, 158, 195). In patients with sepsis and 
septic shock tPA levels are increased and related to outcome and severity of disease (268, 
358). However, we could not detect significant differences in the initial levels of tPA in 
survivors and nonsurvivors with meningococcal septic shock (158,195). In adult patients 
with non-meningococcal septic shock, levels of plasminogen and alpha-2-antiplasmin are 
low in septic shock but not related to outcome (168, 358). In contrast in children with 
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meningococcal septic shock, alpha-2-antiplasmin levels as well as the ratio PAI-1/tPA 
were related to outcome in patients with meningococcal septic shock (42,100,158). These 
changes in fibrinolytic parameters result in an ineffective fibrinolysis. Of interest, a genetic 
polymorphism in the promotor of the PAI-1 gene is suggested to explain higher PAI-1levels 
in non-survivors at a similar TNF stimulus (195). 
The massive consumption coagulopathy is characterized by low levels of coagulation 
factors VII, X, V, prothrombin, fibrinogen, and platelets. Because of the massive demand 
of anticoagulation factors due to widespread activation of the anticoagulant pathway, the 
host's endogenous anticoagulants ,are depleted causing purpura fulminans (279). This 
depletion is possibly age-related (158, 279). Platelets also interact with neutrophils through 
a selectin-mediated mechanism. These interactions may bring activated platelets close to 
the endothelium (147). Even without adherence to the endothelium, platelets can 
profoundly affect endothelial function by the release of vasoactive substances from 
platelet storage granules. Such substances include adenosine diphosphate (ADP), 
serotonin, PAF and lipoxin A4, which may mediate vasodilatation (175). Platelet adhesion 
to vascular endothelium is mediated by coagulation factor VIII (von Willebrand factor), 
which is found in plasma, endothelial cells and in the storage granules of platelets. Platelets 
also form and release thromboxane A2 and leukotriene C1, which may mediate 
vasoconstriction (293). The result is a procoagulant state which is reflected in formation of 
microthrombi in the skin, the extremities and the adrenals. The excessive consumption of 
coagulation factors results in a hemorrhagic diathesis and local tissue hemorrhages. 
1.6 Circulatory dysfunction 
Shock or circulatory collapse in patients with fulminant meningococcal sepsis are caused 
by a combination of an inappropriate vascular tone, myocardial dysfunction, capillary 
leakage and intravascular microthrombosis. Initially, patients with meningococcal sepsis 
present with intense vasoconstriction. Subsequently, the systemic vascular resistance falls 
due to vasodilatation in the course of the treatment requiring volume suppletion and 
vasopressors. A dysbalance between forces causing vasodilatation and those causing 
vasoconstriction of the blood vessels results in generalized vasodilatation and 
hypotension, but in some capillary beds like the skin and the pulmonary circulation it leads 
to vasoconstriction. Vasoconstrictor substances that are elevated in patients with shock 
include catecholamines, renin, aldosterone, thromboxaneA2 and endothelin(34, 192, 321, 
357). A deficiency ofPGI, synthesis by the endothelium is also involved in vasoconstriction 
during meningococcal disease (169). On the other hand, bradykinin and nitric oxide are 
potent vasodilator compounds leading to hypotension (221, 295, 329). 
The major mechanism of death in meningococcal sepsis is circulatory collapse resulting 
from a combination of capillary leak, intravascular volume depletion, myocardial failure and 
37 
Chapter 1.3 
vasodilatation (238). As compensatory mechanisms fail, hypotension ensues, perfusion of 
vital organs becomes inadequate and the resuliing hypoxia and acidosis contribute to 
myocardial dysfunction. There is only a limited number of hemodynamic studies in pediatric 
patients with meningococcal sepsis (38, 328, 242). Probably the most detailed is the one 
of Mercier et al. The results of this study suggest a different cardiovascular pattern in 
children with meningococcal sepsis than in adult patients with sepsis. All of the non-
survivors had a decreased cardiac index (CI) and nearly all of the survivors had a normal 
CI in stead of the increased CI which can be encountered in adult patients with sepsis (238). 
The timespan in which the circulatory failure takes place is different in meningococcal 
sepsis in comparison with other forms of sepsis. Mortality happens in the first 48 hours, 
while recovery seemed much longer in adulis (7-10 days) than in children (1-3 days) (38). 
The mechanism of the myocardial failure in human sepsis remains partly speculative. 
Circulating myocardial substances like TNF-a , IL-1 and endotoxin itself and not 
myocardial hypoperfusion is probably responsible for this depression (197, 198, 210, 265). 
However, also other aspecls of the systemic inflammatory response including circulating 
cytokines, tissue damaging, leukocyte-endothelial cell- myocyte interaction leading to 
severe myocardial edema and mismatch of oxygen supply and demand in cardiac 
microvasculature will cause this myocardial depression (238, 364). To what extent these 
mechanisms are also applicable to meningococcal sepsis is not clear yet. 
2 THERAPEUTIC INTERVENTIONS 
The most important complication requiring urgent intervention is the development of shock 
in the presence of a profound capillary leak. The aim of the whole treatment is to provide 
sufficient fluid to maintain the intravascular volume and electrolyle balance, while 
minimizing the accumulation of extravascular fluid. When shock continues despite 
aggressive correction of the volume deficit, inotropic support should be given (189). 
Recently, extracorporeal membrane oxygenation (ECMO), is suggested as a support 
therapy for patients with severe cardiorespiratory failure. Venoarterial ECMO provides 
both circulatory and respiratory support and could assist septic patients if conventional 
medical managment is failing. The potential risk of haemorrhage is of concern, because of 
the necessity for anticoagulation during ECMO. The little experience of ECMO for 
meningococcal disease is encouraging with two-thirds of the patients surviving and most 
survivors leading functionally normal lives (19, 64,134). The question remains whether 
these patients would have survived without ECMO. 
New therapies directed towards modulating the systems involved in the pathophysiology, 
have so far shown little benefit in clinical practice (table 2). To neutralize circulating 
endotoxin, antibodies against the lipid A moiety of endotoxin (HA-1A) have been studied. 
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Table 2. Experimental treatment in meningococcal septic patients 
author experimental treatment type of study number of patients concJusion 
BecaJ'~ ECMO retrospective, descriptive study n=9 ch'lldren (5 SUrv'IVOrs) ECMO supported the circulatlon successfully. 
Goldman AP 134 ECMO retrospective, descriptive study n=12 children (8 survivors) ECMO might be considered to support 
patients with meningococcal disease, 
Champion MP ().1 ECMO descriptive n=2 (both survivors) ECMO may have a role in refractory shock. 
van Deuren M 342 plasma or whole blood descriptlve, with historical controls n=15 children and young early initiation of PEBE may improve 
exchange (PEBE) adults (12 survivors) the rate of survival. 
Reeves J H :168 hemofiltration retrospectlve case notes n=18 children (5 survivors) hemofiltration or plasmafiltration is safe, 
plasmaflltration n= 9 children (3 survivors) but their effect on outcome remains unknown, 
Best C22 early hemo-dlafiltration descriptive n=4 children (all survivors) use for treatment is speculative, 
Frieling JTM "6 plasma or whole blood prospectlve, descriptive n=9 children (6 survivors) plasma or whole blood exchange increase the 
exchange concentration of soluble IL-6 receptors. 
Westendorp RGJ 37, leuka-plasmapheresis open, prospective with historical n=13 children (10 survivors) leuka-plasmapheresis might be of value, 
controls 
Gerard, P '2~ heparin descriptive n=19 children (17 survivors) heparin must be considered as an adjunctive 
therapeutic agent. 
Haneberg B 149 heparin randomlzed therapeutic trial n=26: heparin: 9/11 survivors, heparin has no influence on outcome, 
no heparin 13/15 survivors 
Kuppermann N 1~ heparin retrospective, descriptive study n=24: heparin: 3/6 survivors, heparin may I'Imlt dig'it and extremity necrosis. 
no heparin 10/18 survivors 
Gerson wr'~ protein C descriptive study n=1 child (survived) could be instrumental in survival. 
Rivard GE m protein C pilot study n=4 children (all survivors) safe, possible contribution in decreaSing morbidity 
and mortality rates, 
Smith OP J11 protein C, heparin and pilot study n=12 children and young decrease in mortality and 
hemo/dla-filtration adults (all survivors) morbidity, call for a double blind randomized 
controlled trial. 
Fourrier F 11, antithrombIn III descriptive n=5 young adults could contribute in decreasing morbidity and 
(all survivors) mortalIty, 
Keeley SR'~7 tissue plasminogen activator descriptive n=1 child (survived) (rt.PA) possibility to decrease the morbidity of amputations, 
Zenz,W3IJo rt·PA descriptive n=2 children (both survivors) rt-PA may be an additional approach, 
ZenzW3g0 rt·PA deSCriptive n=2 children (all survivors) should be considered as an adjuvant therapeutic 
option. ~ A'lutoLT" rt-PA descriptive n""1 child (survived) 'Improvement of organ perfusion and cardiac 
performance. -§ 
<0-Giroir BP 132 r·BPI open, dose escalation, with n=26 children (25 survivors) marked biological effect of rBPI. ~ 
w histor'lcal controls -
'" 
w 
Chapter 1.3 
HA-1A has been evaluated in adults (236, 391) and recently in children with 
meningococcalseptic shock. In a European multicenter trial in children with meningococcal 
septic shock, the morbidity and mortality were not statistical significant different between 
children in the HA-1A and in the placebogroup (manuscript in preparation). New studies to 
evaluate the efficacy of recombinant-BPI and high density lipoproteins (HDL) in children 
with meningococcal sepsis, are recently started. A phase 2 trial of rBPI-21 showed a 
mortality of 4% in patients with a predicted mortality range of 20-50% (132). Early 
haemofiltration with plasma or whole blood exchange may be useful in the management of 
meningococcal sepsis in children (22, 273, 288, 324). However, Frieling et al. showed that 
plasma or whole blood exchange did not significantly influence IL-6 concentrations but as 
a possible side effect, did increase the soluble IL-6 receptor concentration directly after an 
exchange session followed by a rapid decrease (117). Although, several authors 
underlined the possible value of this treatment in meningococcal sepsis, no controlled 
studies are available. Inhibition of cytokines by anti-TNF-antibodies or IL-1-receptor 
antagonist showed no efficacy in patients with sepsis or septic shock (4, 72, 106, 260, 289). 
As agents to control disseminated intravascular coagulation in patients with fulminant 
meningococcemia heparin, antithrombin III concentrate, fresh frozen plasma and protein C 
concentrate have been studied (111, 112, 125, 127, 149, 153, 199,292,311). However 
with the exception of fresh frozen plasma and protein C, which have some fibrinolytic 
properties, these drugs cannot add to the dissolution of fibrin clots. Recombinant tissue 
plasminogen activator (rt-PA) is a new fibrinolytic drug. It induces a clot-selective 
fibrinolysis that is associated with only a little decrease of fibrinogen. Preliminary 
experience with rt-PA in two patients suggests that rt-PA should be considered as an 
investigational therapeutic option in patients with lifethreatening disease and no response 
to conventional treatment (6, 187,389,390). However, severe bleeding can be a serious 
side effect, because titration of the dosage is difficult in the acute phase since PAI-1 levels 
are high in the initial phase, but rapidly decrease in time. A new trial to evaluate the efficacy 
of protein C in the treatment of children with meningococcal septic shock has recently 
started. Possible future treatment modalities include r-BPI (phase 3 trial has started), C1 
esterase inhibitor, protein C, rt-PA and tissue factor pathway inhibitor. 
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CHAPTER 2.1 
AGE RELATED DIFFERENCE IN ENDOTOXIN CLEARANCE AND 
CYTOKINE RESPONSE DURING AN IN VIVO CHALLENGE TO 
MENINGOCOCCAL ENDOTOXIN IN PIGS 
Jan A. Hazelzet, Alexander B. Petrov, Rene Stubenitsky, Betsy Kuipers, Wim C.J. Hop, 
Jan T. Poolman, Ronald de Groot, Pieter D. Verdouw 
This project was supported by grant (NHS-92-360) of the 
Netherlands Heart Foundation 
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1 INTRODUCTION 
Meningococcal sepsis is a rapidly progressive, life threatening form of septic shock 
occurring mainly in children below the age of 5 years. Mortality remains high especially in 
the children below the age of 3 years despite improvements in intensive care treatments 
(158). There is no explanation for the previously documented difference in mortality 
between young and older children. Low levels of antibodies (290), immaturity of cell 
mediated immunity (375) and age related differences in coagulation response have all 
been suggested as possible explanations for this age-related difference in mortality. The 
presence of high amounts of endotoxin linked to membrane fragments (vesicles or blebs) 
of the meningococcus is a characteristic feature in patients with meningococcal sepsis. 
The plasma concentrations of endotoxin are correlated with mortality and severity of 
disease (44). Previously, several authors observed an age related increase in sensitivity to 
endotoxin in rodents (48, 68, 71, 171, 322). The toxicity of endotoxin depends upon two 
mechanisms: 1. the recognition and binding of endotoxin and 2. the endotoxin induced 
cytokine production. We studied in vivo responses to rough meningococcal endotoxin in 
young (3 weeks) and old (4 months) pigs to confirm the presence of age related differences. 
In this paper we report the findings on hematological parameters and pro- and counter-
inflammatory cytokine responses. The hemodynamic consequences of the challenge with 
endotoxin have been reported earlier (Hazelzet et al. Manuscript accepted for publication). 
2 MATERIALS AND METHODS 
2.1 Endotoxin 
Outer membrane (OM) blebs were prepared from Neisseria meningilidis group B strain 
H44/76 using a standard method (275). Briefly, bacteria were treated with 0.2 M LiCI and 
0.01 M EDTA at pH 7.0 during 2 h at 45"C. The mixture was centrifuged at 15,000 rpm for 
10 min to remove bacteria and the supernatant ultra centrifuged to peel of the outer 
membranes. The pellet was resuspended in saline with 2% sucrose and 0.02% merthiolate 
and stored in vials at4-s"C. LPS (blebs) was analyzed for KOO (2-keto-3-deoxy-O-manno-
octonate) content (186), and quantified by electrophoresis (50S-PAGE) following silver 
staining (338). The concentration of protein in the blebs mixture was 50~g/ml. 
2.2 Assays 
2.2.1 endotoxin 
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Endotoxin-free equipment and chemicals were used through all experiments. Before 
determination, plasma samples were thawed and diluted 1:10 in distilled pyrogen free 
water. All samples, standards and controls were heat-inactivated for 12 min at 75°C and 
cooled to room temperature. The chromogenic limulus lysate assay (BioWhittaker, 
Brussels, Belgium) was used. The detection limit was 0,1 EU/ml with the standard curve 
0.1-1.0 EU/ml (1 EU=0.1 ng). Duplicate plasma samples were tested in separate runs and 
the mean value was used. 
2.2.2 cytokines (TNF, IL-6, IL-10) 
Tumor necrosis factor (TNF-a) was measured with an ELISA (Predicta TNF-a, Genzyme, 
Boston, MA). Each sample was assayed in duplicate in dilutions of 1:2 and 1:10 according 
to manufacturers' instructions. Cross-reactivity of this assay with pig TNF-a has been 
demonstrated (350). 
Interleukin 6 (IL-6) was determined with the IL-6 dependent mouse hybridoma cell line 
B13.29 clone B9 (2). Plasma samples were heat inactivated at 56°C for 30 min and serial 
dilutions were incubated for 72 h with B9 cells in microliter plates. During the last 4 h of 
incubation 0.5 ~Ci of6-3H thymidine (Amersham, UK) was added. The cells were harvested 
simultaneously with a 96 well sample harvester (PharmacialLKBlWallac, Turku, Finland). 
The complete filters containing 96 spots were placed in plastic bags. Scintillation liquid 
(PharmacialLKBlWallac, Turku, Finland) was added and the bags were sealed. 
Radioactivity incorporated into DNA was measured simultaneously for 30 s with a LKBI 
Wallac 1205 Betaplate counter (Genterm Pharmacia/LKBlWallac, Turku, Finland). A 
sofiware package was used to operate the system and to calculate mean cpm and SO of 
6 replicate cultures. Recombinant IL-6 (CLB, Amsterdam, The Netherlands) was included 
as a standard. The detection limit was 0.5 pg/ml of the rIL-6. 
Interleukin 10 (IL-10) was measured with an ELISA (Medgenix, Belgium) developed for 
measuring human IL-10 (80). For this pig assay Mab clone 4C4 was used for the capture 
and 1A9 for the detection. The cross-reactivity for pig IL-10 has been established in a swine 
whole blood stimulation experiment. Detection limit is 3 pg/ml, plasma levels in healthy 
volunteers were 7.8 pg/ml. 
2.2.3 chemical analysis 
Serum lactate (Sigma Diagnostics, St Louis, USA) was measured by enzymatic end-point 
determination. White blood cell and platelet counts were determined using a cell counter 
(OSM-2, Sysmix, Kobe, Japan). 
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2.3 Animals 
land-race x Yorkshire domestic piglets of 4 months of age, 40.5±0.8 kg (n=19) and of 3 
weeks of age, 7.2±0.3 kg (mean±SEM) (n=16) were studied. The animals were randomly 
assigned to a group receiving either a low (1 ~g per kg body weight) or a high (10 ~g per 
kg body weight) dose of endotoxin, yielding a total of 4 groups of animals: old low dose (Ol) 
and old high dose (OH), and young low dose (Yl), and young high dose (YH). 
All experiments were performed in accordance with the "Guiding Principles in the Care and 
Use of laboratory Animals" as approved by the Council of the American Physiological 
Society and with the approval of the Animal Care Committee of the Erasmus University 
Rotterdam. 
The animals were fasted for 15 h prior to the surgical procedure. This procedure and the 
experimental sepsis protocol are described in detail previously (Hazelzet et al. manuscript 
submitted). Briefly: older animals were sedated with intramuscular (im) injection of 25 mgl 
kg ketamine (Ketalin®, Apharmo, Arnhem, The Netherlands), followed by induction of 
anesthesia with an intravenous (iv) injection of 10 mglkg methomidate (Hypnodil®, 
Janssen Pharmaceutical, Tilburg, The Netherlands) through an ear-vein cannula. The 
younger animals were sedated by mask inhalation of a mixture of O,tN,o mixture (1 :2) and 
isoflurane (3%), followed by induction of anesthesia with iv methomidate. All animals were 
intubated and ventilated. Anesthesia was maintained with an O,tN,O mixture (1 :2) and 
isoflurane (0.25-3%). To maintain fluid and metabolic balance, 5 mllkglhr glucose 5% in 
NaCI 0.225% was administered iv continuously. Under ster!le conditions both external 
jugular veins and common carotid arteries were surgically exposed through a ventral 
paramedian incision. On the right side a catheter was inserted and positioned in the 
descending aorta for blood sampling and measurement of arterial blood pressure; and 
through the jugular vein a thermodilution catheter (ArroW®, Reading, USA) was introduced 
and inserted into the pulmonary artery to monitor the mean pulmonary artery pressure 
(MPAP), cardiac output (CO), and central venous pressure (CVP), and to sample mixed 
venous blood. The left carotid artery was cannulated with a pressure transducer-tipped 
catheter (Sensodyn MTC®, Braun Medical, Uden, The Netherlands), which was positioned 
in the left ventricle to measure the left ventricular pressure. A separate lumen in this 
catheter was used to inject micro spheres. A catheter was inserted into the external jugular 
vein for drugs and fluid administration. Once the proper position of the catheters was 
verified, using fluoroscopy, arterial blood was sampled for in vitro analysis and all catheters 
were tunneled subcutaneously to the dorsal side of the neck and secured with sutures. 
After weaning from anesthesia and ventilation, the animals were extubated and allowed to 
recover from surgery. Catheters were protected with a vest (Tubigrip®, Seton Health Care 
group, Oldham, UK) and flushed with heparin-solution (500 IUlml) once a day. 
Prophylactically, the animals received 25 mglkg amoxicilline (Clamoxyl®, SB-Farma, 
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Rijswijk, The Netherlands) and 5 mg/kg gentamicin (A.U.v. Cuyk, The Netherlands) ivonce 
daily starting on the day of the surgical procedure. Everyday, the animals were adapted to 
the laboratory facilities (7-10 days) to ensure hemodynamic stability. The experimental 
protocols were executed when the animals could rest unrestrained and quietly for up to 4 
h, and systemic hemodynamic parameters therefore remained stable. 
2.4 Experimental sepsis 
On the day of the endotoxin protocol the needed amount of endotoxin (OM-blebs) was 
diluted with saline to a total volume of 10/20 ml (young/old). The dose of endotoxin was 
estimated from experience obtained in pilot experiments. The low dose (1 ~g/kg) was 
previously found to be non-lethal, and the high dose sub-lethal (50% mortality). Because 
of the rapid increase in pulmonary vascular resistance (259) in the early phase of endotoxin 
infusion, oxygen (3-5 I/min) was supplemented to prevent hypoxia in the initial phase. 
When the mean pulmonary artery pressure (MPAP) increased threefold (usually at 10 min), 
the endotoxin infusion was interrupted until MPAP had decreased to below 2 times the 
baseline value (usually at 30 min). At that time the infusion was restarted at a higher rate 
to end the infusion within 1 h. During the whole protocol 5 ml/kg/h fluid was iv administered 
(glucose 5% in NaCI 0.225%). After the endotoxin infusion a period of 1-2 h was allowed 
to establish a stable hemodynamic situation before starting an infusion of 30 ml/kg plasma 
(Haemaccel®, Behring Pharma, Amsterdam, The Netherlands) infused over 30 min. After 
completion of the volume loading a washout period of 2 h was taken, before termination of 
the protocol. At regular intervals (10, 30, 60, 90,120,180,240,300 min) arterial blood was 
sampled for blood gas, white blood cell and platelet count determination or centrifuged and 
stored at -70°C for later analysis. Moribund animals during the protocol were humanely 
euthanized. 
2.5 Statistical analysis 
Statistical analysis was performed using (SPSS®, Chicago, USA) Wilcoxon signed rank 
test or paired Student I-tests to compare values at baseline with subsequent time points 
within groups. Differences between groups were tested with repeated measurements 
ANOV A. When appropriate, logarithmically transformed values were used. Factors related 
to survival were tested with multiple regression analysis. Data are expressed as mean 
value ± SEM, or median (range). P values below 0.05 were considered significant. 
3 RESULTS 
3.1 In vivo response 
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3.1.1 survival and General Manifestations 
The clinical picture which evolved during infusion of endotoxin consisted of restlessness 
and even agitation in the period of sudden increase in pulmonary vascular resistance (10-
30 min after start of the infusion), tachypnea (breathing frequencies >80/min), vomiting, 
shivering, reduced reaction to stimuli and finally lethargy. This clinical picture was similar 
in all groups. The core temperature increased approximately 2°e in all four groups. There 
was no mortality in the low dose, young animal group, but 3 animals died in high dose, 
young animal group (mortality 37.5 %),1 old animal died in the low dose group (12.5 %) and 
4 old animals in the high dose group (44 %). The moment of death was 149 ± 13 min after 
the start of the endotoxin infusion. 
3.1.2 blood cell counts, endotoxin and cytokine concentration 
The baseline WBe was 11.6 (8.0-17.2) and 14.5 (10.5-22.4) 10'/L for the young and old 
animals respectively (p=0.005). In Fig: 1 the relative change from baseline is shown for the 
different age and dose groups. Already during the ET infusion there was a steep decrease 
in WBe, the lowest level was reached about 3 h after the start of the ET infusion. 
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Figure 1. Time course of white blood 
cell count, relative change from 
baseline, from young (circles) and 
old pigs (triangles), low (open) and 
high dose (closed). ET= endotoxin 
infusion, VL= volume loading. Data 
are mean ± sem; T::: significant 
change from baseline. 
From that moment the WBe in the younger animals started to increase again, while in the 
older the numbers remained low. 
The platelet count showed a comparable pattern (Fig: 2); the median levels at baseline 
were 197 (96-430) and 247 (140-529) 10'/L for the young and old animals respectively (not 
significantly different). Similar to the white blood cell count, the platelet count started to 
decrease during the ET infusion and the lowest level was reached at 180 min. 
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Figure 3. Time course of levels of endotoxin (upper panels) and TNF-a (lower panels) from young (circles) 
and old pigs (triangles), low (open) and high dose (closed). 
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The endotoxin levels are shown in Fig: 3. Maximal levels were reached for all groups at 
about 60 min, which is the end of the infusion. Medians of the maximal levels were different 
between the groups: 128 (60-315) and 2480 (354-8675) EU/ml for low vs high in the young 
animals (p < 0.001); 23 (5-200) and 641 (110-2190) EU/ml (p < 0.001) for low versus high 
in the old animals. In the low dose group of the young animals endotoxin levels were still 
elevated at 240 min; in the old this period was shorter. Also in the high dose groups this was 
different between the two ages. Repeated measurements ANOVA showed age and dose 
related differences at all time points (p < 0.001), except for 10 and 30 min. In the young 
animals the median of the maximal ET levels was 4.4 times higher than in the older animals. 
Maximal TNF levels were reached at about 60 min. Median maximal levels were: 224 (90-
488) and 323 (275-800) for the young animals; 375 (162-1031) and 581 (218-1088) for low 
vs high in the old animals (differences not significant). In the high dose old animals, the TNF 
levels remained increased for a longer period. The pattern of IL-6 response was similar 
between young and old (Fig: 4). Maximal levels were reached at about 100 min, and 
notably in the high dose groups the levels remained high during the whole experiment. 
Median maximal,levels were: 35.7 (9.0-131) ng/ml and 1000 (27.5-1500) for low vs high in 
the young animals; 57.0 (6.0-161.3) and 243.0 (3.4-2000) ng/ml for low vs high in the old 
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animals (differences not significant). Levels were at all time points affected by dose 
(RmANOVA, p=0.017). IL-10 reached maximal levels at about 60 min and also remained 
elevated, but not as high as the IL-6Ievels. RmANOVA evaluating the levels until volume 
loading showed age (p=0.047) and dose (p=0.016) related differences. At 30 min and at 
120 min the median IL-10 levels in the younger animals were significantly higher as 
compared to the older animals. Median maximal levels were 1353 (498-1682) pg/ml and 
2363 (912-2831) pg/ml for low and high dose in the young animals; 1403 (397-2051) pg/ml 
and 1444 (412-2185) pg/ml for low vs high in the old animals (no significant difference 
between the low dose groups, p=0.043 for the high dose groups). Except for the IL-6levels 
in the young animals, there was no relation between endotoxin or cytokine levels and 
survival. 
4 DISCUSSION 
The present study was designed to examine the presence of differences in cytokine 
responses in young and near adult piglets to an in vivo meningococcal endotoxin 
challenge. The major findings of the in vivo studies were that (i) there was a dose-related, 
but not an age-related difference in mortality, (ii) the same dose on weight base of 
endotoxin resulted in higher levels and longer presence of endotoxin in blood of young 
animals, (iii) despite these higher endotoxin levels in the young animals the levels of TNF 
and IL-6 were similar to the old animals, and the levels of IL-10 were slightly, but 
significantly higher in the young animals. 
The importance of the level of endotoxin in relation to severity of disease in meningococcal 
disease has well been established (43, 44, 46). Also the difference in structure (40, 81) and 
bioactivity (13) as compared to other forms of LPS has been noticed. This is the first sepsis 
model using rough meningococcal endotoxin. Purified meningococcal LPS has been used 
in small laboratory animals to study the pathophysiology of meningococcal meningitis and 
sepsis. Age related sensitivity for LPS has been studied in mice, rats and rabbits (71, 91, 
98,171,178,251,284,312,322,367). The conclusions of those studies were not uniform, 
although with the exception of neonatal animals there seems to be an age dependent 
increase in sensitivity to endotoxin. This difference in sensitivity has previously been 
explained by differences in cytokine production. In vitro LPS stimulation of monocytes from 
preterm and term neonates as well as adults resulted in lower production of IL-6 in the 
younger individuals (301,382). Antigen and mitogen induced production of IL-2, IL-4, IL-6 
and IFN-y by peripheral blood mononuclear cells from children was lower than from adults 
(216); Similarly, TNF-o:, IL-4, and IFN-y production after LPS stimulation was lower in 
mononucleated cells from cord blood versus from adult blood. In in vitro whole blood 
stimulation experiments with meningococcal LPS, we found a lower IL-6 production in 
young animals in comparison with old animals. However, this difference disappeared when 
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adult plasma was added to blood cells from young animals. Hence, LPS binding capacity 
of plasma probably plays a role in this difference in sensitivity to endotoxin. This was 
confirmed in our in vivo experiment in which an equal amount on weight base of LPS 
resulted in higher serum levels and different clearance of endotoxin in the young animals. 
Whether there also is an age related difference in cytokine production capacity is difficult 
to estimate, but at least the pattern of cytokines is different between young and old. Peak 
values of TNF were somewhat lower, although not significant, and IL-10 levels higher in 
young animals. these data were in contrast with the findings of Tadeda et al. who found 
higher levels of both TNF and IL-10 in aged animals (322). The endotoxin levels in the 
young animals were about 10 fold higher than reported in patients with meningococcal 
sepsis (44). However, it is likely that the native endotoxin binding and clearance capacity 
is exceeded more gradually in patients. In the old animals LPS was eliminated from the 
circulation with a half-life of about 1-2 h; in the young animals this was longer (3-4 h). About 
the same (1-2h) elimination rate was found in patients with meningococcal sepsis (44). 
Whether this longer elimination time has clinical consequences is not clear, but in our study 
there was no difference in mortality. LPS is probably cleared from the circulation by the liver 
and spleen. It is interesting to notice that in our hemodynamic comparison between young 
and old animals we found in the young animals after infusion with meningococcal endotoxin 
a lower increase in flow to the liver and a higher decrease in flow to the intestines and 
spleen than in the old animals (Hazelzet et al. Manuscript in press). Major plasma factors 
capable of binding endotoxin are LPS-binding protein (LBP) (55) bactericidalipermeability-
increasing protein (BPI), and lipoprotein (notably HDL) (168). LBP amplifies the activity of 
LPS, in contrast to BPI and HDL, which neutralize the effects of LPS. It has been suggested 
that endogenously derived plasma levels of BPI are likely to be inadequate to compete for 
LPS binding to the much more abundant LBP in the circulation, at least in adult volunteers 
(55). Not much is known about LBP levels in pigs, but it is most likely that the differences 
in endotoxin levels between young and old animals are caused by differences in endotoxin 
binding capacity between young and old. There is also no knowledge about LBP, BPI or 
HDL levels in meningococcal sepsis patients, but the result of a phase 1-2 study with rBPI 
were promising(132), so a phase 3 study has recently been started. Further studies will be 
necessary to examine whether these age related differences in endotoxin binding and 
clearance will have consequences for the choice of therapy in patients with meningococcal 
sepsis. 
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CHAPTER 2.2 
RELATION BETWEEN CYTOKINES AND ROUTINE LABORATORY 
PARAMETERS IN CHILDREN WITH SEPTIC SHOCK AND PURPURA 
Jan A. Hazelzet, , Edwin van der Voort" Jan Lindemans, Paul G.J. ter Heerdt and 
Herman J. Neijens 
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1 INTRODUCTION 
Septic shock combined with purpura is a clinical syndrome with a sudden onset and a rapid 
progression. Most patients are children under the age of 10 years and the infection is 
mostly caused by meningococci. The severity of the clinical condition on admission in the 
hospital and the progression with which the disease is going on may be difficult to estimate. 
For this reason several scoring systems including laboratory parameters have been 
proposed to predict the prognosis of the disease. Recently Leclerc et al (206) presented a 
study in which they indicated that there was a good correlation between the serum C-
reactive protein (CRP) level and the prognosis of children with severe infectious purpura 
and shock. Giraud et all (131) showed that in 35 adult patients with meningococcal purpura, 
low fibrinogen level (1.5 g/l) was the sole variable with prognostic value. 
The last decade, a new group of proteins, called cytokines, has been identified as important 
mediators of the host response to sepsis. Most extensively studied are probably tumor 
necrosis factor (TNF) and interleukine 1 (IL-1), especially in relation to meningococcal 
infections (56, 76, 129, 360). More recently it has become clear that another cytokine, 
interleukin 6 (lL-6), is also involved in the systemic changes during severe infections (140). 
The biological activities of IL-6 partly overlap those of IL-1 and TNF, but IL-6 is probably 
also involved in the regulation of TNF and IL-1 production (302). IL-6 is secreted by 
macro phages, fibroblasts, and endothelial cells, it stimulates the synthesis of acute-phase 
proteins and is an endogenous pyrogen. 
During acute admission of a patient with septic shock several laboratory parameters are 
routinely determined to estimate the clinical condition of the patient, for instance: lactate as 
end-product of anaerobic metabolism, a marker of cellular hypoxia, C-reactive protein 
(CRP) as acute-phase protein a marker for inflammation and tissue injury, and fibrinogen, 
an acute-phase protein and coagulation factor. 
The aims of this study were to investigate the relation between cytokines and these 
established laboratory parameters on admission and the association of these parameters 
to the severity of the disease. This relation so far, has not been studied in children with 
septic shock and purpura. 
2 PATIENTS AND METHODS 
The study protocol was approved by the Institutional Review Board, and this Board waved 
the need for informed consent. 
patients. The patients who were studied were all admitted to the Pediatric Intensive Care 
Unit from the Sophia Children's Hospital in Rotterdam with the suspicion of severe 
infectious purpura i.e a clinical diagnosis of sepsis (manifested by two or more of the 
58 
Chapter 2.2 
following conditions: temperature> 38.5°C or < 36°C; heart rate above 2 s.d of the age 
related mean normal value; respiratory rate> 25 breaths per minute; and white blood cell 
count> 12.000/mm3 , or < 4000/mm3 ), in combination with petechiae andlor pupura. The 
patients were divided into a shock-group and a nonshock-group, according to standard 
criteria ( two or more of the following features: systolic blood pressure below 2 s.d of the 
age-related mean normal value, diuresis less than 0.8 mllkglhr, capillary refill time more 
than 3 s, need for inotropic support, sudden change in mental state). The PRISM-score 
(274) was recorded using the most abnormal value of each parameter recorded in the first 
4 hours after admission. 
assays. On admission arterial blood was sampled as soon as possible: one ml was 
collected in fluoride-oxalate for measurement of lactate, one ml was taken in citrate for 
determination of fibrinogen, two ml were allowed to clot and serum stored at -70°C for 
measurement of cytokines and CRP in a later stage. 
Lactate was measured by enzymatic end-point determination (228), CRP by immuno-
nephelometric assay (315), and fibrinogen by standard procedures (69). 
TNF and IL-1 were measured using an immunoradiometric assay for quantative 
measurement (IRMA, Medgenix Diagnostics Benelux), and IL-6 by using an enzyme 
amplified sensitivity immuno-assay (EASIA, Medgenix Diagnostics Benelux). These 
assays measure free and recptor-complexed cytokines. 
statistical analysis. Differences between patient groups were analyzed using the unpaired 
two-tailed Student's t-test with separate variance estimation. The logarithmic values of the 
cytokine concentrations were used in this test. Relationships of cytokines to laboratory 
parameters were determined by calculating the Spearman correlation coefficient and a 
two-tailed significance. 
3 RESULTS 
From August 1989 till July 1990 seventeen patients fulfilled the criteria. In 15 patients 
Neisseria meningitidis and in 2 patients Haemophilus influenza was isolated in blood andl 
or cerebrospinal fluid. Inotropic support was started only in one patient within 0.5 hour 
before admission, in the other patients when necessary after admission. According to the 
defined criteria 9 patients were in shock of whom 4 did not survive. The laller 4 patients 
were considered a separate group. 
The values of lactate, fibrinogen, CRP, TNF, IL-1, and 6 for the different groups are 
presented in Fig. 1. Significant differences exist between all three groups concerning 
lactate, TNF, and IL-6. Fibrinogen, CRP and IL-1 discriminate only between survivors and 
non-survivors. Regarding the PRISM-scores, there were only significant (p<0.01) 
differences between survivors (10.1±6) and non-survivors (30.5±10) 
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A highly significant correlation (Table 1) exists between cytokines, the PRISM-score and 
lactate (TNF: r=0.69, IL-1: r=0.56, IL-6: r=0.65, PRISM: r=0.65). A significant inverse 
correlation exists between cytokines and CRP ( TNF: r=-0.55, IL-1: r=-0.64, and 11-6: r=-
0.56), and IL-6 and fibrinogen (r=-0.65). No significant correlations are found between 
TNF, IL-1, PRISM and fibrinogen, and PRISM and CRP. 
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Figure 1. Serum concentrations for cytokines (TNF, IL-1, and IL6) and routine laboratory data (CRP, 
fibrinogen, and lactate) on admission for the 3 groups (triangles represent non·shock patients, open circles 
shock patients who survived, and the closed circles are shock patients who did not survive). 
Table 1. Non·1inear correlalion·coefficients (Spearman) between routine laboratory parameters, PRISM-
score and cytokines, and linear correlation coefficients between laboratory parameters and PRISM·score. 
lactate CRP fibrinogen PRISM 
TNF 0.71·· -0.50· -0.43 0.66·· 
IL-1 0.56· -0.64·· -0.05 0.49 
IL-6 0.67"" -0.51" -0.65· 0.79··· 
PRISM 0.65·· -0.50 -0.57 
p=O.OS 
p=0.01 
p=0.001 
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4 DISCUSSION 
Septic shock with purpura is a life threatening clinical syndrome with an 
overwhelming course and is frequently fatal. Most often it is caused by severe 
meningococcal disease (SMD) and the highest incidence is found in children under the age 
of 10 years. In The Netherlands the attack rate of meningococcal sepsis has increased 
from 100 cases in 1986 to 320 in 1991 on a total number of 15 million inhabitants. This 
increase has also been reported in other countries in Europe. On admission of those 
patients, it is not always easy to estimate the severity of the clinical situation. Nevertheless, 
one has to decide on the necessity for aggressive therapy and the level of supportive care. 
As we are more and more aware, septic shock is initiated by peripheral cellular alterations 
that lead to systemic dysfunction and organ failure. Some of these functional alterations 
may be caused directly by the infectious organisms or their products. An important portion 
of the pathogenesis however is mediated by endogenous host factors, particularly 
cytokines (56). In clinical studies, especially in SMD, the presence and concentration of 
TNF, IL-1, and IL-6 in serum turned oulto be related to severity of disease and survival (57, 
76, 109, 129, 131, 140, 249, 320, 360). Also the results in this study confirm the existence 
of a clear relation between the serum levels ofTNF and IL-6 and both severity and survival 
of pediatric SMD-patients. A practical drawback of cytokines is the time required for the 
performance of the assays, taking several hours or even a day. Routine laboratory 
parameters like lactate, CRP and fibrinogen are easier and much faster to determine, but 
their relations to the level of cytokines and the severity of the disease have not been 
completely elucidated in SMD. Lactate, an end-product of anaerobic metabolism and in this 
way a marker of cellular dysfunction and tissue hypoperfusion (240), proved in this study 
to correlate well with severity of disease. Most of the studies regarding lactate in critically 
ill patients are in agreement with these results (140, 240, 285). However in a recently 
published study no significant difference in lactate was found between survivors and non-
survivors in septic patients (90). 
In our study a negative correlation was found between CRP-Ievel and severity of disease 
with a significant difference between survivors and non-survivors. This is in agreement with 
the study of Leclerc (206). Other clinical studies on septic shock patients (90, 140), burn 
patients (249, 383), and experimental studies (109), have presented positive correlations 
between CRP or other acute phase proteins and survival. CRP has been demonstrated to 
bind to damaged tissue in vivo. When bound, CRP is capable of activating the complement 
system via the classical pathway (383). In addition, CRP stimulates the secretion of TNF, 
IL-1, IL-6, resulting in a self-amplifying inflammatory sequence (56, 383) and in this way 
plays a critical role in the inflammatory response to infection and injury. Nevertheless, a 
negative correlation between CRP and the level of cytokines was found. An explanation for 
this phenomenon might be either that in SMD, CRP is massively bound in the initial phase 
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of the illness or the fact that GRP may not yet have had enough time to increase in severe 
SMD. Peltola (267) described a group of patients with epiglottitis in whom the GRP level 
was related to the duration of the history. Leclerc found no relation between GRP level and 
the time between measurement and onset of symptoms (206). 
We found significant differences in the fibrinogen level between survivors and non-
survivors. There was a negative, non-significant correlation between fibrinogen and 
cytokines. These results are also described in other studies (129, 131). Fibrinogen is an 
acute phase protein, which is increased during infections and inflammation. It is an 
important clotting factor and the level is decreased during diffuse intravascular coagulation 
(DIG). In SMD the level of fibrinogen probably reflects more the severity olthe DIG, than the 
extent of the acute phase protein reaction. 
The serum levels of cytokines and lactate correlated well with the PRISM-score, which in 
another way suggests their relation with the severity of the disease. 
5 CONCLUSIONS 
A log-linear, positive relation exists between cytokines and arterial plasma lactate in 
children with septic shock and purpura. In this condition we observed a negative, 
exponential relation between cytokines and GRP, and fibrinogen on admission. Gytokines, 
as well as lactate, GRP and fibrinogen have a good prognostic value for survival. However 
lactate, TNF and IL -6 correlate significantly with the PRISM-score and differentiate also for 
the severity of the disease. These parameters can be used to select patient groups for the 
use of new therapeutic modalities, to follow the effect of these therapies, and to compare 
patient groups. 
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1 INTRODUCTION 
Septic shock with purpura is a clinical syndrome predominantly caused by N. meningitidis 
and characterized by a sudden onset and rapid progression of disease. Children younger 
than 10 years are most frequently affected. Lipopolysaccharide (LPS) released from gram-
negative bacteria such as meningococci initiate the production of pro-inflammatory 
cytokines by cells of the mononuclear-macrophage lineage and endothelial cells. 
Circulating levels of these cytokines, including tumor necrosis factor (TNF)-o:, interleukin 
(IL)-1 (360), IL-6 (154,366), IL-8 (145), and IL-10 (85,195), are increased in children with 
septic shock and purpura. Severity of disease is related to the initial plasma levels of LPS 
(44) and of these cytokines. 
Interleukin 12 (IL-12) is a recently described cytokine (191,333) initially called natural killer 
cell stimulatory factor or cytotoxic lymphocyte maturation factor. Among cytokines, IL-12 is 
unique in that it is a heterodimeric protein composed of two different polypeptide subunits, 
p40 and p35 (for review: (65, 332, 333, 335-337». The precise role of IL-12 in vivo is not 
known, although this cytokine seems to playa key role in the differentiation ofTh1 cells (65, 
218), and in the host defense against bacterial, parasitic and viral infections (333). IL-12 
also induces the production of interferon (lFN)-y by T-cells and natural killer (NK)-cells 
(163,381). The plasma levels of IFN-y are increased in experimental models for sepsis 
(49, 162, 129) as well as in human sepsis (54, 129), although not consistently (360). 
Recently, IL-12 was characterized as a major cytokine in the pathogenesis of gram-
negative endotoxemia in mice (163) and in primates (182). We therefore questioned 
whether IL-12 and IFN-y playa role in the pathogenesis of septic shock and purpura in 
humans. To this purpose initial plasma levels of IL-12 and IFN-y were measured in children 
with this disease and their relation with outcome and severity of disease were studied. In 
addition, plasma levels of TNF-o:, IL-6, IL-8, and IL-10 were determined and the possible 
correlation between these cytokines and IL-12 and IFN-y, respectively, was studied. 
2 RESULTS 
2.1 Patients 
Forty-six patients admitted to the PICU were enrolled in the study: 29 males (63%) and 17 
females (37%). The median age was 3.4 years (range 0.5-17.9). Cultures of blood, 
cerebrospinal fluid or skin biopsies revealed Neisseria meningitidis in 40 patients and 
Haemophilus influenzae in 1 patient. Cultures were sterile in 5 patients. Thirty-one (67%) 
patients needed mechanical ventilation. Forty-four of the children participated in a 
randomized, placebo controlled trial to study the efficacy of a human monoclonal antibody, 
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HA-1-A (Centoxin®, Centocor, Malvern, PA, USA), in meningococcal septic shock. HA-1-
A or placebo were administered after blood was collected for the determination of cytokines 
and other laboratory parameters. Twenty four of these patients were treated with a 
placebo, 17 patients survived (71 %) 7 patients died (29%). The results of only these 24 
patients were used for outcome analysis. 
2.2 Clinical and laboratory parameters 
Clinical and laboratory parameters obtained on admission (PRISM-score, arterial lactate, 
WBC, serum levels of glucose and CRP) for the total group and separately for survivors and 
non-survivors of the placebo group, are indicated in Table 1. As expected, all parameters 
were significantly associated with outcome. 
Table 1. Clinical and laboratory parameters on admission of children with septic shock with 
purpura and their relation with outcome 
Tolal group Survivors* Non-survlvors* p valueH 
(N =46) (N = 17) (N = 7) 
Age (years) 3.8 (0.5-17.9) 4.9 (0.5-17.9) 2.2 (1.4-12.3) 0.259 
Male I female 29/17 918 3/4 0.653 
PRISM (score) 13(1-38) 9 (1-20) 21 (17-25) <0.001 
Lactate (mmol!l) 5.0 (1.1-20.0) 4.2 (1.1-15.5) 7.2 (4.0-20.0) 0.047 
WBC (x10'1I) 9.2 (1.3-44.4) 17.0 (6.1-44.4) 4.9 (1.3-8.2) <0.001 
GlUcose (mmol/O 5.6 (1.0-14.2) 8.4 (1.9-14.2) 2.8 (1.0·10.1) n.s 
CRP (mgll) 110 (34-250) 167 (39-250) 70 (38-162) 0.002 
All data shown are median (range); *dala shown were obtained in patients that did not receive mAb; 
p-value for the difference between survivors and non-suvivors (Mann Whitney U-test). 
2.3 IL-12 p40 and p70 levels on admission 
Levels of IL-12 p40 in surviving (and also in non-surviving) patients were significantly 
higher than in the controls (p=< 0.001).The median (range) plasma IL-12 p40 level on 
admission (Fig. 1) was 457 (244-2677) pg/ml in non-survivors versus 189 (40-521) pg/ml 
in survivors (p= < 0.001). In contrast, IL-12 p70 was elevated in only9 patients. The median 
level of IL-12 p40 for those patients with detectable IL-12 p70 levels (n = 9) was 
significantly higher (p= 0.007) in comparison with those without detectable levels of IL-12 
p70 (n = 32): 457 (76-2677) and 207 (40-1007), respectively. The ratio (p40/p70) in the 9 
patients with detectable IL-12 p70 levels was 117 (26-203) (Fig. 2). 
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Figure 1. Plasma levels of IL·12 p40 on admission ofchifdren with septic shock with purpura (placebo treated, 
n=24) and of healthy controls (0=26). Solid lines represent median values. Dotted lines indicate the range of 
normal values. 
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Figure 2. Scattergram of IL-12 p40 versus IL-12 p70. Data represent the levels on admission. Dotted lines 
represent the lower detection limits. 
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2.4 Relation between IL-12 and other cytokines on admission 
IL-12 p40 plasma levels on admission were positively correlated with TNF-, IL-6, IL-B, and 
IL-10 (Table 2). The association between IL-12 p70 and the other cytokines was different 
in comparison with that between IL-12 p40 and the other cytokines. Patients with 
detectable IL-12 p70 levels had significantly higher levels of IL-B (p = 0.042) and IL-12 p40 
(p = 0.007) levels than patients with undeteclable levels of IL-12 p70. 
Table 2. Correlation between IL~12 p40 and TNF~, IL·6, IL·S, or IL~10 on admission of children with septic 
shock and purpura 
IL-12 p40 
(N = 41) 
" 
P value 
TNF·a 0.45 0.003 
IL-6 0.56 <0.001 
IL-8 0.60 <0.001 
IL-10 0.51 0.001 
* Spearman's rank coefficient of correlation. 
2.5 Relation of IL-12 to clinical and laboratory parameters 
A negative correlation was found between CRP levels or WBC versus plasma IL-12 p40 
levels (Table 3). Plasma IL-12 p40 levels correlated positively with the PRISM-score and 
negatively with serum glucose levels. Patients with detectable levels of IL-12 p70 had 
significantly lower serum glucose levels (p = 0.019). 
Table 3. Correlation between IL-12 p40 and several clinical or laboratory parameters on admission of 
children with septic shock and purpura 
PRISM 
lactate 
WBC 
Glucose 
CRP 
" 
0.42 
0.16 
-0.56 
-0.39 
-0.33 
IL-12 p40 
(N = 44) 
* Spearman's rank coefficient of correlation. 
p value 
0.005 
0.286 
<0.001 
0.01 
0.028 
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2.6 Interferon-y 
Twelve oflhe 41 (29 %) patients had detectable levels of IFN-y. In those 12 patients. levels 
ofTNF-a, IL-6, IL-8, and IL-10, but not IL-12 p40 were significantly (p < 0.005) increased 
in comparison with patients with undetectable levels of IFN-y. In addition, those 12 patients 
had significantly (p < 0.005) lower WBC and a significantly (p < 0.05) higher serum lactate. 
From the 9 patients with a detectable level of IL-12 p70, 5 had a detectable level of IFN-y 
(56%), while from the 30 patients without detectable levels of IL-12 p70, only 6 had a 
detectable level of IFN-y (20%). Due to small numbers this difference just did not reach 
statistical significance (p=0.08). 
3 DISCUSSION 
This is the first report showing that levels of IL-12 p40, and to a lesser extent those of IL-
12 p70, are elevated in meningococcal sepsis. Plasma levels of IL-12 p40 were related to 
outcome and to severity of disease. 
IL-12 or NK cell stimulatory factor is a recently described (191) heterodimeric cytokine. 
which appears to play an important role as a functional bridge between natural resistance 
and adaptive immune response (332). During endotoxemia in mice, IL-12, both p40 and 
p70, was detected shortly after injection of LPS. Bioactive IL-12 circulated in serum before 
the appearance of IFN-y. Pretreatment with anti-IL-12 antibodies blocked the production 
of IFN-y (163), thus protecting against lethality (262). Similar findings were reported in a 
model of a generalized Shwartzmann reaction in mice (381). In baboons challenged with 
Escherichia coli (182), the systemic release of IL-12 p40 and p70 was also reported. Our 
study confirms that circulating levels of IL-12 are also increased in human sepsis. 
IL-12 p70 was detected in only 9 of the patients and these levels were only slightly 
increased. In these 9 children IL-8, IL-12 p40 and IFN-y levels were significantly higher 
than in patients with undetectable IL-12 p70. Levels of p40 were approximately 100 times 
higher than those of p70. Such an excess-production of IL-12 p40 was also found in in vitro 
experiments with human peripheral mononuclear (65, 78) and polymorphonuclear cells 
(63) as well as in septic baboons (182) The physiological significance of this excess-
production of the free p40 subunit in comparison with the biologically active p70 
heterodimer is not clear. It has been suggested that the p40 subunit has a biological activity 
distinct from that of p 70 heterodimer. Matlner et al. have suggested that IL-12 bioactivity is 
inhibited by free p40 molecules (235). Studies by Ling et al. (217) revealed that human p40. 
as described in mice, exists in a monomeric and dimeric form. Again as in mice, the dimeric 
form was at least 20-fold more effective than the monomer to inhibit the activity of IL-12 or 
its binding to human IL-12 receptor (IL-12R). However, in contrast to the mouse 
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homodimer, which binds to the mouse IL-12R with similar affinity as heterodimeric mouse 
IL-12 itself, the receptor binding and bioactivity of the human homodimer were only 10 % 
of the receptor binding and bioactivity of the human heterodimer. Perhaps the excess 
production of p40 in relation to the p70 has a regulatory role (126). Nevertheless, in vitro an 
in vivo studies have clearly shown that the production of p40 is linked to that of IL-12 (182, 
333), and hence elevated levels of p40 subunit in our patients probably reflected the 
production of bioactive IL-12. Consistent herewith was the observation that patients with 
detectable IL-12 p70 levels had higher IL-12 p40 levels than those without detectable IL-
12 p70 levels. Apparently the threshold of the IL-12 p70 assay is too high. 
The positive correlation between plasma levels of IL-12 p40 or p70, and other 
proinflammatory cytokines, was not surprising since this probably reflects stimulation of 
cells by endotoxins. However, plasma levels of IL-10, a counter-inflammatory cytokine, 
also correlated positively with IL-12. In vitro, IL-1 0 is a potent inhibitor of LPS-dependent IL-
12 production (63, 79, 122). Moreover, a negative correlation between IL-10 and IL-12 was 
found in baboons with sepsis suggesting that IL-10 downregulates the release of IL-12 in 
this sepsis model (182). Thus, the positive correlation between IL-12 and IL-10 in our 
patients was in contrast to the findings in baboons. We propose that the synthesis of pro-
and anti-inflammatory cytokines is so strongly and continuously stimulated (44, 195) in 
patients with meningococcal sepsis, that counterregulatory mechanisms are insufficient to 
suppress excessive production. 
IL-12 can induce IFN-y production by T- and NK-cells in the presence of cofactors as TNF-
Ct. or IL-1 fl (191). The role of IFN-y during in vitro LPS-challenge (77), in vivo endotoxemia 
in mice (44, 162, 163, 193, 381), or the generalized Shwartzmann reaction in mice (26, 27, 
262), has well been established. Disseminated intravascular coagulation and shock 
associated with meningococcal sepsis are considered to be the clinical counterparts of the 
"classical" generalized Shwartzmann reaction. However, it is not known whether IFN-y 
similarly contributes to mortality in human sepsis. IFN-y levels and outcome were not 
correlated in adult patients with septic shock (541) and in children with meningococcal 
septic shock (360). In contrast, Girardin et al. reported high levels of IFN-y in children with 
severe meningococcal septic shock. Their plasma concentrations of IFN-y were related to 
severity of the disease and correlated with serum levels of TNF-Ct. (129). In our study only 
12 patients had plasma IFN-y levels above the detection limit. Those children also had 
significantly higher levels of other cytokines. The proportion of children that had elevated 
IL-12 p70 levels was higher, although just not significantly, in the group with detectable IFN-
y, compared to the group with undetectable IFN-y. A possible explanation for the absence 
of a relation between IFN-y and IL-12 p40 is that these cytokines were not released 
simultaneously, as was observed in animal models for sepsis (182). 
The clinical and laboratory parameters in this study are commonly used to assess the 
severity of disease in patients with meningococcal septic shock. PRISM score is a scoring 
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system to calculate the risk of mortality in pediatric intensive care patients (274). Serum 
lactate is related to the degree of circulatory failure (159). WBC and CRP are negatively 
correlated with the fulminant evolution of meningococcal septic shock (205, 206). Low 
serum glucose levels are reported by some authors (93), although this finding is not well 
understood. IL-12 p40 levels in our patients, correlated with all these parameters reflecting 
severity of the disease, except for serum lactate. IL-12 p70 was only related to low serum 
glucose. IFN-y was negatively related to the WBC. 
In conclusion, this study is the first to report a systemic release of IL-12 and its relation with 
outcome, severity of disease and other cytokines, in children with septic shock and 
purpura. We suggest that new immunomodulatory agents in sepsis should also be studied 
for their effects on IL-12 production. 
3.1 Patients and Methods 
3.1.1 study protocol 
Children above 3 months and below 18 years of age with septic shock and petechiae/ 
purpura were enrolled in this study. Primary or secondary referrals were admitted to the 
pediatric intensive care unit (PICU) of the Sophia Children's Hospital between April 1991 
and October 1994 Patients were eligible for inclusion when they met the following criteria: 
1. presence of petechiae/purpura for less than 12 hours; 2. presence of shock defined as 
sustained hypotension (systolic blood pressure < 75 mm Hg for children between 3-12 
months, < 80 mm Hg for 1-5 years, < 85 mm Hg for 6-12 years, < 100 mm Hg for children 
older than 12 years) requiring intensive care treatment, or evidence of poor end-organ 
perfusion, defined as at least two of the following: a. unexplained metabolic acidosis (pH ,; 
7.3 or base excess" -5 mmolll or plasma lactate levels> 2 mmol/I); b. arterial hypoxia 
(PaO," 75 mm Hg, a PaO,lFiO, ratio < 250, or a transcutaneous SaO,'; 0.96) in patients 
without overt cardiopulmonary disease; c. acute renal failure (diuresis < 0.5 ml/kg/hr for at 
least one hour despite acute volume-loading or evidence of adequate intravascular 
volume) without preexisting renal disease; or d. sudden deterioration of the baseline 
mental status. The pediatric risk of mortality (PRISM) score (274) was calculated using the 
most abnormal value of each variable recorded during the first 4 hours after admission at 
the PICU. All patients received maximal supportive therapy: antibiotics, volume suppletion, 
inotropic support, and mechanical ventilation. Informed consent was obtained from the 
parents or legal representatives. The Medical Ethics Committee of the University Hospital 
Rotterdam approved the study protocol. 
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3.1.2 collection of blood 
On admission arterial blood was collected within two hours. Blood for cytokine analysis was 
collected in vials containing 3.8% trisodium citrate. immediately chilled on ice. and 
centrifuged at 2800 g for 15 minutes and then at 45000 g for 30 minutes at +4°C. Plasma 
was stored at -70°C until tests were performed. 
3.1.3 assays 
White blood cell count (WBC), as well as lactate, glucose and C-reactive protein (CRP) 
levels were determined routinely. WBC were determined using a flow cytometer 
(Technicon H1-system, Technicon Instruments, N.Y.). Lactate was measured by 
enzymatic endpoint determination. CRP by a nephelometric assay (315). 
Plasma levels ofTNF-o:, IL-6, IL-8, IL-10, and IFN-y were measured with enzyme-linked 
immunosorbent assays obtained from the Department of Immune Reagents (Central 
Laboratory of the Bloodtransfusion service CLB, Amsterdam) and were performed 
according to manufacturers' instructions. Normal levels (detection limit, taking the dilution 
of samples into account) for these assays are: < 5 (1 pg/ml) for TNF-o:; < 10 (1 pglml) for 
IL-6; < 20 (4 pg/ml) for IL-8; < 30 (30 pg/ml) for IL-10; < 10 (2 pg/ml) for IFN-y. 
3.1.4 assays of IL-12 
IL-12 p40 antigen was measured with an ELISA (278). Briefly, mAbC11. 79 and biotinylated 
mAbC8.6, both directed against the IL-12 p40 subunit (78), were used as coating and 
detecting antibodies, respectively. Streptavidin polymerized horseradish peroxidase 
(poly-HRP; CLB, Amsterdam, The Netherlands) was used to quantify bound antigen. 
Recombinant human p40 was used as a standard. Taking the dilution of tested samples 
into account, the lower limit of detection was 20 pglml. Normal values in 21 healthy adults 
were'; 160 pglml. We measured the IL-12 p40 levels in 5 normal children age: 43 months 
(36-48), the median value was: 28 pglml. As levels of IL-12 p40 were similar in children and 
adults (and healthy children of young age are difficult to obtain blood from), we used both 
groups together as control for the septic children. 
IL-12 p70 antigen was measured using a newly developed ELISA (182). Shortly, 
mAb20C2, which has relative specificity for the IL-12 p70 heterodimer (78), and mAb C8.6 
were used as a capture and detecting antibodies, respectively. The ELISA did not measure 
recombinant human p40 unless concentrations > 20 nglml were tested. In contrast, 
recombinant human p70, which was used as a standard, could be detected at 
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concentrations as low as 0.25 pglml. To avoid cross reaction with the p40 chain, plasma 
samples were analyzed at least at a tenfold dilution. Therefore, the actual detection limit 
was 2.5 pglml. Normal values are below this detection limit. 
3.1.5 statistical analysis 
Results are expressed as medians (range) unless otherwise specified. Differences 
between groups were tested with the Mann-Whitney U-test or Fisher's exact test in case of 
percentages. Correlation coefficients given are Spearman's. Two-tailed p values'; 0.05 
were considered statistically significant. 
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CHAPTER 3.1 
PROTEIN C AND S DEFICIENCY IN SEVERE INFECTIOUS PURPURA 
OF CHILDREN: A COLLABORATIVE STUDY OF 40 CASES 
F Leclerc, J.A Hazelze!, B. Jude, W. Hofhuis, V. Hue,A. Martino! E. Van der Voort 
In!ens Care Med 1992; 18:202-5 
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1 INTRODUCTION 
Protein C (PC) and protein S (PS) are vitamin K dependent plasma proteins synthesized 
in the liver. In vitro studies have shown that, when PC is cleaved by thrombin in the 
presence of thrombomodulin, the activated PC thus formed is a potent anticoagulant and 
promotes fibrinolysis; PS serves as the cofactor for activated PC anticoagulant and 
fibrinolytic activities (70). 
Microvascular thrombosis and skin necrosis with disseminated intravascular coagulation 
occur in severe infectious purpura (204, 205) in which PC and PS deficiencies have been 
reported (46, 222, 230, 280), and in homozygous PC deficiency (231) and homozygous PS 
deficiency (224). 
The aim of this study was to examine, in severe infectious purpura of children, the 
relationships between PC and PS levels determined on admission, and shock, DIC, and 
outcome. 
2 METHODS 
Forty consecutive children, hospitalized with severe infectious purpura in Rotterdam (n = 
22) and Lille (n = 18) between January 1988 and February 1990, were prospectively 
studied. Mean age was 52 months (ranging from 6 -185 months). Purpura on admission 
was petechial in 11, ecchymotic in 20, and necrotic in 9. Neisseria meningilidis was 
recovered from 29 children and Hemophilus influenzae from one. No organism was 
identified in the remaining children, but in these cases antibiotics were started before 
admission. 
Shock was defined (205) by two of the following criteria: systolic blood pressure less than 
2 standard deviations of normal (144), capillary refill time longer than 3 s, and urine output 
less then 1 ml/kg/h. 
The hemostatic studies, on admission, consisted of platelets, fibrinogen, factors II, V, VII, 
X, fibrin degradation products, and fibrin monomer measurements. We also determined on 
admission, antithrombin III (AT III) activity and PC activity by chromogenic test 
(StagoFrance), PC antigen and total PS by ELISA (Stago-France); in 16 children from Lille, 
free PS was determined by ELISA (Stago-France). Results were expressed as % of 
normal adult values. DIC was defined by the combination of 3 of the following features: 
platelet count less than 150x109/1, fibrinogen less than 2g/l, factor V less than 60%, and 
presence of fibrinogen degradation products or fibrin monomers. 
Statistical analysis was performed using Wilcoxon rank-sum test, and analysis of 
covariance for age-adjusted comparisons, with a general linear model procedure 
(Statistical Analysis System, Cary, NC). 
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3 RESULTS 
Mean age, frequency of shock and DIG, between children from Rotterdam and those from 
Lille were not statistically different. Mean age between shock and non-shock children, 
between children with and without DIG, and between survivors and non-survivors, were not 
statistically different. 
Of the 30 children in shock, 20 had DIG. All children with DIG, and 10 without DIG were in 
shock. Of 20 children who were in shock and had DIG, 7 died (2 from Rotterdam and 5 from 
Lille: difference not significant) and 3 survived with amputation; no child without shock or 
DIG died. 
Gammon hemostatic variables are shown in Table 1. In our children as a whole, factor II 
levels correlated with PG antigen, PG activity, and total PS levels (p<0.005); factor VII 
levels correlated with PG activity levels (p< 0.05), but did not correlatie with PG antigen, and 
total PS levels; factor X levels correlated with PG antigen, PG activity, and total PS level (p< 
0.05). PG antigen, PG activity and total PS levels in the different groups of children are 
shown in Figs. 1 - 3. 
Table 1. Hemostatic variables (mean ± SO) on admission in 40 children with severe infectious purpura 
Variable Shock + Shock - DIG+ DIG- Nan-survivors Survivors 
(N = 30) (N = 10) (N = 20) (N = 20) (N = 7) (N = 33) 
Plalelels (10'/1) 103 ± 14 u 217 ± 29 60±37~H 203 ± 81 44 ± 18 H 150 ± 95 
Fibrinogen (gil) 2.8 ± 2.7" 5±1.4 1.3± 1 a* 5.4 ± 2.1 0.3 ± 0.4 a* 4 ± 2.4 
Factor II (%) 50± 27 * 66 ± 13 36±18 HT 72 ± 16 2S±18** 60±22 
Factor V (%) 44 ± 39' 74 ± 30 21 ± 14*** 80 ± 32 11 ± 7" 60 ± 37 
Faclor VII (%) 25 ± 20 32 ± 17 19 ± 11 33 ± 22 20 ± 14 28±20 
Factor X (%) 58 ± 39 56 ± 25 41 ± 18" 73 ± 41 32 ± 20 63 ± 35 
DIC, disseminated intravascular coagulation; +, present; - absent; "p<O.05; Hp<O.005; Hp<O.OOO1 
PG antigen and PG activity were significantly decreased in shock children, in children with 
DIG, and in non-survivors. Age-adjusted levels of PG antigen and PG activity were also 
significantly decreased in shock children, in children with DIG, and in non-survivors (PG 
antigen: shock children/non-shock children (p<0.05), children with DIG/children without 
DIG (p<0.0005», non-survivors/survivors (p<0.05); PG activity: shock children/non-shock 
children (p<0.05), children with DIG/children without DIG (p<O.0005), non-survivors/ 
survivors (p<0.005). Total PS was not different between shock and non-shock children but 
was significantly decreased in children with DIG and in non-survivors. Age-adjusted levels 
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Figure 1. Protein C antigen levels on 
admission (mean ±SO) expressed as % of 
normal adult values in severe infectious 
purpura, DIG, disseminated intravascular 
coagulation; +, present; w, absent. 
Figure 2. Protein C activity [evels on 
admission (mean ±SO) expressed as % of 
normal adult values in severe infectious 
purpura, DIG, disseminated intravascular 
coagulation; +, present; -, absent. 
Figure 3. Total protein S levels on 
admission (mean ±SO) expressed as % of 
normal adult values in severe Infectious 
purpura, DIG, disseminated intravascular 
coagualation; +, present; -, absent. 
of total PS were also significantly decreased in children with DIG (p< 0.005), and in non-
survivors (p < 0.005). In the 16 children in whom free PS levels were determined, free PS 
level (mean ± so = 36±15) correlated (p<0.005) with total PS levels (mean ± SO = 39 ± 18); 
because of the small number of free PS level determinations, comparisons between the 
different groups were not performed. AT III activity was also significantly decreased in 
shock children (shock children: 55±21 /non-shock children: 73±19; p<0.05), in children with 
DIG (children with DIG: 47±16/children without DIG: 72±20; p<0.0005), and in non-
survivors (non-survivors: 42 ± 22/survivors: 63 ± 20; p<O.05). 
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4 DISCUSSION 
On admission of our patients, PC deficieney was always present, even in the absence of 
shock and DIC; PC deficiency could not be explained by age because Nardi et al. showed 
that PC levels were in the adult range by 1 year of age (246): only 4 of our 40 children were 
younger than 1 year. Moreover, PC antigen and PC activity levels in our patients were 
under 75.8 % ± 11 %, the value given by Nardi et al. in children between 8-12 months of age 
(246). Acquired PC deficiency was reported by Griffin et al. in adult patients with DIC: 6 of 
9 adult patients with severe infection in the absence of liver disease had decreased PC 
level (patients who died had a lower PC level than those who survived, but there was no 
significant difference); however 5 of 15 patients without fibrinogen degradation products 
had a decreased PC level (136). PS deficiency was also reported in adult patients with DIC 
(160). 
PC and PS deficiencies were reported by Fourrier et al. in 5 adult patients with severe 
infectious purpura who survived (112). Since the report from Marlar et al. (1 case with 
meningococcal sepsis) (230), Powars et al. reported acquired PC and PS deficiencies in 6 
children with meningococcemia and purpura fulminans (280). Brandtzaeg et al. studied 13 
children with fulminant meningococcal septicemia; in these children PC levels were lower 
than in children with meningococcal meningitis and meningococcemia with shock, but PC 
levels were not different between survivors and non-survivors (46). Blanco et al. reported 
PC deficiency in 23 children with meningococcal sepsis; surprisingly, PC levels were not 
different in children with DIC as compared with those without DIC (28). Madden et al. 
recently reported 2 children with infectious purpura fulminans and PC and PS deficiency 
(222). In 1 patient of Powars et al. (280), in the 2 patients of Madden et al. (222), and in 4 
of our patients, PC level was measured after recovery: it rose to normal value; this excluded 
congenital PC deficiency revealed by an infection as reported by Ozsoylu et al. (263). 
PC level depression in DIC is probably due to ongoing consumption of the protein and not 
to impaired synthesis: Heeb et al. have demonstrated that in many cases of DIC, PC is 
activated and complexed with a PC inhibitor and then cleared from circulation (160). As PC 
antigen and PC activity levels were also decreased in our children without DIC, an impaired 
synthesis cannot be ruled out; however, these results might also be explained by the 
drastic definition of DIC we chose. 
In our patients who had patent DIC, PC was far more decreased than PS, suggesting a 
peculiar implication of PC in the hemostatic abnormalities. This selective consumption was 
also noted by Madden et al. (222). 
Taylor et al. have shown that exogenously added activated PC prevents the coagulopathic 
response and lethal effects of E. Coli injections in baboon; in additional experiments they 
found that blocking PC activation in vitro led to a more severe pathologic response to 
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sublethal concentration of E. coli organisms: this response was prevented by coinfusion of 
activated PC: the mechanism by which activated PC may function in this shock model is as 
an anticoagulant (323). Activated PC probably also functions as a profibrinolytic agent; 
Okajima et al. have suggested that PC might regulate the plasminogen activator inhibitor 
1 activity under some conditions such as in septicemia in which PAI-1 activity increases 
remarkably (258). Furthermore, Pralong et all. in patients with septic shock (282), and 
Brandtzaeg et al. in children with systemic meningococcal disease (42) have shown that 
PAI-1 levels are significantly higher in patients with a fatal outcome than in survivors. 
In the literature, congenital PC deficiency has been treated by fresh frozen plasma or factor 
IX concentrates (231). However infusion of large volumes of fresh frozen plasma achieves 
a plasma PC level of only 10 % of normal, and thromboembolic complications following 
administration of factor IX concentraties have oceasionally been reported (359). A severe 
congenital PC deficiency was successfully treated by Vukovich et al. with a concentratie of 
human PC and PS given every 48 h (359). Nowadays, advances in recombinant DNA 
technology permit the production of pure PC and activated PC. Madden et al. have shown 
that recombinant PC has similar properties to the plasma form of PC (223). 
We conclude that PC and PS levels were decreased in our children with severe infectious 
purpura of proved or suspected bacterial origin, and that PC levels were significantly 
decreased in shock children, in children with DIC, and in non-survivors. As PC has 
anticoagulant and profibrinolytic actions, PC supplementation, and AT III supplementation 
(which has been proposed in aduit meningococcemia (112)) should be evaluated in 
children with severe infectious purpura with shock and DIC. 
84 


CHAPTER 3.2 
AGE-RELATED DIFFERENCES IN OUTCOME AND SEVERITY OF DIC IN 
CHILDREN WITH SEPTIC SHOCK AND PURPURA 
Jan A. Hazelzet, Inge M.Risseeuw-Appel, Rene F. Kornelisse, Wim C.J.Hop, Ina Dekker, 
Koen F.M.Joosten, Ronald de Groot, C.Erik Hack 
Thromb Haemost 1996, 76: 932-8 
87 
Chapter 3.2 
1 INTRODUCTION 
Septic shock with purpura is an overwhelming, rapidly progressive and often fatal 
syndrome. This syndrome is frequently diagnosed in children and adolescents and 
predominantly caused by N. meningitidis. A key event in the pathophysiology is 
disseminated intravascular coagulation (DIC), leading to microvascular thrombosis and 
end-organ damage during the early stage and occasionally to permanent tissue 
destruction and amputation. Septic purpura-associated ole is characterized by a marked 
activation of coagulation, consumption of platelets and coagulation proteins, and inhibition 
of the activated fibrinolytic system (25, 268, 212, 319, 330). Natural anticoagulants, such 
as antithrombin III (ATIII) and protein C and S play an important role in this process (96, 97, 
110, 112). Levels of protein C and S are decreased in septic shock and purpura, which may 
explain the severe procoagulant state (46, 100, 112, 127, 167, 207, 279, 280, 307). 
Although consumption of protein e certainly contributes to the decreased levels, 
immaturity of the protein C system may also playa role. The latter could explain the rapid 
evolution and the high incidence of purpura fulminans in young children (279). We 
observed the highest mortality in our population in younger patients. We therefore 
questioned whether higher mortality in young children is associated with more severe 
clotting abnormalities. To this purpose coagulation and fibrinolysis parameters and plasma 
levels of TNF-o: , IL-6, IL-8, IL-10 were prospectively measured on admission of children 
with septic shock and purpura. The relation between these parameters and the outcome 
and severity of disease was studied. 
2 PATIENTS AND METHODS 
2.1 Study protocol 
Children above 3 months and below 18 years of age with septic shock and petechiae/ 
purpura were enrolled in this study after informed consent was obtained from their parents 
or legal representatives. They were admitted to the pediatric intensive care unit (PICU) of 
the Sophia Children's Hospital between August 1988 and December 1994. Our PICU is the 
only center for pediatric intensive care in the south-western part of The Netherlands. All 
children younger than 14 years who need pediatric intensive care are referred to the PICU. 
Children between 14 and 18 years are occasionally referred to adult intensive care units 
irrespective of the severity of disease. Patients were eligible for inclusion when they met the 
following criteria: 1. presence of petechiae/purpura for less than 12 hours; 2. presence of 
shock defined as sustained hypotension (systolic blood pressure < 75 mm Hg for children 
between 3-12 months, < 80 mm Hg for 1-5 years, < 85 mm Hg for 6-12 years, < 100 mm 
Hg for children older than 12 years) requiring intensive care treatment, or evidence of poor 
88 
Chapter 3.2 
end-organ perfusion. The latter was defined when at least two of the following criteria were 
present: a. unexplained metabolic acidosis (pH:5 7.3 or base excess:5 -5 mmol/l or plasma 
lactate levels> 2 mmol/l); b. arterial hypoxia (PaO, :5 75 mm Hg, a PaO ,1FiO ,ratio < 250, 
or a transcutaneous SaO, :5 0.96) in patients without overt cardiopulmonary disease; c. 
acute renal failure (diuresis < 0.5 ml/kg/hr for at least one hour despite acute volume 
repletion or evidence of adequate intravascular volume defined by the presence of a 
palpable liver, a cardiothoracic ratio on chest radiography> 0.4, and a central venous 
pressure> 5 mmHg) without pre-existing renal disease; or d. sudden deterioration of the 
baseline mental status. The pediatric risk of mortality (PRISM) score (274) was calculated 
using the most abnormal value of each variable recorded during the first 4 hours after 
admission at the PICU. All patients received maximal supportive therapy: antibiotics, 
volume-administration, inotropic support, and mechanical ventilation. Disseminated 
intravascular coagulation (DIC) was defined by the combination of three of the following 
features: platelet count less than 150x1 09/1, fibrinogen levels below 2 gil, factor V less than 
60%, or increased levels of fibrin degradation products. 
The study protocol was approved by the Medical Ethics Committee of the University 
Hospital Rotterdam. 
2.2 Collection of blood 
Within two hours after admission arterial blood samples were collected. Blood for analysis 
of cytokines and coagulation parameters was collected in vials containing 3.8% trisodium 
citrate and in CTAD tubes (containing citrate-theophylline-adenosine-dipyridamole). The 
vials were immediately chilled on ice, and centrifuged at 4000 g for 10 minutes and then at 
20000 g for 30 minutes at +4'C. Plasma was stored at -80'C until tests were performed. 
2.3 Assays 
White blood cell and platelet counts were determined using an automated platelet counter 
(Technicon H1-system, Technicon Instruments, N.Y.). Lactate was measured by 
enzymatic end-point determination and CRP by nephelometric assay (315). Plasma levels 
ofTNF-a., IL-6, IL-8, and IL-10 were measured with enzyme-linked immunosorbent assays 
obtained from the Department of Immune Reagents (CLB, Amsterdam) and were 
performed according to manufacturers' instructions. Normal levels (detection limit, taking 
the dilution of samples in the assays into account) for these assays are: < 5 (1 pg/ml) for 
TNF-a.; <10 (1 pg/ml) for IL-6; <20 (4 pg/ml) for IL-8; < 30 (30 pg/ml) for IL-10. The clotting 
assays as well as the chromogenic assays were performed with commercially available 
reagents and methods from Behring Diagnostica (Behring-Werke A.G., Marburg, 
Germany). The enzyme-linked-immuno-sorbent (ELISA) determinations were done with 
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reagents from Diagnostica Stago (Asnieres sur Seine, France). Results are expressed in 
% of normal adult values unless indicated otherwise. The activated-partial-thromboplastin-
time (APTT) was measured with the Neotromtin reagent, in which vegetable phospholipids 
and ellagic acid as a particulate activator are used. (N 28-40 sec.). Fibrinogen was 
determined with a modified Clauss method (69) (N > 2 gil). The activities of coagulation 
prothrombin, factors VII, V and X were measured by one stage clotting assays, based on 
the thromboplastin time, using the commercial deficient plasmas. (N 70 -140%). Factors 
VIII and IX were done with one stage assays based on the APTT. The quantitative 
determination of the Von Willebrand Factor was performed with a sandwich type ELISA. (N 
80-120%). The same procedure was performed for the amounts of protein C and S antigen. 
(N 70-120%). The functional protein-C assay was measured by a chromogenic assay with 
a specific snake venom as the particulate activator. (N 70 -140%). The antithrombin III (AT 
III), the plasminogen as well as the alpha-2 antiplasmin activities were determined in 
quantitative kinetic tests by a synthetic chromogenic substrate method (N 70-140%). 
Fibrinogen degradation products (FDP) were determined in a semiquantitative assay using 
latex particles coated with antibodies to FDP (N<5 ~glml). C4BP amounts were measured 
in quantitative determinations by electroimmunodiffusion (Laurell rocket technique). (N 68-
140%, ± 250 ~glml). Plasminogen activator inhibitor-1 (PAI-1) antigen was determined 
using an ELISA and expressed as nglml. Thrombin-antithrombin III complexes (TAT), 
plasmin- 2-antiplasmin complexes (PAP), and tissue-type plasminogen activator (t-PA) 
were measured with ELISA's (TAT, t-PA) or radioimmunoassay (PAP) previously 
described (32). Results were expressed as nmolll (PAP), ~gll (TAT) or nglml (t-PA). 
2.4 Statistical analysis 
Results are expressed as medians (range) unless otherwise specified. Differences 
between groups were tested with the Mann-Whitney U-test or Fishers exact test in case 
of percentages. Correlation coefficients given are Spearman's. Two-tailed p-values,; 0.05 
were considered as statistically significant. 
3 RESULTS 
3.1 Demographics 
Seventy-nine patients fulfilling the entry criteria and admitted to the PICU were enrolled in 
the study. Forty-seven were males (60%), 32 females (40%) (Table 1). The median age 
was 3.1 years (range 0.3-17.9). The patients were divided into two groups according to the 
median age, I.e. 3.1 years or younger, or above 3.1 years. Fifty-eight of the 79 patients 
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(73%) survived and 21 (27%) died. The mortality in children below 3.1 years was 40 %, 
which was significantly (p=0.006) higher than in patients above 3.1 years (13%). Sixteen 
of the 21 patients who died were younger than 3.1 years; five were older than 3.1 years. In 
each group one patient died due to brain edema leading to herniation and brain death. In 
the other 19 patients the principal cause of death was circulatory collapse. Cultures of 
blood, cerebrospinal fluid or skin biopsies revealed Neisseria meningitidis in 67 (85%) 
patients and Haemophilus influenzae in 2 patients. Cultures were sterile in 10 patients. 
Fifty-one (65%) patients needed mechanical ventilation. For practical reasons, i.e lack of 
sufficient plasma sample size, coagulation parameters were not determined on admission 
in 3 patients. Fifty-two of the 79 children participated in a randomized, placebo controlled 
trial to study the efficacy of a human monoclonal antibody, HA-1-A (Centoxin®, Centocor, 
Malvern, PA, USA), in meningococcal septic shock. HA-1-A or placebo were administered 
after blood was collected for the determination of cytokines or coagulation parameters. 
3.2 Severity parameters 
Clinical and laboratory parameters obtained on admission (PRISM-score, presence of 
DIC, need for mechanical ventilation, need for inotropic support for more than 24 hours, 
arterial lactate, WBC, serum levels of glucose and CRP) are indicated in Table 1 after 
stratification according to outcome (survivors versus non-survivors) and age (younger or 
older than 3.1 years). The ages of survivors and non-survivors were significantly (p=0.013) 
different: the median age was about 2 years higher for the survivors. All clinical and 
laboratory parameters, with the exception of lactate and need for inotropic support, were 
significantly associated with outcome and age. Inotropic support longer than 24 hours was 
necessary in 74 of the 79 patients. In only two of the 40 children < 3.1 years (5%), and 3 of 
the 39 children> 3.1 years (7.7%) inotropic support was not started or could be 
discontinued within 24 hours. These five children with a relatively rapid recovery still 
needed 36 mllkg (range: 32-50ml) plasma to normalize their blood pressure. Four of the 
five children had an increased arterial lactate level (4.2 mmolll; range:1.1-5.5). There was 
no significant age related difference in duration of inotropic support in the survivors. 
3.3 Cytokines 
Cytokine levels were measured in 49 patients. The median plasma levels of TNF-a, IL-6, 
IL-8, and IL-10 were significantly higher in non-survivors as compared to survivors (Table 
2). These parameters did not significantly correlate with age. 
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Table 1. Clinical and laboratory parameters on admission in children with septic shock and purpura in relation 
with outcome and age 
Parameter Total group Survivors Non-survivors :S 3.1 years > 3.1 years 
(N=79) (N=58) (N=21) (N=40) (N=39) 
Age (years) 3.1 (0.3-17.9) 4.4 (0.3-17.9) 2.1 (0.4-12.3)' 1.3 (0.3-3.1) 9.0 (3.2-17.9) 
Sex mlf 47/32 35/23 1219 26/14 21/18 
Need for Introples 74 (94%) 53 (91%) 21&& 38 (95%) 36 (92%) 
Mechanical ventilation 51 (65%) 30 (52%) 21 (100%) && 33 (83%) 18 (46%) && 
PRISM 14 (1-44) 11 (1-38) 21 (8·44) && 17 (8·44) 8 (1-25) && 
ole 62177 (81%) 42157 (74%) 20/20 (100%) H 33/39 (85%) 29/38 (76%) 
lactate 5.0 (1.1-20.0) 4.2 (1.1-15.5) 7.3 (2.9-20.0) && 5.1 (1.8-16.7) 4.4 (1.1-20.0) 
WBe 8.1 (1.3-44.4) 12.5 (1.4-44.4) 5.3 (1.3-12.9) && 6.4 (1.3-26.5) 12.9 (1.4-44.4) & 
Glucose 5.8 (1.0-14.2) 6.8 (1.0-14.2) 3.7 (1.0-10.1)& 4.9 (1.0-11.4) 6.9 (1.3-14.2) & 
eRP 98 (14-250) 132 (34-250) 65 (14-162) && 80 (14-224) 128 (38-258) • 
Values are medians (range) or numbers (%); significance of the difference between groups (Mann-Whitney U·test or 
Fisher's exact test): 
*=ps: 0.05, **=p:s 0.01, &=p:S 0.005, &&=ps: 0.001. 
Table 2. Cytokines on admission in children with septic shock and purpura in relation with outcome and age 
Cytokine Survivors Non·survivors :S 3.1 years > 3.1 years 
(N=35) (N=14) (N=22) (N=27) 
TNF-(( (pgfml) 7 (2-165) 32 (1-272)' 14 (1-79) 8 (2-272) 
IL-6 (pglml) 15200 (36-1.5x105) 280000 (87-2.0x105)& 66000 (36-2.0x105) 15000 (87-1.5x105) 
IL-8 (P9Iml) 1100 (13·0.38x105) 88000 (23·0.37x105) && 6500 (13·0.37x105) 1100 (23·0.38x105) 
IL-10 (pglml) 2260 (41-0.11x105) 19000 (30·0.10x105) * 7200 (41-0.10x105) 2260 (30·0.11x106) 
Values are medians (range); significance of the difference between groups (Mann-Whitney U-test): 
;i=p:S 0.05, &=p:s 0.005, &&=p:S 0.001. 
92 
Chapter 3.2 
Table 3. Coagulation parameters in children with septic shock and purpura in relation to outcome and age 
Coagulation Survivors Non-survivors :s; 3.1 Years > 3.1 Years 
parameter (N=57) (N=19) (N=38) (N=38) 
platelets (x10911) 106 (15-214) 53 (14-141) && 85 (15-214) 101 (14-189) 
APTI(s) 52 (29-200) 103 (56-220) && 68 (33-220) 51 (29-200) && 
Fibrinogen (gf) 2.6 (0.3-5.8) 1.1 (0.2-2.5) && 1_7 (0.2-5.3) 2.7 (0.2-5.8) & 
Prothrombin 51 (24-82) 41 (11-57)& 43 (12-79) 55 (11-82)' 
FV(%) 40 (5-116) 16 (2-48) && 25 (2-116) 38 (3-77) • 
FVU(%) 19 (3-41) 21 (5-41) 25 (5-41) 18 (3-34)' 
F Ville (%) 84 (3-286) 22 (2-62) && 42 (4-133) 87 (2-286) && 
FvW(%) 422 (200-711) 394 (227-629) 376 (227-570) 454 (200-711)' 
FvWNHlc 5.0 (1.9-147) 17.5 (5.7-264) && 8.6 (2.4-30.6) 5.2 (1.9-264) • 
FIX(%) 50 (16-118) 40 (22-86) & 48 (16-86) 47 (23-118) 
FX(%) 50 (27-98) 44 (17-60)' 49 (21-90) 52 (17-98) 
TAT (ng/ml) 14 (3-455) 175 (12-811) && 40 (3-467) 14 (3-811) 
All data shown are medians (range); significance of the difference between groups (Mann-Whitney V·lest): 
~::p:::; 0.05, &=ps: 0.005, &&::ps: 0.001. 
Normal 
values 
150-350 
28·40 
1.8-3.5 
70-120 
70-120 
70-120 
70-150 
80-120 
1 
70-120 
70-120 
<4 
Table 4. Anti-coagulation and fibrinolysis parameters in children with septic shock and purpura in relation 
to outcome and age 
Anti·Coag/Fibr Survivors Non-survivors :s; 3.1 Years > 3.1 Years Normal 
parameter (N=57) (N=19) (N=38) (N=38) values 
Protein C act (%) 23 (5-58) 14 (5-32) & 19 (5-47) 23 (6-58)' 70-120 
Protein C ag (%) 22 (3-63) 13 (5-36)" 16 (3-49) 22 (12-63) 70-120 
Protein S ag (%) 63 (21-112) 44 (27-80) && 48 (21-112) 62 (30-92) 70-120 
C4BP(%) 72 (33-108) 53 (24-89) • 61 (24-100) 73 (32-108) 70-140 
AT III (%) 65 (29-93) 56 (25-68) && 58 (29-93) 68 (25-88)' 70-140 
Plasminogen (%) 62 (25-94) 52 (27-72)' 56 (25-94) 62 (37-93) 70-140 
2-AntipJasmin (%) 64 (30-108) 51 (12-75) && 55 (29-103) 65 (12-108)' 70-140 
FOP (~9/ml) 63 (5-325) 125 (70-325) && 110 (5-325) 50 (5-275) & <5 
PAP (nmoJII) 14 (3-56) 23 (4-54)" 17 (3-52) 14 (3-56) <7 
t-PA (ngfml) 24 (5-79) 27 (7-77) 19 (5-58) 26 (8-79) <10 
PAl (ng/ml) 670 (92-3268) 2679 (828-4578) && 1409 (924351) 617 (1264578) <30 
PAllt-PA 26 (6-206) 90 (28-298) && 82 (6-298) 26 (6-205) && <3 
All data shown are medians (range); significance of the difference between groups (Mann-Whitney V-test): 
.=p.5 0.05, "*=p.5 0.01, &=p.5 0.005, &&=p~ 0.001. 
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3.4 Coagulation parameters 
The relation between coagulation parameters and outcome or age is indicated in Table 3. 
The median number of platelets was significantly decreased in non-survivors compared 
with survivors. The APTT was markedly increased in non-survivors versus survivors, and 
in patients below versus above 3.1 years. Fibrinogen, prothrombin and plasma coagulation 
factors (V, VII, Villc, IX, and X) were all decreased. Factors VII and X levels were not 
significantly different between children above and below 3.1 years and between survivors 
and non-survivors, respectively. Levels of factor IX and TAT were only different between 
survivors and non-survivors. The plasma level of Von Willebrand factor (vWF) was 
significantly lower in patients below 3.1 years, but in both groups very high. 
The results of anti-coagulant and fibrinolytic tests are summarized in Table 4. Protein C 
was markedly decreased and serum levels were significantly related to outcome and age. 
Plasma levels of ATIII, antiplasmin, and FDP were also related to outcome and age. In 
addition PAI-1 levels tended to be higher in children below 3.1 years than in children above 
3.1 years. The ratio between PAI-1 and t-PA was significantly different between survivors 
and non-survivors, but also between younger and older children. When survivors were 
analyzed separately, this ratio was still significantly (p=O.011) different between children 
above and below 3.1 years. 
3.6 Relationship of cytokines to coagulation parameters 
APTT, fibrinogen, FVlllc, TAT, PAP, t-PA, PAI-1, as well as the PAI-1/t-PA ratio correlated 
well with the levels of most of the cytokines. A weak, positive correlation was found 
between FVII and the cytokine plasma levels and an inverse relation between cytokine 
levels and C4BP. Correlation coefficients were estimated separately for the patients 
younger and older than 3.1 years. The results are summarized in Table 5. Only those 
parameters are listed which showed significant correlation with 3 or more cytokines. 
Differences between the correlation patterns for both groups were: the strong negative 
correlations between fibrinogen, FVlllc, or protein C levels and cytokine levels in the 
younger age groups, which correlations were weaker or absent in the older age group; the 
strong positive correlation in the younger age group between APTT and plasma cytokine 
levels, which was not found in the older age group; finally, PAI-1 in both groups correlated 
with cytokines, yet the production of t-PA in the younger age group was not related to 
plasma cytokine levels, whereas in the older age group a strong, positive correlation 
between these parameters was found. 
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4 DISCUSSION 
This study in 79 children confirms that disturbances in the coagulation system are 
associated with outcome and severity of the disease in children with severe septic shock 
and purpura. The coagulation profile in these children is characterized by excessive 
activation resulting in massive consumption of platelets and coagulation factors. These 
abnormalities in coagulation result from activation of endothelial and other cells by 
endotoxins and cytokines, and are the cause for microvascular thrombosis with 
hemorrhagic necrosis. However, our observation of age-related differences in coagulation 
parameters suggests that part of the observed abnormalities results from age dependent 
relative liver insufficiency. 
Previously we and others reported that protein C (PC) levels in patients with 
meningococcal sepsis had decreased to a level at which they are at risk to develop 
thrombosis (100, 207, 274, 280). There were no differences between PC antigen and PC 
activity. Increased levels of PC inhibitor did, therefore, not explain the decreased PC levels 
(230). We propose that decreased PC levels reflect massive consumption. In agreement 
herewith, administration of activated protein C to baboons with lethal septic shock not only 
prevented coagulopathy, but also improved outcome (323). In addition, inhibition of PC 
activation using a neutralizing antibody resulted in a more severe response even against 
a sublethal dose of E.coli, implying that decreased PC levels in patients with 
meningococcal sepsis predispose for a more severe disease. Furthermore, PC not only 
regulates coagulation, but also enhances fibrinolysis by inhibition of PAl (70). Together, 
these data suggest that administration of protein C concentrates may have beneficial 
effects in children with septic shock and purpura. 
Activation of coagulation is accompanied by activation of fibrinolysis. In animal 
experiments (30), studies in volunteers (319), and human septic shock patients (268), 
elevated levels of tissue plasminogen activator (t-PA) antigen have been demonstrated. In 
one study these were related to the severity of the disease as reflected by the APACHE 
score (358). In our study t-PA levels, though increased, were not associated with outcome 
and only correlated weakly with serum lactate (r=0.45, p=0.001) and WBC (r=0.31, 
p<0.05). The levels oft-PA did correlate weakly with the TAT complexes (r=0.34, p < 0.05), 
indicating that the fibrinolytic and coagulative responses may have been linked either 
because one (fibrinolysis) occurred in response to the other, or because both were induced 
by the same stimuli. a2-Antiplasmin levels were significantly lower in non-survivors, as 
was previously reported (42, 168). This presumably reflects consumption of this 
antifibrinolytic protein, since nearly all patients had increased circulating PAP-complexes. 
Decreased a2-antiplasmin levels facilitates enhanced fibrinolytic activity. Yet, we believe 
that overall fibrinolysis was relatively inhibited in our patients due to the release of high 
amounts of PAI-1 into the circulation. 
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Increased levels of PAI-1 indeed have been shown in experimental sepsis (30), and in 
human sepsis (42, 94, 168,268,282) and are associated with a decrease in levels of PAP-
complexes (272). We speculate that the levels of PAP complexes, though increased, 
presumably reflect an insufficient fibrinolytic response. Increased levels of PAI-1 were 
strongly related to outcome and, as was previously reported by our group, an increased 
PAI-1 response to TNF-o: may be associated with fatality, probably because of 
polymorphism of the PAI-1 gene (195). 
Mortality of patients with septic shock and purpura is probably related to the severity and 
extent of coagulation disturbances which lead to micro-thrombi and hemorrhagic necrosis. 
Mortalily rates differ from 10 % to 40 % depending on patient selection crileria. Additionally 
10 % of all palients with meningococcal disease suffer from serious sequelae like 
ampulation, secondary to the coagulopathy. This study shows that mortality was three 
times higher in patients below three years. Although the maturation of the coagulation 
system is only partly unraveled, most coagulation factors do not reach adult levels until 
after the first 6 monlhs of life (8). Protein C is somewhat unusual since it does not reach 
adult levels until the fourth year of life (246). Powars et al. have suggested that infants are 
more susceptible to severe depletion of protein C. These authors showed a relation 
between protein C and both age and outcome in children with meningococcal sepsis (279). 
We studied the relation between coagulation parameters and age, and did not only find 
differences in protein C, but also in other parameters of coagulation and fibrinolysis. So, 
eilher both patient groups had the same degree of inflammatory stimulus, and the younger 
patients a more disturbed coagulation, or, the younger patients were more severely ill and 
for this reason had a more severely disturbed coagulation. Yet, cylokine levels were 
comparable in both groups indicaling that younger and older children had at least 
comparable inflammatory responses. Thus, apparently a similar inflammatory response 
yields a more severe coagulation response in the younger children. We suggest that this 
more severe coagulation response was due to the immature state of their clotting system, 
in particular of the anticoagulant pathways, resulting in extensive consumption of 
coagulation factors. But since we only analyzed some of the cytokine levels and no other 
fluid phase cascade systems, there remains uncertainty about the degree of intravascular 
inflammation in the 2 groups. Plasma levels of PAI-1 of both age groups correlated strongly 
with cytokine levels, as well as with TAT-complexes (r=0.73, p<0.001; r=0.80, p<0.001). 
Furthermore, in contrast with the older age group, t-PA levels in the younger age group did 
not correlate with those of cytokines. Moreover, the correlation between t-PA levels and 
TAT-complexes, was different for both groups: whereas no correlation was found in the 
younger age group (r=-0.05, p=0.81), there was a very strong correlation found in the older 
age group (r=0.80, p=<0.001). This may indicate, that in addition to the relative deficiency 
of coagulation factors, an inadequate fibrinolytic response may have contributed to the 
activation of coagulation. This seems to be contradictory to the finding that FDP's were 
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significantly higher in patients,; 3.1 years vs > 3.1 years and in non-survivors vs survivors. 
However, FDP's are a combination of fibrinogen and fibrin degradation products. 
Fibrinogen was much lower in non-survivors than in survivors. So, fibrinogen consumption 
was more pronounced in non-survivors. Consistent herewith TAT complexes were much 
higher in non-survivors, making it likely that more fibrin was formed in this group. Although 
there was detectable activation of fibrinolysis as estimated by increased FDP's and PAP-
complexes, we speculate that this was insufficient to compensate for coagulation 
activation. 
The parameters reflecting severity of disease (PRISM, lactate, WBC, glucose, and CRP) 
were also different between the two age groups, the patients younger than 3 years being 
more severely ill than the older patients. We speculate that this resulted from the increased 
tendency to develop a more severe coagulopathy. Additionally, lack of immune 
competence i.e. lack of bactericidal and opsono-phagocytic antibodies combined with 
certain Fc-y receptor allotypes on specific cells may contribute towards the bad prognosis 
in infants and young children. 
The question remains whether coagulopathy and microthrombosis contributes to 
circulatory collapse and mortality. The coagulopathy could be causally related to the 
circulatory collapse but could also be two separate manifestations of massive 
endotoxemia. The laUer has been shown in baboon experiments. Blocking FXII did 
ameliorate the hypotensive response but the activation of the coagulation was not 
influenced (270). However, the same group established that protein C treatment prevented 
the coagulopathic as well as the lethal effects (323). The same combined effect was 
described for tissue factor pathway inhibitor (60). Therefore one may argue that FXIt is 
more related to hypotension and that blocking of this system possibly leads to improvement 
of hypotension without changing the coagulopathy. However, this does not prove that 
circulatory collapse and coagulopathy are separate manifestations. 
So, despite a similar degree of inflammatory response, a more severe coagulopathy was 
found in children below the age of 3.1 years, consisting of a relative deficiency of 
coagulation factors, as well as an inadequate fibrinolytic response, both related to age, 
which may have contributed to the higher mortality observed in younger children with 
meningococcal sepsis. 
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THE RELATIONSHIP BETWEEN 
PLASMINOGEN ACTIVATOR INHIBITOR-1 AND PRO-INFLAMMATORY 
AND COUNTER-INFLAMMATORY MEDIATORS IN CHILDREN 
WITH MENINGOCOCCAL SEPTIC SHOCK 
R.F. Kornelisse, JA Hazelzet, H.F.J. Savelkoul, W.C.J. Hop, M.H. Suur, AN.J. 
Borsboom, 10M. Risseeuw-Appel, E. van der Voort, R. de Groot 
Journal of Infectious Diseases 1996; 173: 1148-1156 
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1 INTRODUCTION 
Septic shock with purpura is a serious life-threatening disease in otherwise healthy children 
and young adults. The syndrome is most frequently due to Neisseria meningitidis, although 
occasionally Haemophilus influenzae type b is involved (44, 129, 146,205,331,349). 
Lipopolysaccharides (endotoxin), a component of the outer membrane of gram-negative 
bacteria, induces the release of pro-inflammatory cytokines (tumor necrosis factor, TNF-a, 
and interleukin, IL-1r." -6, -8) in patients with sepsis. Subsequently, endotoxins and 
cytokines stimulate the production of a wide range of additional inflammatory mediators 
(Le., arachidonic acid metabolites, complement, platelet-activating factor), influence the 
function of leukocytes and endothelial cells, and activate hemostasis (36, 47, 340, 341, 
344). The production of pro-inflammatory cytokines and the extent of the inflammatory 
response is downregulated by counter-inflammatory compounds, such as IL-10, and 
naturally occurring antagonists of TNF-a including the soluble extracellular domains of the 
55- and 75-kDa membrane-bound TNF receptors (sTNFR-55 and -75). 
IL-10 is produced by activated monocytes and suppresses the endotoxin-induced 
production of TNF-a and IL-1r." -6, and -8 (363). The biologic activity of TNF-a is also 
neutralized by sTNFR-55 and -75 (82, 194,203,219,300). sTNFR is shed from the cell 
surface of, for example, polymorphonuclear cells in response to many of the same 
inflammatory stimuli that induce TNF-a 277. 
Endothelial cells are among the principal targets for the action of endotoxin, TNF-a and IL-
1 r.,. These cells change to a procoagulant state and can modulate the fibrinolytic system by 
secretion of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 
(PAI)-1, which respectively activate and inhibit fibrinolysis. The activation of coagulation 
together with the inhibition of the fibrinolysis are responsible for the development of a 
hypercoagulable state, fibrin deposition, and microthrombi (319). Fibrin deposition and 
complement activation cause extensive endothelial damage and are associated with 
multiple organ failure (61,141,161). 
Inflammatory mediators and coagulation disorders are involved in the pathophysiology of 
septic shock and should be associated with disease severity. Thus, we investigated the 
balance between pro-inflammatorycytokines (TNF-a, IL-6, IL-8) and counter-inflammatory 
compounds (lL-10, sTNFR-55, sTNFR-75) in admission serum samples of 38 consecutive 
children with meningococcal septic shock (MSS) and studied their relationship with 
indicators of hemostasis. 
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2 METHODS 
2.1 Patients 
We prospectively recruited patients between ages 3 months and 18 years with septic shock 
and petechiae or purpura. Primary or secondary referrals were admitted to the pediatric 
intensive care unit (PICU), Sophia Children's Hospital, between October 1991 and 
September 1994. Patients were eligible for inclusion if they met the following criteria: 
Presence of petechiae or purpura for < 12 h and presence of shock (systolic blood pressure 
< 75, < 80, < 85, or < 100 mm Hg in children ages 3 months to 1 year or 1-5, 6-12, and> 
12 years old, respectively). Children were also included when poor end-organ perfusion 
was present (defined as occurrence of at least two olthe following criteria): (1) unexplained 
metabolic acidosis (pH" 7 .3), base excess -5 mmol/L or lower, or arterial plasma lactate 
levels> 2.0 mmol/L; (2) arterial hypoxia (PO,'; 75 mm Hg, PO,-to-FiO, ratio < 250, or TcO, 
,,96% in patients without overt cardiopulmonary disease); (3) acute renal failure (oliguria 
with urine output < 0.5 mLlkg/h for> 1 h despite acute volume loading or evidence of 
adequate intravascular volume and without preexistent renal disease); or (4) sudden 
deterioration of the patient's mental status. Most of the patients were enrolled in a 
randomized, placebo-controlled trial to study the efficacy of the human monoclonal anti-
endotoxin antibody HA-1A (Centoxin; Centocor, Malvern, PAl in MSS. Initial blood 
samples were obtained before administration of HA-1A or placebo. There was no selection 
in the HA-1A trial to bias the present study. 
On PICU admission, the severity of illness was assessed using the pediatric risk for 
mortality (PRISM) score, a severity-of-iliness index (274). Parents were asked to indicate 
the onset of symptoms as precisely as possible. The time of onset of petechiae was defined 
as the mean time between observation of the child with and without petechiae. The times 
of initiation of antibiotic treatment, PICU admission, and blood sampling were carefully 
registered by the investigators. Decisions regarding the use of antibiotics, intravenous 
fluids, inotropic and vasopressor support, and initiation of mechanical ventilation were 
made by the patient's attending physician. 
2.2 Laboratory studies 
Cerebrospinal fluid and blood specimens were routinely cultured. Blood samples for the 
determination of biochemical parameters, TNF-a, IL-6, -8, and -10, and sTNFR-55 and -75 
were obtained from an arterial catheter and collected into sterilized siliconized glass tubes 
(Vacutainer; Becton Dickinson, Meylan, France) and allowed to clot at room temperature. 
The samples were centrifuged at 1600 9 for 10 min at 4' C. Aliquots were stored at -80' C 
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until assayed. Blood for the platelet and leukocyte counts was collected in a microtainer 
containing EDTA(K,). Blood for the coagulation and fibrinolysis assays was collected in 
0.109 M trisodium citrate (anticoagulant to blood 1:9 vOl/vol) and in a 0.109 M trisodium 
citrate mixture (theophylline, adenosine, dipyridamole; Diatube H, Diagnostica Stago, 
Asnieres-sur-Seine, France). These samples were immediately chilled on ice and 
centrifuged at 2800 9 for 15 min and then at 45,000 9 for 30 min at 4' C. Platelet and white 
blood cell counts were determined by flow cytometer (H1 system; Technicon Instruments, 
Tarrytown, NY); C-reactive protein (CRP) was measured by immunonephelometric assay 
(315). 
2.2.1 cytokines and inhibitors 
Levels of TNF-o:, IL-6, -8, and -10, and sTNFR-55 and -75 in serum were determined by 
ELISA (Medgenix, Fleurus, Belgium). Mediators were determined according to the 
manufacturer's instructions with the following detection limits (lowest positive standard): 
TNF-o:, 15 pg/mL; IL-6, -8, and -10, respectively, 30, 7, and 11 pg/mL; and sTNF-55 and-
75, respectively, 0,4 and 1.0 ng/mL. 
2.2.2 parameters of coagulation and fibrinolysis 
All assays were done with commercially available reagents and methods. Clotting assays 
were used for the determination of the activated partial thromboplastin time (APTT). Factor 
V was determined with a one-stage assay using factor V-deficient plasma and fibrinogen 
according to the Clauss method (69) (Behringwerke, Marburg, Germany). Antithrombin III 
(A Till) activity and protein C activity were determined by chromogenic substrate assays 
(Behringwerke). Total protein S was measured by ELISA (Diagnostica Stago). 
Plasminogen was determined spectrophotometrically using a chromogenic synthetic 
substrate (Behringwerke). Plasma t-PA antigen concentration was measured by ELISA as 
described (348) as was PAI-1 (Diagnostica Stago). Asemiquantification of fibrin-fibrinogen 
degradation products (FDP) in plasma was done by latex agglutination (Diagnostica 
Stago). 
Disseminated intravascular coagulation (DIC) was defined by the combination of three of 
the following features: platelet count < 150 x 109/L, fibrinogen < 2 giL, factor V < 60%, and 
the presence of FDP (207). 
2.3 Statistical analysis 
Results are expressed as mean ± SD unless stated otherwise. Differences between groups 
of variables were tested by the Mann-Whitney test. Frequencies of various findings 
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between groups were compared by Fisher's exact test Pearson's correlation coefficient 
was used to evaluate the relation between specific variables. Multiple regression analysis 
was done to evaluate factors that might affect the difference in levels of mediators between 
survivors and non-survivors. Two-tailed P values ,; .05 were considered statistically 
significant 
3 RESULTS 
During the 3-year study period, 43 patients with septic shock and purpura were admitted to 
the PICU. Five patients did not fulfill the entry criteria: 3 had purpura> 12 h before 
admission, 1 was < 3 months old, and informed consent was not obtained for 1 child. 
3.1 Patient characteristics 
Thirty-eight patients (23 boys, 15 girls) entered the study. Of these, 36 participated in the 
clinical trial to study the efficacy of HA-1A human monoclonal antibody. The median age 
was 4.1 years (range, 0.7-17.9 years). Twenty-nine patients were referred from another 
hospital. The PRISM scores at PICU admission ranged from 1 to 25. Cultures of blood, 
cerebrospinal fluid, or skin biopsies from 34 children grew N meningitidis. In 4 cases with 
sterile cultures, the diagnosis was made on the basis of typical clinical findings. None of the 
patients received antibiotic treatment before or during transport to the hospital. The 
duration (mean ± SD) of symptoms and the interval between the appearance of petechiae 
and admission to Sophia Children'S Hospital were 17.4 ± 7.2 and 5.4 ± 3.3 hours 
respectively. All patients needed inotropic and vasopressor support. Twenty-five of the 38 
patients required mechanical ventilation. The overall fatality rate was 29%. Table 1 shows 
the demographic and clinical characteristics of the 27 survivors and 11 fatalities. Survivors 
and non-survivors were evenly distributed in regard to time of onset of petechiae and time 
of hospitalization. The interval between onset of petechiae and PICU admission was 
significantly shorter in non-survivors. Serum CRP levels were also significantly lower in 
non-survivors than in survivors and were highly correlated with the interval between the 
onset of symptoms and petechiae and the moment of blood sampling (r= .56, P< .001 and 
r = .45, P = .005, respectively). 
The parameters of coagulation and fibrinolysis are summarized in Table 2. DIC was 
observed in all non-survivors and in 13 (48%) of the 27 survivors (P= .003). The APTT was 
significantly more prolonged in those who did not survive. The inhibitors of coagulation 
(ATIII, protein C, and protein S) were generally decreased, but more so in the non-
survivors. Plasminogen levels were similar in survivors and non-survivors. The t-PA, PAI-
1 antigen, and FDP levels were higher in non-survivors than in survivors. 
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Table 1. Characteristics of patients with meningococcal septic shock. 
Survivors Non-survivors 
Characteristic (n = 27) (n = 11) P 
Age (years) 7.3 ± 5.7 5.1 ± 3.9 .43 
Sex (% male) 16 (59) 7 (64) 1.0 
Transferrals" 22 (82) 7 (64) .40 
Interval (h) trom 
Onset symptoms 
to admission PICU 18.5 ± 7.7 14.4 ± 4.8 .09 
Appearance of petechiae 
to admission PICU 6.1 ± 3.3 3.6 ± 2.4 .04 
Duration of antibiotic trealment (h) 4.7±1.8 2.8 ± 1.8 .10 
PRISM score 8.6 ± 5.4 18.6 ± 5.5 <.001 
Clinical hematology 
White blood cells (x 10'/L) 15.1 ± 10.3 5.4 ± 3.2 .004 
Clinical chemistry 
Creannlne (pmoIlL) 102 ± 68 135 ± 65 .08 
C-reaclive protein (mg/L) 131 ± 60 81 ± 43 .02 
Microbiology 
N. meningitidis 25 (93) 9 (82) .56 
No growth 2 (7) 2 (18) 
Note. Date are mean ± SO or no. (%). Abbreviations: PICU, pediatric intensive care unit; PRISM, pediatric 
risk for mortality score. *Patienls transferred from first institution to PICU, Sophia Children's Hospital. 
3.2 Pro-inflammatory cytokines and counter-Inflammatory compound levels at 
admission 
At admission, serum levels of pro-inflammatory cytokines and counter-inflammatory 
compounds were significantly higher in the patients who subsequently died (Table 3). 
Highly significant positive correlations were observed between all of these mediators 
(Table 4). In addition, serum cytokine levels were negatively correlated with the interval 
between the appearance of petechiae and blood sampling (P< .001 for all; TNF-a: r= -.55; 
IL-6: r = -.57; IL-8: r = -.58; IL-10: r = -.59; Figure 1). Multiple regression analysis for the 
relation between serum cytokine levels and survival and duration of skin lesions showed 
that the time-adjusted concentrations of the cytokines TNF-a and IL-6, -8, and -10 were not 
significantly higher in children who died versus survivors. sTNFR-55 and -75 were 
significantly higher in non-survivors and also correlated with the interval between the onset 
of petechiae and initial serum measurements (sTNFR-55: r = -.36, P = .03; sTNFR-75: r= 
-.61, P < .001). Both sTNFRs remained markedly elevated during the first 24 h after 
hospitalization (data not shown). 
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Table 2. Coagulation and fibrinolysis data in patients with meningococcal septic shock 
Reference Survivors Non-survivors 
Characteristic range (n = 27) (n = 11) P 
Coagulation 
Plalelels (x 10'/L) 150-450 120 ± 45 65 ±37 .002 
APTI' (sec) 28-40 52 (33->200) 92 (58-200) <.001 
Factor V (%) 70-140 43 ± 23 22 ± 12 .007 
ATIII acl. (%) 80-120 66 ± 14 51 ± 12 .01 
Protein C activity (%) 70-140 21 ± 11 17 ± 8 .08 
Protein S tolal (%) 65-108 57 ± 18 41 ± 10 .006 
Fibrinogen' (giL) 1.8-3.5 2.6 «0.4-5.3) 1.2 «0.4-2.5) .005 
Fibrinolysis 
Plasminogen (%) 75-140 62± 13 53 ± 14 .10 
I-PA antigen (ng/mL) <10 25 ± 14 35 ± 19 .13 
PAI-1 antigen (ng/mL) 4-40 971 ± 848 2500 ± 1390 <.001 
FOP' (mg/L) <5 70 (20->300) 120 (100-220) .02 
Note. Data are mean ± SO unless specified otherwise. Abbreviations: APTT, activated partial 
thromboplastin time; ATJII, Antithrombin III, I-PA, tissue-type plasminogen activator; PAl, plasminogen 
activator inhibitor; FOP, fibrin/fibrinogen degradation products. 
*Median (range). 
Table 3. Serum levels of cytokines and soluble (5) tumor necrosis factor (TNF) receptors (R) in patients 
with meningococcal septic shock 
Survivors Non-survivors p 
(n = 27) (n=11) 
TNF-a (pg/mL) 144 450 .03 
(35 - 3130) (74 - 2680) 
IL-6 (pg/mL) 107,600 1,081,000 .005 
(2990 - 4,515,000) (25310 - 5,758,000) 
IL-8 (pg/mL) 746 30,760 .005 
(31-113,100) (599 -118,500) 
IL-10 (pg/mL) 1479 14,780 _01 
(68 - 20,440) (636 - 28,070) 
sTNFR-55 (ng/mL) 15.5 27.2 .05 
(6.2 - 32.3) (8.5 - 36.6) 
sTNFR-75 (ng/mL) 51.2 79.6 .04 
(22.5 - 149.4) (10.0 - 119.7) 
Note. Data are median (range). IL, interleukln. 
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Table 4. Correlation between serum levels of cytokines and soluble (s) receptors (R) for tumor necrosis 
factor (TNF) in patients with meningococcal septic shock. 
TNF-a IL-6 
IL-6 .90 
IL-8 .90 .92 
IL-10 .79 .85 
sTNFR-55 .82 .84 
sTNFR-75 .87 .82 
IL-8 
.89 
.80 
.78 
IL-10 
.82 
.75 
sTNFR-55 
.77 
Note. Probabilities for all correlations Were < .001. Abbreviation: IL, interleukin. 
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Figure 1. Relation between initial serum concentrations of inflammatory compounds (tumor necrosis factor, 
TNF-o: , interleukin IL-6, -8, -10) and interval between onset of petechiae and blood sampling in 38 children 
with meningococcal septic shock. Solid and dotted Jines indicate regression through values for each 
parameter. Slopes between regression lines of survivors and non-survivors did not significantly deviate from 
parallelism for each parameter. 
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Figure 2. Initial plasma levels of 
plasminogen activator inhibitor (PAI~ 
1; n = 36). Left, relation between PAI-
1 levels and survival. Righi, inWal 
PAf-1 plasma levels in relation to 
interval between onset of petechiae 
and blood sampling. Slope between 
survivors and non-survivors did not 
significantly deviate from parallelism. 
Time-adjusted PAI-1levelswere 2.1 
times higher in non-survivors (P = 
.02). 
Figure 3. Relation between initial 
levels of tumor necrosis factor 
(TNF)-a and plasminogen activator 
inhlbitor-1 (PAI-1) in 36 patients with 
meningococcal septic shock. Slope 
10' +--~~~~,,-~~~~,--~~~~rro betweenregress!onlinesofsurvivors 
101 102 103 104 and non-survivors did not significantly 
TNFa (pgImL) deviate from parallelism (P = .31). 
Serum cytokine levels were also associated with the duration of antibiotic treatment (TNF-
a: r = -040, P = .02; IL-6: r= -.37, P = .03; IL-8: r = -.33, P = .05; IL-10: r = -.39, P = .02). 
However, these associations were weaker than those with the duration of petechiae. The 
duration of petechiae and the duration of antibiotic treatment were significantly correlated 
(r = .50, P = .002). When these time intervals were simultaneously related by multiple 
regression analysis to the levels of mediators, the duration of petechiae was most 
predictive (P < .005 for TNF-a, IL-6, IL-8, IL-10) while an additional significant predictive 
value was not observed for the duration of antibiotic treatment. 
3.3 Correlation between inflammatory cytokines and clinical features 
The relationship between cytokines and certain hematologic parameters was assessed. 
The peripheral white blood cell count and the CRP level were negatively correlated with 
levels ofTNF-a (r= .59, P < .001 and r= .46, P = .004), IL-6 (r= .67, P < .001 and r= .62, 
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P < .001), and IL-8 (r = .68, P < .001 and r = .62, P < .001) and with the interval between 
the onset of petechiae and blood sampling (r = .54, P < .001 and r = .45, P = .005). Initial 
serum TNF-a levels correlated significantly with the APTT (r = .47, P = .003) and the 
concentrations offactor V (r = -.51, P < .001), t-PA (r= .63, P < .001) and PAI-1 (r = .75, P 
< .001). PAI-1 levels were significantly higher in non-survivors than in survivors (2500 ± 
1390 vs. 971 ± 848 ng/mL; P < .001) even when adjusted for duration of skin lesions before 
blood sampling (P = .02) (Figure 2). Of interest, PAI-1 concentrations were 1.9 times higher 
in non-survivors (P = .01) than in survivors at similar TNF-a serum levels as shown by 
analysis of covariance (Figure 3). This relationship between the levels of PAI-1 and 
TNF-u. was not affected by their association with the time interval (partial r= .60, P< .001). 
4 DISCUSSION 
Systemic meningococcal disease has a wide spectrum of severity, ranging from benign 
meningococcemia to fulminant septic shock with multiple organ failure and death. TNF-a 
and IL-1 B are thought to playa central role in the pathophysiology of this disease. These 
cytokines are involved in the induction of other pro-inflammatory cytokines, such as IL-6 
and -8, and are involved in the activation of the coagulation and fibrinolysis. Our study 
confirms the findings of other investigators that disease severity and outcome are related 
to concentrations of TNF-a, IL-6, -8, and -10, and sTNFR-55 and -75 (44,129,130, 145, 
159, 211, 343). 
A wide inter-individual variability in TNF-u. release after stimulation by endotoxin has been 
demonstrated in vitro in whole blood samples and peripheral blood mononuclear cells 
isolated from healthy volunteers (87,241). The high initial TNF-a levels in those who do not 
survive MSS have been interpreted as the result of an exaggerated response to circulating 
endotoxin (372). This production of inappropriately large quantities ofTNF-a may be due 
to the presence of a genetic variant in the promotor region of the TNF gene (TNF2 allele) 
as previously observed in patients with cerebral malaria (237). The TNF2 allele has been 
associated with higher constitutive expression and greater secretion of TNF-a after 
induction (374). 
The initial concentrations of TNF-a in this and previous studies were significantly higher in 
MSS non-survivors than in survivors. However, the magnitude of TNF-a serum levels and 
of other pro-inflammatory cytokines (e.g., IL-6 and -8) is also determined by the duration of 
disease when blood samples are obtained, perhaps because these cytokines rapidly 
disappear during the acute phase of septic shock. (85, 90, 211, 260). Accordingly, we found 
a strong negative correlation between initial cytokine levels and the interval between onset 
of purpuric skin lesions and blood sampling. This association is in contrast to previous 
reports (85, 129, 145). In addition, in the present study, CRP levels, which indirectly reflect 
the duration of illness (267), were significantly correlated with the interval between the 
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onset of petechiae and blood sampling. This significantly shorter interval and the lower 
level of CRP in non-survivors suggest a shorter disease course and may therefore explain 
the higher levels of cytokines. The earlier PICU admission of non-survivors may indicate 
that persons who do not survive accumulate more native lipopolysaccharide in a shorter 
time, trigger all mediator systems more intensively, and are recognized as more severely 
ill earlier in the course of disease. Alternatively, non-survivors may have been admitted 
earlier because of a more rapid deterioration due to greater responsiveness to 
lipopolysaccharides or pro-inflammatory cytokines. 
The clinical features of patients with MSS show similarities to those observed in 
experimental endotoxemia in humans. A challenge with endotoxin in healthy volunteers 
results in a transient occurrence of a sepsis-like syndrome. The peak levels of cytokines 
correspond with the transient leukopenia that occurs shortly afler the endotoxin challenge 
(239, 344). In experiments in baboons infused continuously with Escherichia coli, peak 
levels of TNF-o: also occured very early in the course of disease (103, 239, 287). Similarly, 
high levels of TNF-o:, IL-6 and -8, low white blood cell counts, and low CRP levels were 
observed in patients from whom blood was obtained shortly after the onset of petechiae. 
We therefore assume that the onset of petechiae is a useful setpoint during the course of 
invasive meningococcal disease. This assumption is supported by multiple regression 
analysis, which indicated that serum levels of cytokines are dependent on the duration of 
petechiae and not on the duration of antibiotic treatment. 
Of interest, the differences in the concentrations of mediators between survivors and non-
survivors disappeared after adjustment for the time between onset of petechiae and blood 
sampling. These data suggest that the survivors and non-survivors in the present study 
may have had similar releases of inflammatory cytokines (TNF-o:, IL-6, IL-8). 
The pro-inflammatory cytokines are counteracted by counter-inflammatory compounds. 
We observed significantly higher concentrations of IL-10 in non-survivors with MSS. 
Lehmann et al. (211) recently reported that high IL-1 0 levels in patients with meningococcal 
disease are associated with fatality. In contrast, Derkx et al. (85) did not confirm this 
observation in patients with MSS, which may be explained by the relatively small number 
of patients evaluated. However, the time-adjusted IL-10 levels in the present study were 
similar between survivors and non-survivors. IL-10 acts as a potent inhibitor of the release 
of the pro-inflammatory cytokines TNF-o: , IL-111, IL-6, and IL-8 from T-cells (355), 
polymorphonuclear leukocytes (62), and monocytes and macro phages (33, 102, 363). In 
animal models of sepsis, IL-10, given before or soon after challenge with gram-negative 
bacterial endotoxin or staphylococcal enterotoxin B, reduced TNF-a production and 
mortality (17,124,176). Chernoff et al. (66) showed that a single intravenous injection of 
IL-10 in humans reduces mitogen-induced T cell proliferation and suppresses TNF-o: and 
IL-111 production from whole blood stimUlated ex vivo with endotoxin. In the present study, 
the strong correlation between IL-10 and the pro-inflammatory cytokines TNF-o:, IL-6, and 
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IL-8 in survivors and non-survivors suggests the presence of an adequate IL-10 response 
to down-regulate the production of pro-inflammatory cytokines. 
In addition, sTNFR-55 and -75 can neutralize the biologic activity of TNF-a. Girardin et al. 
(130) found that high levels of the sTNFRs are associated with an increased likelihood of 
fatality, and Froon et al. (118) suggest that increased serum levels of sTNFRs in patients 
with sepsis syndrome are merely the result of renal failure. Normally, the majority of 
sTNFRs is removed from the circulation by the kidneys, although the liver and lungs are 
probably also involved (21). The higher serum creatinine levels of non-survivors (P = .08) 
in the present study may at least partly explain the differences in sTNFR concentrations. 
Abnormalities of coagulation and fibrinolysis play an important role in the pathophysiology 
of MSS. It has been known for some time that endotoxin, TNF-u. and IL-111 contribute to the 
activation of the coagulation and fibrinolysis (14, 271). Normally the endothelial cell 
provides a blood vessel lining that reduces the coagulability of blood. TNF-a causes 
endothelial cells to have procoagulant activity by enhancing the expression of tissue factor 
and by suppressing cofactor activity for the anticoagulant protein C (14, 23, 24, 247, 348). 
The prolonged APTT in patients in the present study indicates a massive consumption of 
coagulation clotting factors, leading to a bleeding tendency. In addition, the plasma levels 
of the natural inhibitor of coagulation, ATIII, and of protein C and protein S were markedly 
depressed, resulting in a procoagulant state. The hypercoagualability that occurs during 
DIC results in the generation and deposition of fibrin, leading to the formation of 
microvascular thrombosis in various organs and perhaps to multiple organ failure and 
ultimately death. In the present study, DIC occurred in 13 of the 27 survivors and in all of 
the non-survivors (P = .003). 
Endotoxin, TNF-a, and IL-111 modulate the fibrinolytic system to secrete both t-PA and PAI-
1, which respectively activate and inhibit fibrinolysis (74, 92, 151, 213, 272, 303, 345). 
Moreover, fibrin and thrombin formed during coagulation are also potent inducers for the 
release of t-PA and PAI-1 (123, 177). Fibrinolysis can be initiated by the release of t-PA 
from vascular endothelium that converts plasminogen into the active enzyme plasmin that 
degrades fibrin in the thrombi. The activity of t-PA in patients is counter-regulated by PAI-
1 that binds to and thereby inhibits t-PA. Protein C can inhibit PAI-1 activity. In the present 
study, the levels of PAI-1 antigen were significantly higher in non-survivors. This finding 
together with decreased protein C activity result in insufficient fibrinolytic activity during a 
markedly procoagulant state that is associated with vital organ micro embolization (61, 141, 
161,219). Administration of recombinant t-PA may therefore be considered an adjuvant 
therapeutic option in patients with fulminant meningococcemia as suggested by Zenz et al. 
(389). 
In previous studies, PAI-1levels rapidly decreased after hospitalization (42, 94), and PAI-
1 and TNF-a levels were strongly associated (121,233). Further analysis of our findings 
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showed that PAI-1 levels were significantly dependent on the interval between onset of 
petechiae and blood sampling and survival. Of interest, PAI-1 concentrations in this study 
were significantly higher in non-survivors at a similar TNF-a concentration. We questioned 
whether inter-individual differences in responsiveness to TNF-a, for example, may 
contribute to outcome in patients with MSS. The presence of a single base pair insertion/ 
deletion (allele frequency 0.5310.47) polymorphism in the promotor of the PAI-1 gene has 
been associated with differences in release of PAI-1 in postoperative patients (264) and in 
patients with an increased risk of recurrent myocardial infarction (148). 
The promotor containing the deletion allele produced six times more mRNA than the 
insertion allele in response to IL-111 (79). The insertion/deletion polymorphism in the PAI-
1 promotor is of functional importance in the regulation of the expression of the PAI-1 gene 
(79). These data support the hypothesis that individuals homozygous for the del allele may 
respond with increased PAI-1 expression in the acute phase of MSS. The possible 
presence of PAI-1 gene polymorphism in patients with MSS is strengthened by the 
relatively low PAI-1 response (945 ng/mL) in 1 patient with an extremely high TNF-a level 
(3130 pg/mL) who survived MSS. 
The possible beneficial effects of the HA-1A human monoclonal antibody against 
endotoxin on the outcome of children with MSS is not yet known. However, a recent study 
did not find a reduction in the 14-day mortality rate in patients with gram-negative 
bacteremia and septiC shock (236). 
We conclude that high levels of pro-inflammatory cytokines and counter-inflammatory 
compounds are associated with fatality. After the levels of inflammatory mediators are 
adjusted for time after the onset of petechiae, the differences between survivors and non-
survivors disappeared. We therefore propose that the outcome in patients with MSS is 
probably not related to TNF gene polymorphism. However, the increased PAI-1 response 
to, for example, TNF-a in the fatal cases suggests the presence of polymorphism in the 
expression of the PAI-1 gene that may contribute to the outcome of MSS. 
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1 INTRODUCTION 
The complement system is involved in many aspects of the inflammatory response in 
patients with sepsis: amongst others it mediates chemotaxis of neutrophils and 
opsonization of particles and micro-organisms, stimulates the release of granules from 
leucocytes, induces vasodilatation, and enhances vascular permeability, either or not via 
its influences on the cytokine network and coagulation system (31). Septic shock with 
purpura in children is mainly caused by meningococci. It is generally accepted that this 
condition results from the release of large amounts of lipopolysaccharide (LPS) into the 
circulation leading to a capillary leakage, severe hypotension, micro-thrombosis, and 
ultimately to organ failure and death (39, 158). The capillary leakage which occurs during 
sepsis, is considered to be induced by the release and activation of endogenous 
inflammatory mediators such as cytokines and activated components of the complement 
and contact systems. Genetic deficiencies of the complement system, in particular those 
of the membrane attack complex, lead to a higher susceptibility for and recurrent infections 
with N. meningilidis (99). However, most children with severe meningococcal disease 
(SMD), are complement sufficient (18,170). Thus, excessive complement activation, and 
not complement deficiency, is responsible for low levels of native complement components 
in most patients with severe meningococcal sepsis (31, 35,47,89,141,329). The degree 
of complement activation in SMD is related to the concentration of lipopolysaccharide 
(LPS) in plasma (41, 47). Patients with mild disease (low or undetectable LPS plasma 
levels) have a low degree of complement activation, whereas patients with septic shock 
and purpura are characterized by high circulating levels of LPS as well as excessive 
complement activation. 
This study was designed to assess the extent of complement activation, and the possible 
route and regulation of this activation in children with septic shock and purpura. Moreover, 
we investigated the relation between complement activation and severity of disease, as 
reflected by the degree of capillary leakage, and by circulating levels of several 
inflammatory mediators. 
2 PATIENTS AND METHODS 
2.1 Study protocol 
Children above 3 months and below 18 years of age with septic shock and petechiae! 
purpura were enrolled in this study after informed consent was obtained from their parents 
or legal representatives. They were admitted to the pediatric intensive care unit (PICU) of 
the Sophia Children's Hospital between August 1988 and December 1994. Patients were 
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eligible for inclusion when they met both the following criteria: 1. presence of petechiaei 
purpura for less than 12 hours; 2. presence of shock defined as sustained hypotension 
(systolic blood pressure < 75 mm Hg for children between 3-12 months, < 80 mm Hg for 1-
5 years, < 85 mm Hg for6-12 years, < 100 mm Hg for children older than 12 years) requiring 
intensive care treatment, or evidence of poor end-organ perfusion. The latter was defined 
when at least two of the following criteria were present: a. unexplained metabolic acidosis 
(pH,; 7.3, or base excess,; -5 mmol/l, or plasma lactate levels> 2 mmol/l); Q,. arterial 
hypoxia (PaO,'; 75 mm Hg, a PaO/FiO, ratio < 250, or a transcutaneous SaO,'; 0.96) in 
patients without overt cardiopulmonary disease; l<. acute renal failure (diuresis < 0.5 ml/kgl 
hr for at least one hour despite acute volume suppletion or evidence of adequate 
intravascular volume [defined by the presence of a palpable liver, a cardio-thoracic ratio on 
chest radiography> 0.4, and a central venous pressure> 5 mmHgJ) without pre-existing 
renal disease; or d. sudden deterioration of the baseline mental status. The pediatric risk 
of mortality (PRISM) score (274) was calculated using the most abnormal value of each 
variable recorded during the first 4 hours after admission at the PICU. The exact amount 
of volume suppletion (human plasma or fresh frozen plasma) administered during the stay 
in the ICU to restore the hemodynamic condition of the patient, was recorded. All patients 
received maximal supportive therapy: antibiotics, volume-administration, inotropic 
support, and mechanical ventilation. 
The study protocol was approved by the Medical Ethics Committee of the University 
Hospital Rotterdam. 
2.2 Collection of blood 
Arterial blood samples were collected within two hours after admission, and after 24 and 72 
hours. Blood for analysis of complement parameters was collected in vials containing 3.8% 
trisodium citrate, immediately chilled on ice, and centrifuged at 4000 g for 10 minutes. 
Subsequently, platelet-poor plasma was obtained by centrifugation of the supernatant at 
20000 g for 30 minutes at +4·C. Plasma was stored at -80·C until tests were performed. 
2.3 Assays 
White blood cell and platelet counts were determined using an automated platelet counter 
(Technicon H1-system, Technicon Instruments, N.Y.). Lactate was measured by 
enzymatic end-point determination and CRP by nephelometric assay (315). 
C3a levels were determined by a radio-immuno-assay (RIA) described previously (143) 
and expressed as nM. Levels of C3a in healthy persons are below 5 nM. Activation of C4 
was assessed with an ELISA as described previously (377). In brief, mAb anti C4-1, which 
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recognizes a neo-epitope on the C4 activation products C4b, C4bi, and C4c, together 
referred to as C4b/c, and not on native C4, was used as a catching Ab. Biotinylated 
polyclonal rabbit anti-human C4 Abs were used as detecting Abs. Results were expressed 
in nM. Activation of C3 was assessed with a similar ELISA (377). In brief, mAb anti-C3-9 
recognizing a neo-epitope on C3b, C3bi, and C3c (C3b/c) was used as catching Ab and 
biotinylated polyclonal rabbit anti-human C3c Abs were used as detecting Abs. Results 
were expressed in nM. Complement-CRP complexes were determined using a novel 
method (377). In short, purified complement complexes were quantified by differential 
antibody ELiSAs. In these ELiSAs monoclonal antibodies directed against C4d and C3d 
were used to capture complexes. These antibodies capture C4b/C4bi/C4d and C3b/C3bii 
C3d, respectively. CRP-complement complexes were detected by biotinylated monoclonal 
antibodies against CRP. Results were expressed as pM of complement fixed to CRP. 
Levels of both types of complexes in normal healthy volunteers were below the limit of 
detection (4 pM). 
Functional and proteolytically inactive C1-lnh (fC1-lnh and iC1-lnh, respectively), were 
determined with RIAs (252). The concentration in normal pooled plasma of fC1-lnh and 
iC1-lnh was 2.5 ~M and 0.08 ~M, respectively; levels in patients were expressed as % of 
this plasma pool. Type II secretory-phospholipase A2 (sPLA,) was determined by ELISA 
(379). SPLA, levels in heallhy volunteers are below 5 ~g/l. Lactoferrin and elastase-u',-
antitrypsin (u',AT) complexes were determined with RIAs (254). IL-6 and IL-8 were 
measured with ELiSAs obtained from the Department of Immune Reagents (CLB, 
Amsterdam). These ELlSA"s were performed according to manufacturers' instructions. 
Normal levels are <10 pg/ml for IL-6, and <20 pg/ml for IL-8. C4BP concentrations were 
measured by electro-immunodiffusion. Normal levels are 68-140% of normal. 
2.4 Statistical analysis 
Results are expressed as medians (range) unless otherwise specified. Mann-Whitney U-
test and Wilcoxon signed rank test were used to evaluate between and within groups 
differences. Relationship between parameters were tested by assessing Spearman's rank 
correlation. Mulliple regression analysis, taking account of duration of skin lesions, was 
used to compare survivors and non-survivors regarding the logarithmically transformed 
levels of inflammatory parameters. Logistic regression was performed to evaluate the 
relation of the various parameters to mortality. This analysis proceeded on two steps. In the 
first step parameters were grouped into categories (cytokines parameters, neutrophil 
degranulation, complement activation products, and complement regulation). For each 
category separately the variables most predictive for mortality were determined using 
backward elimination. In the second step, the remaining variables after the first step were 
combined and again the backward elimination procedure was applied. The same 
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procedure was used with multiple regression to assess the relation between the various 
parameters and capillary leakage and lactate respectively. Two-tailed p values'; 0.05 were 
considered statistically significant in each test. 
3 RESULTS 
3.1 Demographics 
Fifty-two patients fulfilling the entry criteria and admitted to the PICU were enrolled in the 
study. Thirty-two were males (62%), 20 females (38%) The median age was 3.3 years 
(range 0.4-17.9). Thirty-eight of the 52 patients (73%) survived, the other 14 (27%) died. 
Cultures of blood, cerebrospinal fluid or skin biopsies revealed Neisseria meningitidis in 46 
(89%) patients and Haemophilus influenzae in 1 patient. Cultures were sterile in 5 patients. 
Thirty-three (64%) patients needed mechanical ventilation. Due to the lack of sufficient 
plasma, complement parameters were not determined on admission in 7 patients. Forty-
nine of the children participated in a randomized, placebo-controlled trial to evaluate the 
efficacy of a human monoclonal antibody, HA-1-A (Centoxin@, Centocor, Malvern, PA, 
USA), in meningococcal septic shock. On admission, HA-1-A or placebo were 
administered after blood was collected. There was no significant difference in mortality 
between HA-1-A-treated and placebo-treated patients. 
3.2 Differences between survivors and non-survivors 
In table 1 and 2 clinical and laboratory parameters related to severity of disease, and to the 
extent of cytokine release, neutrophil degranulation and complement activation, are 
compared between survivors and non-survivors. As expected clinical and biochemical 
parameters related to the severity of disease were significantly different between survivors 
and non-survivors. Regarding parameters related to cytokines, IL-6 and IL-8 levels were 
substantially elevated and significantly higher in non-survivors than in survivors. Levels of 
the two acute phase proteins CRP and sPLA" of which the synthesis is induced by 
cytokines and which hence reflect the release of cytokines, were both elevated in either 
patient group but in contrast to cytokines, the highest levels occurred in survivors. All 
patients had evidence of increased degranulation of neutrophils: elastase levels were 
elevated in all patients, although the difference between levels in survivors and non-
survivors did not reach statistical significance (p=0.08). Also circulating levels of lactoferrin 
were increased in all but one child, levels in non-survivors were significantly higher. 
Regarding activation of complement, C3a and C3b/c levels were increased in all but four 
the patients, whereas C4b/c was elevated in all but one. Levels of either 
complementactivation product were higher in non-survivors. All patients had increased 
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Table 1. Clinical and laboratory parameters related to severity of disease on the time of admission in children 
with septic shock and purpura 
Parameter survival normal values 
survivors (N=38) non-survivors (N=14) 
PRISM 10 (1-38) 20 (8-25)' 
lactate (mmolll) 4.3 (1.1-15.5) 7.3 (2.9-20.0)' <2.0 
duration petechiae (h) 5.3 (1.0-11.5) 3.6 (0.5-8.5)' 
WBC (x 10'11) 13.2 (1.4-44.4) 5.8 (1.3-12.6)' 35894 
plasma infusion (mllkg) 65 (12-307) 120 (59-182)' 
Values are medians (range); & p < 0.05; for the difference between groups (Mann-Whitney U-test), 
PRISM, pediatric risk of mortality score; WBC, white blood cell count. 
complement-CRP complexes (C3 and C4) indicating that part of the complement activation 
had occurred via CRP. However, levels of these complexes were lower in non-survivors, 
the difference of C3-CRP complexes between survivors and non-survivors was significant. 
Functional C1-lnh levels varied widely. In survivors levels were decreased in some 
patients, whereas they were normal or elevated in others. In the non-survivors functional 
C1-lnh was decreased or normal, but never elevated. However, differences between 
survivors and non-survivors were not significant. Levels of proteolytically inactivated C1-
Inh were normal in 9 of the patients. In the other patients the levels, though substantially 
elevated, varied widely. The difference between survivors and non-survivors just did not 
reach statistical significance (p=O.07). 
3.3 Relation between inflammatory and clinical parameters 
Multiple regression analysis for the relation between levels of inflammatory parameters 
and survival and duration of skin lesions showed that time adjusted concentrations of IL-6, 
IL-8, C3b/c, C3-CRP complexes, C4BP, and WBC were still significantly different between 
survivors and non-survivors: IL-8 levels were on the average 11.8 times higher in non-
survivors (p=O.003) and were also negatively related to the duration of petechiae 
(p=O.005). Time adjusted levels of C3b/c on admission were on the average 2.2 times 
higher (p=O.004) in non-survivors than in survivors (Fig: 1). C3-CRP levels were on the 
average 1.9 times higher in survivors than in non-survivors (p=O.035), and not related to the 
duration of petechiae. Logistic regression with backward elimination showed that mortality 
was independently related to levels of C3b/c (p=O.03) and C3-CRP complexes (p=O.03). 
Fig: 2 shows the dichotomous distribution between these two parameters. 
IL-6, IL-8 and CRP were closely correlated to all parameters for severity of disease (table 
3). This was also observed for the complement activation products. The strongest 
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Table 2. Parameters related to cytokines, neutrophil degranulation, complement activation and complement regulation on day 0, 1 and 3 after admission in 
children with septic shock and purpura 
Parameter admission d 1 d3 normal 
survivors (N=38) non-survivors (N=14) survivors (N=34) non-survivors (N=5) survivors (N=31) values 
IL-6 (ng!ml) [49] 15.3 (0.036-1507) 280.6 (0.087-2002)' 0.1 (0.01-186)' 20.7 (0.7-50.0)' 0.02 (0.002-7.4)' < 0.001 
IL-8 (ng!ml) [49] 1.1 (0.013-381) 8.8 (0.023-369)' 0.03 (0.001-23.7)' 0.8 (0.15-2.1)' 0.03 (0.001-0.8)' < 0.002 
CRP (mgll) [51] 128 (34-258) 70 (38-162)' 255 (145-444)' 210 (141-378)' 152 (42-401) <2 
sPLA, (ng!ml) [48] 131 (2-1461) 97 (9-1907) 167 (15-847) 102 (12-573) 18 (1-384)' <5 
elastase (ng!ml) [49] 512 (181-3376) 641 (251-3132) 317 (94-572) 410 (277-699)' 177 (67-908)' < 100 
lacto!errin (ng!ml) [49] 2584 (124-32285) 4275 (1757-31717)' 385 (146-3518)' 662 (307-1896)' 206 (88-920)' <400 
C3a (nmol!l) [46J 12 (2-52) 30 (17-58)' 12 (3-49) 20 (6-30) 5.8 «2-67)' <5 
C3b!c (nmol!l) [49] 199 (26-826) 478 (196-1087)' 33 (14-604)' 67 (19-92)' 25 (9-305)' <50 
C3-CRP (pmolll) [31] 291 (68-695) 156 (59-286)' 425 (136-1221)' 266 (210-426)' 374 (79-1562)' <4 
C4b!c (nmol!l) [49] 56 (22-1340) 110 (33-562)' 52 (13-255) 181 (33-310) 47 (20-175) < 25 
C4-CRP (pmol!l) [30] 67 (30-164) 53 (26-77) 99 (33-842)' 85 (52-106) 74 (15-341)' <4 
fC1-lnh (%) [46] 79 (43-156) 72 (34-99) 100 (38-179)' 92 (76-103) 132 (52-192)' 80-120 
iC1-lnh (%) [48J 378 (53-1141) 863 (96-2100) 168 (56-514)' 166 (128-476) 128 (75-181)' < 160 
C4-BP (%) [50] 72 (33-108) 53 (24-89)' 92 (58-139)' 99 (94-107)' 113 (73-224)' 80-120 
Values are medians (range); 8. p < 0.05; for the difference between groups (Mann-Whitney U-test), § p < 0.05 for the differences within groups (Wilcoxon 
signed rank test); [number of measurements when deviant from 52] 
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Table 3. Correlation coefficients between clinical and inflammatory parameters. 
PRISM lact time WBC lnf 
IL-6 0.41 0.43 ·0.52 -0.7 0.62 
IL-8 0.36 0.45 -0.46 -0.7 0.59 
CRP -0.34 -0.3 0.42 0.43 -0.41 
sPLA 0.36 
elast 0.59 
lactof 0.29 0.68 -0.33 0.37 
C3a 0.69 0.46 -0.51 -0.4 0.75 
C3bc 0.53 0.53 -0.39 -0.4 0.57 
C3crp 0.39 
C4bc 0.46 0.33 -0.29 0.38 
C4crp 
fClln 
leiin 
C4BP -0.32 0.36 -0.43 
Values are Spearman rank correlation coefficients; only significant (p < 0.05) values are presented; lact, 
arterial lactate; lime, dUration of petechiae; WBC, white blood cell counts; inf, total amount of plasma infused; 
IL~6, interleukin 6; IL-S, inter/eukin 8; eRP, C-reactive protein; sPLAt secretory phospholipase A2; elast. 
elastase; lactof, lactoferrin; C3a, C3b/c, C4b/c, C3 and C4 activation products; C3crp and C4crp. complexes 
beween eRP and activated C3 or C4 respectively; (Giln, functional C1-lnh; ieiin, proteolytically inactivated 
C1-lnh; C4BP, C4 binding protein. 
correlation appeared to be that between the complement activation products and the 
PRISM score (Fig: 3) or the total amount of plasma infused. Of the neulrophil degranulation 
products lactoferrin correlated with 4 out of 5 severity of disease parameters; Ihere was a 
strong correlation between elastase and the arterial lactate levels (r=0.59, p < 0.001). 
Multiple regression analysis of the various categories of variables showed that the levels 
of C3a, (p < 0.001) and the C4BP levels (p < 0.001) were independently related with the 
tolal amount of plasma infused; Fig: 4 represenls the relation (r=0.77; p < 0.001) between 
Ihe total amount of plasma infused, and the weighted sum (using the regression 
coefficients as weight) of C3a and C4BP (73x(1091OC3a)-1.0xC4BP). Similar statistical 
analysis showed that levels of C3a (p < 0.05), elastase (p=O.OO7), and lactoferrin (p=O.001) 
were independently related with the arterial lactate levels. Fig: 5 represents the relation 
(0.78; p < 0.001) between lactate levels and the weighted sum of C3a, elastase and 
lactoferrin (0.142x(loglOC3a) + 0.280x(loglOelaslase) + 0.257x(1091O lactoferrin)). 
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Table 4. Mutual relation between inflammatory mediators 
CRP sPLA elasl lactof C3a C3b/c C3crp C4b/c C4crp fC1in iC1in C4BP 
IL-6 -0.68 0.4 0.56 0.58 0.59 -0.56 -0.53 -0.33 
IL-8 -0.61 0.41 0.59 0.56 0.65 -0.57 -0.52 -0.3 
CRP 0.32 -0.3 -0.36 -0.3 0.64 0.55 0.36 
sPLA 0.32 0.3 0.41 
elast 0.66 0.5 0.3 
laclof 0.3 0.66 0.39 0.53 -0.47 -0.37 
C3a -0.36 -0.3 0.39 0.72 0.58 0.35 
C3b/c -0.3 0.5 0.53 0.72 0.5 
C3crp 0.64 -0.5 0.91 0.67 
C4b/c 0.3 0.58 0.5 0.38 
C4crp 0.55 -0.4 0.91 0.38 0.6 
fC1in 0.52 
IC1in 0.4 0.39 0.32 
C4BP 0.36 0.67 0.6 0.52 
Values are Spearman rank correlation coefficients; only significant (p < 0.05)values are presented. See also legends 
table 2 for explanation of the abbreviations. 
3.4 Mutual relation between the inflammatory parameters 
Complement activation products levels C3a and C3b/c correlated positively with IL-6 and 
IL-8, and negatively with CRP (table 4). The levels of complement-CRP complexes 
showed an inverse correlation pattern: the correlation of these markers for CRP-dependent 
complement activation with interleukins was negative, whereas that with CRP was positive. 
Levels of C4b/c, representing the activation of the classical pathway of complement, did not 
correlate with IL-6, IL-8 or CRP. However, these levels showed a strong correlation with 
C3a (Fig: 6) and C3b/c levels, as well as with C4-CRP complexes, indicating a substantial 
part of the activation of the complement system had occurred through the classical 
pathway, probably via CRP. C3- and C4-CRP complexes both closely correlated with IL-
6 and IL-8, CRP, lactoferrin and C4BP. The functional C1-lnh levels correlated with levels 
of the other complement regulation protein C4-BP_ The levels of inactivated C1-lnh 
correlated with levels of sPLA,. Finally, levels of elastase and lactoferrin correlated well 
with those of IL-6 and IL-8 (table 4). 
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Figure 1. C3b/c levels on admission versus the time between the onset of petechiae and the moment of blood-
sampling in surviving (open circles) and non-surviving (closed circles) patients. Solid and dashed lines 
represent least of squares regression lines of the wo groups. The wo angles of inclination of the regression 
lines do not significantly differ. Time-adjusted C3b/c-values were on the average 2.2 times higher in non-
survivors (p=O.004). 
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Figure 2. C3-CRP complex versus C3b/c levels on admission in surviving (open circles) or non-surviving 
(closed circles) patients show a dichotomous distribution (dotted lines represent medians). Both variables 
were independently related to survival. 
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Figure 3. C3a levels on admission versus PRISM score in surviving (open circles) or non-surviving (closed 
circfes) patients. Dotted line represents upper level of normal. Solid line represents the least squares 
regression line for all data points (r=0.69, p < 0.001). 
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patients. The solid line represents the least squares regression line for all data points (r=O.77; p < 0.001). 
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3.5 Time course of laboratory parameters 
Table 2 presents the time-course of the different inflammatory variables. Levels of CRP 
and sPLA, remained increased until 72 h, and were not different between survivors and 
non-survivors except for CRP levels on admission. The levels of complement activation 
products C3a and C4b/c were still elevated at 72 h, while those of C3b/c were already 
normalized at 24 h. In 50 % of the patients C3a and C4bc were higher at 24 h than on 
admission. The course of complement-CRP complexes was remarkable in that levels were 
higher in survivors, and that higher levels were observed on days 1 and 3 compared to 
those on admission. Elastase levels decreased until 72 h, but remained elevated. At 24 h 
levels were different between survivors and non-survivors. At 72 h levels in surviving 
patients were still elevated except in 2 patients. Levels of lactoferrin decreased more 
rapidly: at 24 h levels were within the normal range in 50 % of the survivors. The levels of 
functional C1-lnh increased gradually until 72 h. At that time 50 % of the survivors had 
levels above the upper level of normal. There was a more rapid decrease in levels of iC1-
Inh, at24 h 50 % of both survivors and non-survivors had levels within normal limits. C4BP 
levels increased gradually in time, although at 72 h there was a wide range (73-224) of 
plasma levels. 
4 DISCUSSION 
In this study of children with septic shock and purpura a high degree of complement 
activation was observed, which closely correlated with mortality, severity of disease and 
degree of capillary leakage, as estimated by the amount of plasma infused. A substantial 
part of this complement activation was through the classical pathway as can be deduced 
from the close relation between C4 and C3 activation products (C4b/c and C3a or C3b/c). 
This activation persisted for days and in some patients even increased after admission. 
The complement system can be activated through the classical pathway by antigen-
antibody complexes, through the alternative pathway by bacteria or LPS, and through the 
mannan binding protein pathway. As the more severe cases of SMD occur in patients with 
low or no liters of antibodies, the prevailing view is that the alternative pathway mainly 
contributes to complement activation in this disease. Recently Brandtzaeg and colleagues 
measured activation products of both the alternative as well as the classical pathway in 20 
patients with systemic meningococcal disease (41). Activation of C4 was not different 
between patients with or without shock, nor did they find a correlation between C4 and C3 
activation products. They concluded that the classical pathway only lillie contributed to total 
complement activation in patients with shock. In our patients C4b/c significantly correlated 
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with C3b/c or C3a, indicating that at least part of the C3 was activated via the classical 
pathway. Since we included only patients with shock, the difference with the results of 
Brandtzaeg et al. may have been caused by the larger number of children with severe 
disease in our study. Accordingly levels of activated C3 correlated better with severity 
indices than those of activated C4 (see for example table 2), implicating that the latter 
correlation may have been missed with a smaller number of patients. 
Assuming that levels of antibodies against meningococci are low in patients with SMD, one 
can raise the question through which mechanism the classical pathway was activated. 
CRP can activate the classical pathway upon binding to the phospholipid 
phosphatidylcholine, and it has been suggested that this in particular may occur in the 
presence of the enzyme secretory phospholipase A2, another acute phase protein (137). 
We measured CRP-complement complexes as an indicator for CRP-mediated 
complement activation (378), and also assessed the relationship between CRP levels and 
complement activation parameters to address the question whether CRP was involved in 
the observed complement activation. CRP levels were negatively correlated with 
complement activation products C3a, and C3b/c and there was a negative relation 
between C3-CRP levels and survival (Fig: 2). Hence, the contribution of CRP-mediated 
activation to the total complement activation was probably minor. On the other hand the 
correlation between C4b/c levels and C4-CRP complexes was significant, indicating that at 
least a substantial part of the classical pathway activation had occurred via CRP (see table 
4). CRP levels also positively correlated with the duration of petechiae suggesting a shorter 
disease course in the patients with lower CRP levels. CRP levels were lower in non-
survivors than in survivors, at 24 h the levels had further increased in both groups, but there 
was no difference between the groups anymore. Thus, very likely the difference between 
surviving and non-surviving patients regarding CRP levels on admission, reflected that the 
non-survivors were admitted earlier in their disease course. Accordingly levels of sPLA" of 
which levels increase somewhat earlier during an acute phase reaction (283), were not 
different between survivors and non-survivors. 
Activation of the classical pathway of the complement system is amongst others regulated 
by the plasma proteins C1-inhibitor (C1-lnh) and C4b binding protein (C4BP). C1-lnh 
inhibits activated C1, whereas C4BP inactivates C4b by acting as a co-factor for the 
cleavage of C4b by factor I. Both C4BP and C1-lnh are acute phase proteins and during 
severe infections plasma levels are increased. In our patients the levels of C4BP were 
decreased and negatively correlated to outcome and severity of disease (PRISM and total 
plasma infused), and positively to C1-lnh. The decreased levels ofC4BP may be explained 
by suppression of its synthesis by TNF-a (269), binding to serum amyloid protein P (313), 
or binding to bacterial surface proteins (183). To what extent these or other mechanisms 
accounted for the decreased levels of C4BP in our patients is difficult to say. Yet, this 
decrease is remarkable considering the acute phase behavior of C4BP and together with 
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the relatively low levels of C1-lnh may indicate a poor inhibition of the classical pathway. 
Furthermore, decreased levels of C4BP may have implications for the coagulation system: 
low levels of C4BP lead to relatively higher levels of free protein S, which may be of benefit 
during septic shock (167, 324). 
C1-lnh is the only known inhibitor in plasma of activated C1, and the major inhibitor of 
activated factor XII and kallikrein of the contact pathway of coagulation. Inhibition of these 
so-called target proteinases by C1-lnh leads to the formation of proteinase-C1-lnh 
complexes. The formation of these complexes is accompanied by the generation of 
proteolytically inactived C1-lnh species. The laUer species may also resull from 
inactivation by other endogenous (e.g., neutrophilic elastase) or exogenous, I.e. bacterial, 
proteinases. C1-lnh in plasma may thus exist in three forms: functional C1-lnh, inactive C1-
Inh and C1-lnh complexed to a proteinase (252). In our patients the levels of functional C1-
Inh were decreased or normal, which considering its acute phase behavior suggests a 
relative deficiency of this inhibitor, and hence a diminished regulation of the complement 
and contact system, with subsequent release of biologically active peptides. The time 
course of the levels of functional C1-lnh suggested consumption of this inhibitor, in 
particular during the early phase of the disease. The high levels of inactivated C1-lnh have 
been observed in experimental septic shock in baboons (29) as well as in patients with 
vascular leakage syndrome during IL-2 therapy (142). Our data do not allow conclusions 
regarding the mechanism of the generation of iC1-lnh in our patients. 
Neutrophils have been implicated as important mediators of vascular injury (35,310,352) 
by the release of toxic oxygen species and lysosomal proteinases, such as elastase, upon 
stimulation by a large variety of agonists. In addition, elastase may facilitate activation of 
complement, coagulation and fibrinolytic systems by inactivating the major inhibitors of 
these cascade systems (31,254). The levels of elastase and lactoferrin in our patients were 
similar to those found in adult patients with sepsis (254). The levels correlated with 
outcome, as well as with lactate (Fig: 6). Hence, activation and degranulation of neutrophils 
may contribute to tissue hypoxia and capillary leakage, for example by plugging of 
capillaries. Elastase and lactoferrin were also both correlated to complement activation 
products and IL-6 and IL-8, suggesting a cooperative effect of cytokines and complement 
in the process of neutrophil adherence and degranulation. 
During sepsis capillary leakage is caused by an increase in vascular permeability. Vascular 
permeability is dependent on a number of factors and can be affected both by direct 
damage to the endothelium, I.e. by activated neutrophils, and by mediators which alter its 
barrier function. These mediators include TNF, platelet activating factor, complement, 
kinins (such as bradykinin), and leukotriens, though the specific mechanisms for most of 
these remain to be elucidated. In our study the degree of capillary leakage was closely 
related to the extent of complement activation. Individuals with inherited component 
deficiencies have a markedly increased risk for acquiring systemic meningococcal 
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infections and may experience recurrent episodes of these. A striking finding in individuals 
with late complement component deficiencies compared with normal persons is the low 
mortality rate associated with meningococcal disease (83). It is therefore tempting to 
speculate that complement plays a dual role in the pathogenesis of meningococcal sepsis: 
on the one hand it contributes to the defense against meningococci, on the olher hand in 
patients suffering from SMD too excessive activation in particular via mechanisms not 
'triggered' by the micro-organisms themselves, may contribute to tissue damage and a 
complicated course. 
In conclusion, excessive activation of the complement system was demonstrated in 
children with septic shock and purpura, which activation in part had occurred via the 
classical pathway, and was related to outcome, severity of disease and extent of capillary 
leakage. Further studies, for example focusing on the effects of the therapeutical 
administration of C1-esterase inhibitor, may reveal whether this activation contributes to a 
detrimental course. 
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1 INTRODUCTION 
Septic shock with purpura, mainly caused by Neisseria meningitidis, is a life threatening 
entity in previously healthy children. Despite the use of antibiotics and intensive care 
treatment meningococcal sepsis (MS) is still associated with mortality rates up to 40% in 
the youngest children (0-3 years) and 13% in the older children (3-18 years) (158). While 
numerous studies have defined the hemodynamic and metabolic responses to sepsis in 
the adult, these responses have been poorly documented in young subjects and provide no 
clear answer to the finding of a greater morbidity/mortality in our younger patients. There 
is substantial, but controversial, experimental and clinical evidence for age related 
differences between neonatal, pediatric and adult sepsis (71, 91, 171, 172, 215, 266, 284). 
Consequently, information obtained from adult animals or humans cannot simply be 
extrapolated to the pediatric situation. Also, in many experimental sepsis studies 
chemically purified endotoxin from gram negative bacteria was used. However, in contrast 
to other gram negative bacteria, during their growth the N. meningilidis bacteria release 
endotoxin together with membrane material in the form of vesicle-like structures (blebbing). 
It is probable that in this way rough meningococcal endotoxin bears more antigenic potency 
than chemically purified endotoxin. In those studies where purified meningococcal 
endotoxin was used, small laboratory animals were studied, which do not allow as detailed 
an analysis of global and regional hemodynamic changes during sepsis, compared to 
larger animals such as pigs. 
Therefore, the purpose of the present study was to investigate whether significant 
differences exist between the global hemodynamic and regional blood flow responses to 
different dosages of rough meningococcal endotoxin challenge in young (8 kg), 
corresponding to a child of 1 year of age, and older piglets (40 kg), corresponding to a child 
of 10 years of age. Animals were chronically instrumented and studied in the awake state, 
to avoid the effects of anesthesia and acute surgical trauma. Since the major component 
of first therapeutical intervention in the clinical situation of sepsis is intravascular volume 
expansion, the effect of this treatment during placebo and endotoxin infusion was studied. 
2 MATERIALS AND METHODS 
2.1 Experimental groups 
In the present study landrace x Yorkshire domestic piglets of 4 months of age, 40.5±0.8 kg 
(n=19) and of3 weeks of age, 7.2±0.3 kg (mean±SEM) (n=16) were studied. The animals 
were randomly assigned to a group receiving either a low (1 ~g per kg body weight) or a 
high (1 0 ~g per kg body weight) dose of endotoxin, yielding a total of 4 groups of animals: 
old, low dose (Ol) and old, high dose (OH), and young, low dose (Yl), and young, high 
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dose (YH). 
All experiments were performed in accordance with the "Guiding Principles in the Care and 
Use of Laboratory Animals" as approved by the Council of the American Physiological 
Society and with the approval of the Animal Care Committee of the Erasmus University 
Rotterdam. 
2.2 Surgical procedure 
The animals were fasted for 15 h prior to the surgical procedure. The older animals were 
sedated with intramuscular (im) injection of 25 mg/kg ketamine (Ketalin®, Apharmo, 
Arnhem, The Netherlands), followed by induction of anesthesia with an intravenous (iv) 
injection of 10 mg/kg methomidate (Hypnodil®, Janssen Pharmaceutical, Tilburg, The 
Netherlands) through an ear-vein cannula. The younger animals were sedated by mask 
inhalation of a mixture of O/N,O mixture (1 :2) and isoflurane (3%), followed by induction 
of anesthesia with iv methomidate. 
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Figure 1. Schematic description of surgical and experimental procedure. 00-09: days, h: hours, M1-M5: 
microspheres injections, S: blood sample, Vl: volume loading. 
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All animals were inlubated and ventilated with a Servo 900-B ventilator (Siemens-Elema, 
Solna, Sweden). Anesthesia was maintained with an O/N,o mixture (1 :2) and isoflurane 
(0.25-3%). The respiratory rate was set at 25/15 min·' (young/old), while minute volume 
and FiO, were adjusted to keep the arterial PaCO, and PaO, within physiological limits. To 
maintain fluid and metabolic balance, 5 mllkg/h glucose 5% in NaCI 0.225% was 
administered iv continuously. Under sterile conditions both external jugular veins and 
common carotid arteries were surgically exposed through a ventral paramedian incision. 
On the right side a 7/8 (young/old) F catheter (Cordis®, Roden, The Netherlands) was 
inserted and positioned in the descending aorta for blood sampling and measurement of 
arterial blood pressure (MAP); while through the jugular vein a thermodilution catheter 6/ 
7.5 (Y/O) F (ArroW®, Reading, USAISpectramed, Bilthoven, The Netherlands) was 
introduced and advanced into the pulmonary artery to monitor the mean pulmonary artery 
pressure (MPAP), cardiac output (CO), pulmonary artery occlusion pressure (PAOP), and 
central venous pressure (CVP), and to sample mixed venous blood. The left carotid artery 
was cannulated with a 7F pressure transducer-tipped catheter (Sensodyn MTC®, Braun 
Medical, Uden, The Netherlands), which was positioned in the left ventricle to measure the 
left ventricular pressure, and via a separate lumen to inject radio-active labeled micro 
spheres. A 6/7 (Y/O) F catheter (Cordis®) was inserted into the external jugular vein for 
drugs and fluid administration. Once the proper position of the catheters was verified, using 
fluoroscopy, all catheters were tunneled subcutaneously to the dorsal side of the neck and 
secured with sutures. Both the subcutaneous layers and the skin edges were 
approximated with single sutures. After weaning from anesthesia and ventilation, the 
animals were extubated and allowed to recover from surgery. Catheters were protected 
with a soft jacket (317). 
2.3 Post surgical period 
Catheters were flushed with heparin-solution (500 IU/ml) once a day. Prophylactically, the 
animals received 25 mglkg amoxicilline (Clamoxyl®, SB-Farma, Rijswijk, The 
Netherlands) and 5 mg/kg gentamicin (A.U.v. Cuyk, The Netherlands) ivonce daily starting 
on the day of the surgical procedure. Every day, the animals were adapted to the laboratory 
facilities (7-10 days) to ensure hemodynamic stability. The experimental protocols were 
executed when the animals could rest unrestrained and quietly for up to 4 h, and systemic 
hemodynamic parameters therefore remained stable. 
2.4 Endotoxin preparation 
Outer membrane (OM) blebs were prepared from Neisseria meningilidis group B strain 
H44/76 using a previously described method (275). Briefly, bacteria were treated with 0.2 
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M liCI and 0.01 M EDTA at pH 7.0 during 2 h at 45'C. The mixture was centrifuged at 
15,000 rpm for 10 min to remove bacteria and the supernatant ultracentrifuged to peel off 
the outer membranes. The pellet was resuspended in saline with 2% sucrose and 0.02% 
merthiolate and stored in vials at 4-8'C. Blebs were analyzed for KDO (2-keto-3-deoxy-D-
manno-oetonate) content (186), and quantified by electrophoresis (SDS-PAGE) following 
silver staining (338). The concentration of protein was 50~g/ml. On the day of the endotoxin 
protocol the needed amount of endotoxin was diluted with saline to a total volume of 10/20 
ml (Y/O). 
2.5 Experimental setup 
2.5.1 hemodynamic measurements 
The fluidfilled catheters were connected to pressure transducers (DT-XX, Viggo-
Spectramed, Bilthoven, The Netherlands), which drove an amplifier with a digital readout. 
CO was measured in duplicate by the thermodilution technique, using ice cold saline, 3/10 
(Y/O) ml, and a cardiac output computer (Adquipment Medical, Rotterdam, The 
Netherlands). When CO readings differed by more than 10 %, a third measurement was 
made. The first derivative of the left ventricular pressure (LV dP/dt) was obtained via 
electrical differentiation. 
2.5.2 clinical chemistry 
Blood gas, hemoglobin and oxygen saturation were determined by running 0.3 ml of arterial 
and pulmonary arterial blood through a hemoximeter (OSM-2, Radiometer, Copenhagen, 
Denmark) and a blood gas analyzer (ABL 505®, Radiometer, Copenhagen, Denmark). 
Serum lactate (Sigma Diagnostics, St Louis, USA) and glucose (Merck Diagnostics, 
Darmstadt, Germany) were both measured by enzymatic end-point determination. Arterial 
hemoglobin levels were determined using a cell counter (OSM-2, Sysmix, Kobe, Japan). 
2.5.3 regional organ blood flows 
Regional organ blood flows were determined at two time points in the placebo protocol and 
at 3 time points in the endotoxin protocol (M1-M5 in Fig. 1) by injecting a batch of 0.512 x1 0' 
(Y/O) carbonized plastic microspheres (15±1~m in diameter) labeled with either"Sc, 95Nb, 
103Ru, 113Sn or 141Ce into the left ventricle. To calculate regional blood flows a reference 
blood sample was withdrawn from the catheter in the descending aorta at a rate of 5/1 0 mil 
min (Y/O), starting 15 s before the injection of microspheres, until 90 s after completion of 
the injection of the micro-spheres. At the end of the experiments animals were sacrificed 
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with an overdose of sodium pentobarbital (Euthesate, Apharmo, Arnhem, The 
Netherlands), and various organs (adrenals, liver, spleen, small intestine, brain and 
kidneys) and representative aliquots of abdominal skin and skeletal muscle (M. 
sternocleidomastoideus and M. iliopsoas) were excised, weighed and put into vials. The 
hearts were fixated in formaldehyde (3.6%v/v) and 48 h later the atria and right ventricle 
were dissected from the left ventricle and the total myocardium of the left ventricular free 
wall was divided into three layers of equal thickness, i.e. subepicardium, mesocardium, 
and subendocardium. Radioactivity was counted and the amount of blood flow to the 
various tissues (<1>u,) calculated as: 
<1>u,(ml/mln)=(lu/l,rt)x,rt 
where lti' and I," are the radioactivity (cpm) in a particular tissue and that of the arterial blood 
sample, while <1> ,rt is the rate of withdrawal of the blood sample, respectively. Blood flows 
were expressed as ml.min-' per 100 g of tissue. Regional vascular conductances were 
calculated by dividing the respective regional blood flows by the mean arterial blood 
pressure. Full details of the procedures and the calculation of flow data using this technique 
have been reported earlier (376). 
2.6 Experimental protocols 
In each of the four experimental groups, animals underwent a placebo protocol and an 
endotoxin protocol performed on separate days (Fig. 1). 
2.6.1 placebo 
The placebo protocol consisted of infusion of saline with the same sucrose (2%) and 
merthiolate (0.02%) concentration as the endotoxin solution. The volume of placebo 
solution was identical to the volume of endotoxin solution and also diluted with saline to a 
total volume of 10/20 (Y/O) ml. This volume was infused in one hour. To study the 
hemodynamic effect of volume loading, after a washout phase of 1 hour a volume infusion 
was started consisting of 30 mllkg plasma substitute (Haemaccel®, Behring Pharma, 
Amsterdam, The Netherlands) infused over 30 min. After this volume loading there was a 
washout phase of one hour. The time points of blood sampling (S) for blood gas, glucose 
and lactate determination, and microsphere injections (M1 and M2) are indicated in Fig.1. 
The endotoxin protocol was performed at least 48 h later. The two day period between the 
two protocols was chosen to allow wash out of the plasma administered during volume 
loading. 
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2.6.2 endotoxin 
The dose of endotoxin was estimated from experience obtained in pilot experiments. The 
low dose (1 ~g/kg) ought to be non-Ielhal, and the high dose sub-lethal. Since it is known 
that there is a rapid increase in pulmonary vascular resistance in the early phase of 
endotoxin infusion (259), we supplemented oxygen (3-5 I/min) to prevent hypoxia in the 
initial phase. When the MPAP increased threefold (usually at 10 min), the endotoxin 
infusion was interrupted until MPAP had decreased to below 2 times the baseline value 
(usually at 30 min). At that time Ihe infusion was restarted at a higher rate to accomplish the 
infusion within 1 h. During the complete protocol 5 ml/kg/h fluid was iv administered 
(glucose 5% in NaCI 0.225%). After the endotoxin infusion a period of 1-2 h was allowed 
to establish a stable hemodynamic situation before starting the volume loading, which was 
also 30 ml/kg plasma substitute in 30 minutes. After completion of the volume loading a 
washout period of 2 h was taken, before termination of the protocol. Moribund animals 
during the protocol were humanely euthanized. 
2.7 Data acquisition and analysis 
Data were recorded and digitized at a sample rate of 200 samples/sec/channel using an 
eight channel data-acquisition program ATCODAS (Dataq Instruments, Inc., Akron Ohio, 
USA) and stored on a computer for later post-acquisition analysis with a curve analysis 
software program written in Matlab (Matlab®. The MathWorks, Mass, USA) to calculate 
average values of 20-30 heart beats at 30 minute intervals. The cardiac index (CI), stroke 
index (SI), stroke work index (SWI), syslemic vascular resistance index (SVRI), 
pulmonary vascular resistance index (PVRI), 02 content (CO2), oxygen delivery (DO,), and 
oxygen consumption (VO,) were calculated with standard formulas: CI=CO body weight·, 
[L.min·'.kg·'], SI=CI/HR [mL.kg"j, SWI=SlxMAP [L.kg".mmHg], SVRI=(MAP-CVP)xCI" 
[mmHg.L".min.kgj, PVRI=(MPAP-PAOP)xCI"[mmHg.L".min.kgj, Co,=0.6xHbxSaO, 
+0.00131xpO, [mil'], DO,=ClxC02art, VO,=Clx(Co,art-Co,mix ven), respectively. 
Statistical analysis was performed using (SPSS®, Chicago, USA) Wilcoxon signed rank 
test or paired Student I-tests to compare values at baseline with subsequent time points 
within groups. Differences between groups regarding longitudinal measurements, were 
tested with repeated measurements ANOVA on the relative change from baseline values 
(BMDP5V - unbalanced repeated measures models with structured covariance matrices, 
1990 by BMDP Statistical Software, Inc. Los Angeles, CA 90025 USA). When appropriate, 
logarithmically transformed values were used. The values at Ihe start of the separate 
interventions (endotoxin and volume loading) were taken as baseline for the evaluation of 
the particular interventions. Evaluation of dose and age regarding regional blood flow 
measurements were performed using two-way ANOVA. As there were no differences 
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between low dose placebo and high dose placebo, the groups of YL and YH were 
combined to evaluate the effects of placebo. The same applied to OL and OH. In view of 
the number of comparisons made, significance was accepted for p-values of <0.01 (two-
tailed). Data are presented as mean±SEM, or median (range). 
3 RESULTS 
3.1 Survival and general manifestations 
Infusion of placebo was uneventful in all animals, but during infusion of endotoxin both the 
old and young animals became restless and even agitated when pulmonary vascular 
resistance started to increase suddenly between 10-30 min after the start of infusion. This 
was accompanied by tachypnea (breathing frequencies >80/min), vomiting, shivering, 
reduced reaction to stimuli and finally lethargy. Core temperature increased approximately 
2°C during infusion of endotoxin, which was substantially more than during infusion of 
placebo (OSC, p< 0.01). Mortality was 0, 3,1 and 4 animals in group YL (0%), YH (37.5 
%), OL (12.5 %) and OH (44 %), respectively. The time to death was 149 ± 13 min after the 
start of the endotoxin infusion. 
3.2 Hemodynamic responses 
3.2.1 baseline values (table 1 and 2) 
As expected, the baseline values of most hemodynamic parameters were different for the 
old and young animals, with the most pronounced differences in CI, HR, SI, MAP, pulse 
pressure, SVRI, SWI and PVRI. These differences are related to developmental changes 
in cardiac output and vascular resistance (150). 
3.2.2 placebo infusion 
Besides a Significant increase in SVRI in the young animals, there were no changes in 
hemodynamic variables during the placebo infusion or the period immediately after 
placebo infusion (table 1). Volume loading resulted in an increase in: CI, SI, SWI, filling 
pressures, mean pulmonary and systemic pressures, and a decrease in SVRI. There was 
no change in PVRI. Although the variables recovered slightly towards baseline values, 
most parameters were still significantly increased 60 min after completion of the volume 
loading. 
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Table 1. Hemodynamic variables during and after placebo infusion and volume loading in old and young piglets 
Placebo (min) Volume Loading (30 min) Wash out (min) 
Group N 0 60 begin end 60 
CI Old 15 0.13±0.00 0.13±0.00 0.13±0.OO 0.17±0.OO § O.15±O.O1 § 
(llmin/kg) Young 14 O.1:±0.O1 0.19±0.O1 0.19±O,01 0,25±O,01 § 0.22±0.O1 § 
HR Old 17 100±4 97±4 98±4 107±5 104±4 
(beats/min) Young 14 124±6 125±5 124±5 141±6 § 129±7 
SI Old 15 1.3±O.1 1.3±O.1 1.3±O.0 1.6±O.1 § 1.5±O.1 § 
(ml/beatlkg) Young 14 1.6±O.1 1.5±O.O 1.5±O.0 1.B±O.1 § 1.7±O.1 
LVEDP Old 14 7±1 8±1 10±2 23±2B § 16±2 
(mmHg) Young 11 8±1 10±1 10±1 19±111 § 14±1 
LV dP/dt Old 14 2718±17: 2646±178 2548±165 2980±7: § 2655±115 
(mm Hg/s) Young 10 2668±171 2548±179 2446±141 2983±222 272:±216 
MAP Old 17 98±2 97±2 102±2 110±3 § 112±3 § 
(mm H9) Young 14 83± 287±2 89±2 97±411 § 96±3 § 
SAP-DA Old 17 3:±2 40±2 40±2 45±3 40±2 
(mmHg) Young 14 41±3 43±3 43±3 43±3 43±3 
CVP Old 13 1±2 2±2 1±1 9±2P.. § 7±2 
(mmHg) Young 12 3±1 3±1 3±2 8±1 6±2 
SVRI Old 12 776±33 769±37 838±4: 614±23 § 673±14 
(mm Hg.min.kg/I) Young 12 403±1: 436±19 # 457±23 # 330±1: § 41S±17 
SWI Old 15 125±7 127±7 132±5 178±12 § 167±8 § 
(mm Hg.mllb/kg) Young 14 134±7 133±6 13S±S 173±: § 1S:±8 § 
MPAP Old 17 16±1 17±1 18±2 29±2P.. § 26±2 § 
(mmHg) Young 13 17±1 18±1 16±1 23±2B § 18±2 
PVRI Old 9 91±10 104±12 109±9 10:±13 104±8 
(mm Hg.min.kg/I) young 9 67±6 63±7 6HB 63±11 43±7 
CI, cardiac index; HR, heart rate; SI, stroke index; LVEDP. left ventricular end diastolic pressure; LV dP/dt, first derivative to time of LV pressure; MAP, 
g 
{J 
mean arterial pressure; SAP·DAP, pulse pressure; CVP, central venous pressure; SVRI, systemic vascular resistance index; SWI, 
" :;:: stroke work index; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary vascular resistance index; p< 0.01, # vs baseline, § vs prevolume load, & young vs old; VLb, e, ~ 
'" '" 
begin and end volume load. 
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3.2.3 endotoxin infusion and volume loading OL (table 2) 
During the endotoxin infusion and the subsequent 1-2 hours, the CI remained stable, 
despite a nearly 50% decrease of in stroke index (p<0.005). This was possible because 
an increase in heart rate of 100 ± 3 b min" at baseline to 178 ± 11 b min-' at 60 min after 
the end of infusion. The MAP decreased significantly at t=120. There were no significant 
changes in LVEDP and CVP, a trend towards increase of the LV dP/dt, and towards an 
increase in the pulse pressure (SAP-DAP). The SWI decreased more than 50%. An 
increase in MPAP was usually the first hemodynamic sign after the start of the endotoxin 
infusion. At about 10 min, there was an abrupt rise in MPAP to 2-3 fold the baseline level. 
The PVRI, measured at 1 hour intervals, increased significantly to 2 fold the baseline levels. 
The volume loading did not result in a significant increase of CI and SI, the HR decreased 
significantly and this decrease persisted in the hours after the VL. There was a trend to an 
increase in LVEDP, while LV dP/dt and SVRI did not change significanlly. The SWI and the 
MAP increased significantly by the VL, an increase which persisted in the hours after the 
VL. The MPAP and PVRI decreased to baseline levels in the hours after the VL. 
3.2.4 endotoxin infusion and volume loading YL (table 2) 
Except for the CI, LVEDP and pulse pressure, the hemodynamic pattern in the young 
animals was merely the same as the old animals_ The CI did not remain stable during the 
ET infusion, it decreased significantly despite an early increase in HR. There was a 
decrease in LVEDP, this decrease was significant at the beginning of volume loading 
compared to baseline. The pulse pressure decreased significantly in YL, while in OL the 
pulse pressure increased. 
After the volume loading (VL) the LVEDP was significantly higher when compared to pre-
VL levels, an increase which did not persist to the direct post-VL level. The significant 
increase in CVP however, persisted for a longer period. 
3.2.5 endotoxin infusion OH (table 3) 
In the non-survivors (N-Surv) the CI increased while in the survivors (Surv) the CI did not 
change (table 3). Due to the small numbers, the differences were not significant. The 
pattern of change in HR, LVEDP and MAP, was not different between N-Surv and Surv. 
The LV dP/dt increased more in the N-Surv than in the Surv. At 2h and just before volume 
loading (VL) this difference was significant. The pulse pressure tended to increase more in 
the N-Surv than in the Surv as the SVRI, which tended to decrease in the N-Surv. There 
was no difference in the pattern of pulmonary pressure or resistance. Only 1 non-surviving 
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Table 2. Hemodynamic variables during and after low dose endotoxin infusion and volume loading in old and young piglets (see table 1 for legends) 
Hemodyn endotoxin volume loading wash out (min) 
parameter group N 0 60 (min) 120 (min) begin end 60 120 
CI Old 6 0.13±0.01 O.13±0.01 012±0.02 0".±D.02 O.14±0.01 O.12±0.01 0.13±0.01 
Young 8 0.20±0.O1 0.17±O.01 O.17±0.01 0.16±O.01# 0.21±0.02 0.18±0.02 O.19±O.O2 
HR Old 6 101±4 133±5# 170±G# 154±S# 130±6§ 129±10§ 137±6 
Young 8 110±7 169±14# 183±9# 185±9# 166±9§ 142±?§ 153±9§ 
SI Old 6 1.30±0.08 0.97±0.06" 0.73±0.08# 0.72±O.11# 1.05±0.O7 0.95±O.08 O.95±0.05 
Young 8 1.8±O.O7 1.05±0.11# 0.94±O.10# 0.89±0.06" 1.29±0.11§ 1.31±O.12§ 1.26±O.12 
LVEOP Old 3 6±2 7±2 3±3 4±2" 22±6§ 19±7 
Young 5 8±2 2±3 ~1±2 2±1 19±2§ 15±2§ 14±0.3§ 
LV dP/dt Old 3 2378±616 2752±379 2574±621 2817±837 2465±373 1957±369 
Young 5 2425±330 3042±542 2665±417 3231±647 3112±714 1736±94 1874±151 
MAP Old 6 96±6 n±5 67±6" 86±6 104±13§ 115±9§ 109±6§ 
Young 7 89±4 77±5 74±4# 87±5 95±?§ 98±6§ 101±5§ 
SAP-DAP Old 6 33±3 33±1 56±8 45±6 43±3 37±3 36±2 
Young 7 45±4 30±3#& 35±4& 38±3 42±3 41±5 47±8 
CVP Old 5 4±2 8±2 6±5 3±3 12±4§ 11±4 8±4 
Young 7 3±1 4±3 6±2 3±3 8±3 7±2 9±2 
SVR1 Old 5 740±B1 569±56" 534±79 797±154 814±216 934±147 789±4B 
Young 7 447±35 424±33 440±43 525±49 44B±56 540±76 503±59 
SWI Old 6 123±8 75±s" 50±S# 62±11# 109±9§ 109±10§ 101±12 
Young 7 161±11 81±1# 70±10" n±# 105±2D§ 12S±1~ 129±18 
MPAP Old 6 21±2 45±4# 3S±2' 36±3# 37±1 32±2 30±2 
Young 8 17±2 37±3# 32±3# 32±3 31±3 19±3§& 19±1§& §; 
-§ 
PVRJ Old 6 136±13 267±30# 255M3 277±40 166±17 162±24 114±59 a; ~ 
:;;: Young 4 76±B 174±15# 194±40 178±23# 130±32 79±25 80±27 ".. 
"" " 
Chapter 4.2 
animal survived long enough to have a VL, this animal remained to have a high CI despitea 
high PVRI. 
3,2.6 endotoxin infusion YH (table 3) 
Also in these animals the hemodynamic pattern was comparable with the older ones. The 
CI remained stable in the N-Surv, while in the Surv the CI decreased. This was different 
compared to the older animals. The decrease in SI was sooner in the younger animals 
which did not survive: at 1 h the relative decrease was already 40 %, while in the older N-
Surv it was 3 % at that time point. The increase in HR, the LV dP/dt and the pulse pressure 
tended to be higher in the N-Surv than in the Surv. 
3.2.7 comparison between the groups 
Because the baseline values of many of the hemodynamic parameters were different 
between the two age groups, for comparison between the groups the relative change (%) 
from baseline in the time interval until the volume loading was compared. Repeated 
measurements AN OVA (RmANOVA) showed that there was a significant difference 
(p<O.001) in the relative change of CI after start of infusion between old (average increase 
5.7%) and young (average decrease 14.7%). This 20% difference was not significantly 
affected by the dose. In Fig: 2 the absolute values for CI are depicted for the young and old 
animals. The same pattern emerged for the SI, a dose independent decrease of on the 
average 40% was found. This decrease was at all time points about 10% higher for the 
younger ones, however, this difference was not statistically significant (p=0.024) according 
to our criteria. The HR increased on average with 67%, and was not affected by age and 
dose. There were no significant changes in LVEDP and CVP. The LVdP/dt increased with 
39%, the MAP decreased with 16%, and the SWI decreased with 49% all irrespective of 
dose and age. RmANOVA showed that both age and dose affected pulse pressure (SAP-
DAP), in the low dose groups, the older animals showed an increase (43%) in pulse 
pressure, while in the younger a decrease 22% (p=O.01 ) could be observed at all time 
points. For SVRI, there was a 20% difference (p=0.007) in response between younger and 
older animals (younger +3%, older -17%), not significantly affected by dose. The MPAP 
increase was on the average 126% independent of dose and age. Independent of age, the 
PVRI increased in the low dose groups with 134%, in the high dose group 218%, a 
difference which did not reach statistical significance (p=0.02). 
3.3 Blood gases and oxygen transport 
The calculated values for oxygen delivery (DO,), oxygen consumption (VO,), and oxygen 
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Table 3. Hemodynamic and end organ oximetric variables during and after high dose endotoxin infusion 
Old Young 
endotoxin infusion endotoxin infusion 
absolute relative change from baseline (%) absolute relative change from baseline (%) 
Surv N 0 60 120 150 (VLB) Surv N 0 60 120 150 (VLB) 
CI Y 4 0.12±0.01 12±10 2±14 -5±13 y 4 0.19±0.01 -14±8 -16±13 -14±18 
n 3 0.13±0.01 27±14 23±23 19±27 n 3 0.19±0.01 -24±8 15±8 2±10 
HR y 5 89±4 68±14# 9±10# 70±14# Y 4 115±7 55±23 78±28 69±24 
n 4 96±3 28±10 87±8# 90±8# n 3 128±14 36±8# 106±18# 97±15 
LV dP/dt Y 5 2568±193 16±7 7±18 -8±9 y 2 2569±388 5±17 46±10 43±17 
n 4 2627±177 31±26 95±16#s 63±9' n 2 2216±263 -7±6 179±78 140±39 
MAP Y 5 99±5 -32±5# -29±6# -28±7' y 4 78±4 -15±8 -22±8 -11±9 
n 4 92±4 5±18 -26±8 -32±5 n 3 69±2 -31±1# 1±5 -1±5 
SAP-DAP y 5 43±4 28±18 13±13 -6±9 y 3 36±5 17±15 24±9 36±16 
n 3 43±2 84±24 65±23 65±18$ n 3 51±3 -16±9 71±26 84±31 
SVRI Y 4 842±93 -31±9 -17±14 -15±12 y 4 381±27 2±15 13±14 27±29 
n 3 717±68 -16±17 -31±17 -33±16 n 3 359±17 -9±9 -19±6 -6±3 
PVRI y 3 SS±7 143±37 162±36' 193±42 y 3 45±26 438±278 332±189# 329±103 
n 3 99±16 133±96 142±153 n 3 40±5 515±102' 270±157 179±3 
lactate y 4 0.59±0.06 357±179 379±80# 394±73# Y 4 0.59±0.07 527±642' 775±300 720±266 
n 4 0.46±0.14 1520±714 3077±650' n 3 0.45±0.05 755±54# 4066±1447 
VO, y 3 0.23±0.06 31±33 26±30 45±33 y 4 0.34±0.06 34±3# 36±16 32±19 
n 4 0.22±0.03 46±1697±22 n 3 0.34±0.04 17±28 94±7' 
ER-O, y 5 0.38±0.05 10±16 22±14 21±10 y 4 0.41±0.03 32±12 36±23 38±28 
n 4 0.39±0.10 11±1239±10 n 3 0.36±0.04 64±27 102±23 
Values are mean±sem; Surv, survival; CI, cardiac index; HR, heart rate; LV dPfdt, first derivative to time left ventricular pressure; MAP, mean arterial blood pressure; SAP-DAP, 
systolic"<ftastolic arterial blood pressure; SVRI, PVRI, systemic and pulmonary vascular resistance; VO,. oxygen consumption; ER"O~, oxygen extraction ratio. # p< 0.001, 
~ . 
<0 different from baseline; $ p< 0.001. different between survivors and non"survivors, 
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Figure 2. Course of the cardiac index (GI) in time of the young (closed circles) and old animals (closed 
triangles), low and high doses pooled. ET, endotoxin infusion; VL, volume loading. # p < 0.01 vs baseline 
(1"0); & p < 0.01 between groups. 
extraction ratio (ER-O,) for the placebo and the low dose endotoxin groups are depicted in 
table 4. During the placebo infusion there were no significant changes in these parameters. 
RmANOVA considering the change from baseline values of all age an dose groups during 
the endotoxin infusion for the time interval until the volume loading, showed that there were 
on the average 18% lower DO, values at all time points for the younger animals (p"0.01), 
and a trend towards a 22 % higher ERO, (p=0.03). The mean of the highest relative 
increase (%) in V02 was significantly different between N-Surv and Surv: 97 ± 11 % versus 
48 ± 7% (p=0.002). 
The volume loading (VL) after the placebo infusion resulted in an increase in DO" which 
was only significant in the young animals and an increase in VO" which was significant in 
the older animals. The ER-O, did not change significantly in both groups. After the 
endotoxin infusion (table: 4), in both OL and YL the DO, had a tendency to decrease; this 
decrease was not influenced by the Vl. So, in the placebo situation the volume loading (VL) 
resulted in an increase in DO, and in the endotoxin situation the VL resulted in a decrease 
in DO,. 
In Fig: 3 the course of the arterial lactate levels is represented for the low dose groups. 
There were no differences between OL and Yl. In the high dose groups (table: 4), there 
was a trend towards higher lactate levels in YH in comparison with OH (p=0.03). The 
highest peak lactate levels were found in the N-Surv: 14.8 (8.9-24.7) mmolll versus 4.3 
(2.0-19.5) in the Surv (p=0.001). 
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Table 4. Effect of low dose endotoxin infusion and subsequent volume loading on total oxygen delivery. consumption and extraction in old and young pigs 
time (min) 
infusion volume loading 
treatment group 0 60 120 1S0 (begin) 180 (end) 240 300 
DO, placebo O(L+H) 0.67±0.04 0.67±0.03 0.66±0.03 0.74±0.02 0.70±0.04 
endotoxin OL 0.S9±0.OS 0.67±0.03 0.64±0.07 0.S6±0.08 0.S2±0.04 0.54±0.02 0.SS±0.04 
placebo Y(L+H) 0.98±0.OS 0.89±0.04 0.S7±0.OS 1.02±0.06§ 0.98±0.04 
endotoxin YL O.90±O.04 0.93±O.OS 0.S4±0.OS 0.S3±O.06 O.77±O.OS O.74±O.04 0.SO±0.06 
va, placebo O(L+H) O.26±0.02 0.2S±O.02 0.28±0.02 0.32±0.02 O.31±O.03 
endotoxin OL 0.23±0.03 0.31±0.02 0.30±0.06 0.32±O.O4 0.2S±0.03 0.27±0.02 0.26±0.OS 
placebo Y(L+H) 0.36±0.01 O.36±0.03 0.32±O.02 0.40±0.03 O.43±O.03§ 
endotoxin YL 0.3S±0.02 OA7±0.05# 0.44±0.03# OAS±0.02# O.48±0.O4 0.38±0.02 O.37±0.09' 
ER-O, placebo O(L+H) 0.38±0.O1 OA1±O.02 O.41±0.02 OA3±0.02 OA3±0.02 
endotoxin OL 0.39±0.03 0.46±O.O2# 0.S6±O.02# 0.S9±0.03# 0.54±O.03 0.S1±0.03 0.47±O.OS 
placebo Y(L+H) 0.37±O.02 OAO±0.03 0.38±0.O2 O.42±0.04 0.44±0.02 
endotoxin YL 0.38±0.02 0.S1±0.03# O.SS±O.04# O.S6±O.04# 0.63±0.03 O.S2±0.03 OA8±0.04 
Values are mean ± SEM; 002= oxygen delivery (mllminlkg); V02= oxygen consumption (ml/min/kg); ER-02= arteriovenous oxygen extraction ratio; # p<O.01 vs baseline (t=O); 
§p<O.01 vs begin volume load. 
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Figure 3. Arterial lactate level versus time in minutes. INF: infusion of placebo Y (l +H) and 0 (l +H); or 
endotoxin Yl and Ol, Vl: volume loading. #, p < 0.01 vs baseline (t=O), Wilcoxon signed rank test. 
Because of hemodynamic instability andlor agitation during the microspheres injection 
(procedure takes at least 2 minutes), not all measurements could be included. In Fig: 4 the 
3.4 Regional blood flow changes 
conductance of several organs are presented from old and young, low dose, 5 animals 
each. Since there were no differences between the left and right kidney, the results of both 
kidneys were averaged in the further analysis. 
3.4.1 effect of endotoxin infusion 
Since the baseline values of the conductance and flow values were different for the two age 
groups, the relative change from baseline was analyzed for each organ for all data 
available, including the high dose groups using two-way ANOV A. There was a significant 
decrease in conductance of the kidney, which appeared to be age dependent (p=O_013), 
while there was a trend towards a dose dependency (p=O_04): the changes were -21 % 
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Figure 4. The conductance of various organs (ml.100g".min-1.mmHg'l) in the placebo situation, 0 (L +H) and 
Y (L +H); and endotoxin situation, OL and YL. Values are means ± sem. #, p < 0.01 vs baseline (BL, t=O); §, 
p < 0.01 vs begin volume load (Vlb); Vie::: end volume load. 
(n=5), -66% (n=6), -8% (n=5), and -16% (n=6) forYl, YH, Ol, and OH respectively. There 
was an age and dose independent decrease in cerebral blood flow of the total brain of21% 
(p=0.017). The decrease in conductance was not significant. The flow of the muscles after 
the endotoxin-infusion increased 341 ± 130% in the younger animals and 59 ± 23% in the 
older, this difference did not reach statistical significance (p=0.049). In the adrenals both 
flow and conductance increased, the increase in conductance tended to be dose 
dependent, 134 ± 43% and 282 ± 49% for the low and high dose respectively (p=0.043). In 
the liver there was an age (p<0.001) and dose (p=0.001) dependent change in flow and 
conductance in response to endotoxin, Yl: -30 ± 17%; YH: 120± 64%; OL: 233 ± 90%; and 
OH: 1190 ± 410%. The perfusion of the spleen showed remarkable changes: after 
endotoxin there was a decrease in conductance, which tended to be age dependent: -82 
± 4% for the young animals versus -71 ± 3% for the old animals (p=0.046). The skin 
perfusion did not change. In the intestines there was an age dependent decrease in 
conductance: -46 ± 6% for the young animals and 7 ± 13% for the old animals (p=0.012). 
The cardiac blood flow and conductance increased dose and age independent, right 
ventricle more than the left ventricle, epicardium more than the endocardium. The change 
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in endo/epicardium ratio tended to be dose dependent: -10 ± 4 % for the low dose and -20 
± 2% for the high dose groups (p=0.047). The highest increase in conductance was 
achieved in the non-survivors, in the right ventricle more than left, in the OL more than in 
the YL. In table 5 the conductances of the right and left ventricle from the low dose groups 
are represented 
3.4.2 effect of volume loading (Fig: 4) 
Since two-way ANOVA showed no age or dose dependent differences, the response to 
volume loading was analyzed using the relative changes (%) of all groups combined. 
Volume loading after placebo infusion showed no Significant change in flow or conductance 
of the kidneys. Cerebral blood flow increased significantly, both after infusion of endotoxin 
and of placebo with the increase being higher after the endotoxin infusion (p=0.008); the 
conductance increased only in the endotoxin siluation. The muscles flow and conductance 
increased, only in the placebo and not in the endotoxin situation. There was a Significant 
decrease in flow and conductance to the adrenals especially after endotoxin infusion. Flow 
and conduclance to the liver did not change after volume loading. There was a substantial 
increase in flow to the spleen in the placebo and endotoxin situation in young and old 
animals. In the placebo situation the flow to the intestines did not change, after endotoxin 
infusion the flow increased significantly. The total cardiac blood flow increased due to the 
volume loading both in the placebo siluation and in the endotoxin situation. The 
conductance of the right and left ventricle as well as its dislribution over the sub epi-, meso-
, and endocardium showed a significant increase in conductance after placebo 
infusion and a Irend towards increase in the endotoxin situation (p-values between 0.01 
and 0.05). The change in LV endo/epi ratio after volume loading was -2 ± 3% in the placebo 
situation versus 7 ± 4% in the endotoxin situation (p=0.015). 
4 DISCUSSION 
The present study was designed to examine the differences in circulatory responses in 
awake young and near adult piglets to a meningococcal endotoxin challenge as well as the 
response to volume loading after this challenge. Most important findings are that (i) there 
is a dose-related, but not an age-related difference in mortalily, (ii) whereas CI after 
meningococcal endotoxin decreased in the young animals, it was well preserved in the 
older animals, this difference was probably related to a different vascular response: in the 
older animals the SVRI dropped 20%, while in the younger ones there was no change in 
resistance; there was a trend towards a higher decrease in 51, a higher decrease in DO" 
a higher ERO" (iii) there were significant differences in perfusion of the abdominal organs 
(a higher decrease in flow and conductance to kidneys, intestines and spleen, and a lower 
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Table 5, Effect of low dose endotoxin infusion and volume loading on conductance of different regions of the 
heart in old and young pigs 
placebo endotoxin 
infusion 
volumeloading volume loading 
group M1 M2 M3 M4 M5 
RV OL 1.12±0.16 1.65±0.21§ 1.15±0.16 3.83±0.85 3.20±1.58 
YL 1.74±0.21 2.44±0.25 1.70±0.17 3.44±0.23# 3.71±0.80 
LV OL 2.09±0.33 2.97±0.34§ 2.06±0.32 4.25±1.19 3.39±1.56 
YL 2.79±O.33 4.06±0.37§ 2.62±0.34 2.91<0.55 4.5±0.86 
LVendo/epi OL 1.16±0.04 1.18±0.04 1.19±0.04 0.99±0.03 1.10±0.12 
YL 1.25±0.05 1.14±0.06 1.22±0.07 1.15±0.09 1.18±0.07 
Values are mean ± SEM in ml.min·1.100g·1• RV, right ventricle; lV, left ventricle;, endo/epi, ratio bet<.veen endo-and 
epicardium. M1-5 moment of microspher6 injection (Fig: 1). M1: before vo!umeloading after placebo infusion, M2: after 
volumeloadlng, M3: before endotoxin infusion, M4: after endotoxin infusIon before volume loading, M5: after volume and 
loading and endolo!n infusion. M1, M2 from 0 (L+H) and Y (L+H) each 10 animals; M3,4,5 from Ol and YL each 5 
animals. # p<O.01, vs baseline; § p<O.01, vs begin volume loading. 
increase to the liver) of young and old animals, (iiii) subsequent volume loading resulted 
only partly in a recovery of Ihe hemodynamic parameters, bul failed to improve oxygen 
delivery (DO,). 
4.1 Methodological considerations 
Meningococcal sepsis is a particular form of gram negative sepsis. Its special 
pathophysiological fealures are the very high serum levels of endotoxin located on 
bacterial membrane fragments (blebs), the very rapid evolvement of the disease with its 
high mortality in previously healthy children, extreme disseminated intravascular 
coagulation (DIG) with microvascular thrombosis and skin bleeding, capillary leakage, and 
myocardial failure (38, 229, 238, 242). Based mainly on experimental data in rats (71,266, 
306, 367, 384, 387), rabbits (312), dogs (172, 284, 286), or piglets (215) it has been 
proposed that the circulatory response during sepsis is different between neonates and 
adults. It is likely that there are also, probably to a lesser extent, differences between 
pediatric and adult individuals, although these differences in response have hardly been 
studied. The results of these studies are difficult to compare because of the different 
sensitivity to endotoxin of the different species, the dosages of endotoxin used, the different 
ages of the animals, and the difference in methodology. However, the differences between 
young and old animals described in these studies, are most likely related to maturity 
suggesting that, in the young subject, decreased cardio-circulatory and metabolic reseNes 
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might contribute to differences in mortality and morbidity. In the clinical situation we are 
dealing with pediatric patients (median age in our patient population is 3 years), which 
implies that the use of invasive techniques to study the circulatory alterations is limited. 
There is therefore a need for a "pediatric" animal model to study in detail the 
pathophysiology, specific treatments, or preventive measures like vaccines, which 
implicates a large laboratory animal. The pig has been shown to resemble humans quite 
closely in its cardiovascular anatomy and physiology also during sepsis (259), and a young 
pig can be instrumented easily. In order to study possible age related differences, two ages 
were compared: 3 weeks (8 kg) representing a pediatric age, and 4 months (40 kg) 
representing the (near) adult. We chose a chronically instrumented, awake animal model 
in order to avoid interference of anesthesia and acute surgical trauma with cardiovascular 
responses and to prevent anesthesia from interfering with host LPS-clearance 
mechanisms (305). For the induction of experimental sepsis in pigs viable bacteria or LPS 
are used. However, to challenge the animals with viable meningococci would be 
complicated and dangerous for the environment. Previously, purified meningococcal LPS 
has been used in experimental settings, mostly in small laboratory animals (297). However, 
this LPS is not the form which is found in vivo in humans. During their growth, the bacteria 
are continuously spreading membrane material (blebs) containing endotoxin (40). This 
rough material can be separated from the bacteria and standardized to aLPS 
concentration (275). Two different dosages of this endotoxin preparation were used to 
challenge the animals. 
4.2 Cardiovascular responses 
The pattern of response to low to moderate dose of endotoxin was comparable to that 
described in literature (184, 215, 259, 370). However, the older animals in our study were 
able to maintain their CI, despite a 40 % decrease in stroke volume; the LV dP/dtand MAP 
remained stable or increased instead of decreasing (184, 259); in the older animals the 
SVRI decreased instead of increasing (184, 259, 270). This disagreement with earlier 
observations can be explained by the absence of anesthesia in the present study and by 
the difference in type of endotoxin used. Striking was the finding that both in the older and 
the younger animals there was a trend towards a higher CI, LV dP/dt, and pulse pressure 
in the non-survivors in comparison with the survivors, suggesting a difference in vascular 
response. In humans with sepsis, CI is usually normal to elevated and SVRI is typically low, 
at least in adults. In our study the young animals were unable to preserve their CI, nor did 
their SVRI or systolic-diastolic arterial pressure difference change. So the older animals 
show a more normodynamic picture, and younger animals initially show a hypodynamic 
picture. This would be in accordance with the study of Mercier et al. who reported in 
pediatric meningococcal patients, that CI was low to normal in survivors, but was 
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decreased in non-survivors, and that SVRI was normal in survivors but increased in the 
non-survivors (238). This difference between survivors and non-survivors was opposite to 
the finding in our study that the CI was higher in non-survivors than in survivors, both in 
older and younger animals. 
The changes in organ flow and conductance after endotoxin infusion show a pattern of 
redistribution which matches with heavy exercise and high levels of catecholamines: 
decrease of flow to kidneys, spleen and intestines, little or no change in flow to brain, and 
skin, increase in flow to liver, muscle, adrenals and heart and these changes were 
comparable with those described in literature: (73, 165, 172, 196,255,256,259,369). 
However, the design of these sepsis studies was not always cornpletely the same 
(difference in kind of animals, ages, endotoxin, bolus or intermittent infusion, rescue 
therapy). In the low endotoxin dosage, the flow and conductance of different regions of the 
heart of the older animals showed an increase after challenge, which was not apparent in 
the young ones; in the high dosage this increase was present in both groups and most 
extreme in the non-survivors. This finding together with the high lactate levels and the high 
total oxygen extraction ratio might lead to the hypothesis that the increase in cardiac flow 
is secondary to an increased total body oxygen demand. We did not determine the cardiac 
oxygen consumption. However, Herbertson described an awake porcine endotoxin model 
in which the myocardial oxygen extraction ratio was dramatically decreased (166). This 
decrease in myocardial oxygen extraction ratio was due to an increase in overall 
myocardial flow and an increase in heterogeneity of this flow. These changes were 
explained to be induced by components of the inflammatory response of sepsis. 
4.3 Differences between young and old 
In our clinical setting the mortality was significantly different (40 vs 13 %) between younger 
patients « 3 years) and older (3-18 years); 91% of the non-surviving patients died of 
irreversible shock (158). In our experimental study the hemodynamic response to the 
endotoxin was overall comparable in the older and young animals, but there were some 
findings suggesting a difference in cardiac performance, possibly related to preload; and a 
difference in vascular response (more vasodilatation in the older animals). The organ flow 
and conductance showed a significant decrease in renal conductance in the young animals 
and not in the old ones; the flow to the muscles increased more in the young animals; there 
was much less increase in flow to the liver and a greater decrease in intestinal and spleen 
flow in the young animals. With these findings of a more depressed splanchnic perfusion 
in the young animals, one may speculate that the risk of developing organ failure is 
increased in the young animals. However, the mortality was not different between the 
young and the old animals. 
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4.4 Volume resuscitation 
Volume resuscitation using colloid or crystalloid solutions, is a major component of 
management of the acute phase of sepsis. Its aim is to compensate for the extravasated 
fluid and to restore the decreased preload caused by the capillary leakage. In our 
experiments the volume loading (VL) changed all of the hemodynamic variables towards 
baseline values, some of them above (CI), except for the SV and SWI which still remained 
below baseline. Remarkable was that the VL in the placebo situation resulted in an 
increase in DO" while in the endotoxin situation the DO, either did not change (older) or 
decreased (younger). So, from this finding we could suggest that in the clinical situation a 
volume expansion during sepsis should be accompanied by a blood transfusion to improve 
the DO, and not only the CI. Most of the organs in which there was a decrease in flow after 
endotoxin showed an improvement after VL. Striking was after an initial rise caused by the 
endotoxin infusion, the flow to the adrenals decreased after the VL; these changes in flow 
together with the injured endothelial cell lining present during sepsis, might explain the high 
frequency of adrenal bleeding reported in meningococcal sepsis. 
4.5 Conclusions 
To our knowledge this is the first report in which the effect of rough meningococcal 
endotoxin was studied in a large, chronically instrumented awake laboratory animal 
showing a hemodynamic picture comparable with adult animals, but also showing age 
related differences. Our study shows that a model consisting of a chronically instrumented 
piglet of 8 kg is feasible and that a rough meningococcal endotoxin preparation is potent in 
a low dosage and can be used to give a reproducible endotoxin model. On the other hand 
it is possible that many of the circulatory changes can be contributed to the rapid increase 
in PVRI, which is not so extreme in the human situation. This is probably caused by the fact 
that the endotoxin is infused in 1 hour and reaches levels, which are reached only after 
several hours in the human situation. Moreover this study had an observation period of 
about 6 hours, which means that the prolonged or delayed effects of host response to 
endotoxin like coagulation disturbances, are to be missed [Haberstroh, 1995 #537]. This 
problem might be overcome by gradually infusing the endotoxin over time and extend the 
observation period to 24 h. 
This "pediatric" experimental meningococcal endotoxin model in piglets can be used to 
study therapies like vaccines and anti-inflammatory agents specific for meningococcal 
sepsis. 
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1 INTRODUCTION 
Septic shock and purpura or severe infectious purpura with shock is a life-threatening entity 
in previously healthy children. The syndrome is mainly caused by Neisseria meningitidis, 
although occasionally Haemophilus influenzae type b is involved. Meningococcal disease 
(MD) still remains major health problem in both developing and industrialized countries. 
Group B is the predominant serogroup among strains causing MD followed by group C 
(304). 
From 1970 to 1980 the annual incidence of MD in the Netherlands varied between 0.7 and 
2.0 cases per 100,000 population. The incidence of MD gradually increased during the 
1980s, and reached 3,5 per 100,000 inhabitants in 1990. The age-specific incidence is 
highest among children less than 5 years of age (~ 22.8 per 100,000) (229. 304). In 
addition, the percentage of patients with meningococcal sepsis without clinical meningitis 
increased in the same period (1, 291). Despite the use of antibiotics and intensive care 
treatment, septic shock and purpura is still associated with a high mortality and morbidity. 
Mortality ranges between 25% and 50% (129,131,205). A relatively small percentage of 
the survivors has serious sequelae such as extensive skin necrosis requiring skin grafting 
and amputation. 
The use of scoring systems combining data of prognostic significance in the assessment 
of patients with acute meningococcal disease or septic shock and purpura, has attracted 
much interest (86, 93,120,131,185,205,206,258,308,316,328,331, 339). According 
to a number of studies, signs of poor prognosis on admission are the absence of meningeal 
inflammation, the presence of rapidly evolving hemorrhagic skin lesions, hyperpyrexia, 
leukocytopenia, thrombocytopenia, low plasma levels of fibrinogen, disseminated 
intravascular coagulation, metabolic acidosis, and rapid clinical deterioration. 
Combinations of clinical and laboratory features have been used to develop scoring 
systems to predict mortality. However, these systems are often partly based on subjective 
clinical criteria. 
The purpose of the present study was to evaluate the epidemiology, clinical features, 
laboratory features and outcome of meningococcal septic shock in children admitted to the 
Sophia Children's Hospital between 1988 and 1995. Additionally, the prognostic 
significance of several clinical and laboratory features was evaluated and a new prognostic 
score was developed. 
2 PATIENTS AND METHODS 
The records of all patients 18 years and younger admitted from October 1988 through June 
1995 with meningococcal septic shock to the Pediatric Intensive Care Unit (PICU) of the 
Sophia Children's Hospital were prospectively evaluated. Shock was defined as a mean 
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arterial blood pressure more Ihan 2 standard deviations below the normal value for age (9) 
andlor the presence of poor end-organ perfusion defined by at least two of the following 
criteria: a.) unexplained metabolic acidosis (pH" 7.3), base excess" -5 mmollL or arterial 
plasma lactate levels> 2.0 mmol/L; b.) arterial hypoxia defined as a PaO, ,,75 mm Hg, a 
PaO, to FiO, ratio < 250 or TcO, " 96% in patients without overt cardiopulmonary disease; 
c.) acute renal failure defined as oliguria with an urine output less than 0.5 mLlkg/hr for at 
least one hour despite acute volume loading or evidence of adequate intravascular volume 
and without preexistent renal disease; d.) sudden deterioration of the patient's mental 
status. 
A subset of the patients was enrolled in a randomized, double-blind placebo controlled trial 
to study the efficacy of HA-1A human monoclonal antibody (Centoxin, Centocor, Malvern, 
PAl in meningococcal septic shock. 
Medical records were analyzed for demographic, clinical, and laboratory features and 
outcome. The data were abstracted using a standard form. Patients who were initially 
treated at other hospitals but were transferred to this hospital for intensive care treatment 
were also included. Decisions regarding the use of antibiotics, intravenous fluids, inotropic 
and vasopressor support and the initiation of mechanical ventilation were made by the 
patients allending physician. 
2.1 Definitions 
The severity of illness on admission at the PICU was assessed using the pediatric risk of 
mortality (PRISM) score (274). The duration of symptoms and petechiae was estimated as 
precisely as possible. Meningitis was defined as the presence of a positive bacterial culture 
of cerebrospinal fluid (CSF), or the presence of a positive gram-stain in the CSF, or the 
presence of a positive blood culture in combination with clinical evidence of meningitis and 
a CSF WBC count above 10 cells/mm3 . Respiratory distress was defined as a condillon that 
required mechanical ventilation because of respiratory failure. Disseminated intravascular 
coagulation (DIC) was defined by the combination of three of the following features: platelet 
count less than 150 x 10'IL, fibrinogen less than 2 giL, factor V less than 60%, and 
presence of fibrinogen degradation products (FOP) (207). Patients were divided in different 
groups for statistical analyses. Survivors were compared with non-survivors. 
2.2 Laboratory studies 
Bacteriological methods: Specimens of CSF andlor blood were routinely cultured. These 
specimens were obtained from all patients before antibiotic therapy was initiated. Micro-
organisms were identified according to standard procedures (179). Isolates from blood 
andlor CSF were sent to the Netherlands Reference Laboratory for Baclerial Meningitis 
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(Department of Medical Microbiology, University of Amsterdam, Amsterdam and National 
Institute for Public Health and the Environment, Bilthoven, the Netherlands). Neisseria 
meningitidis strains were classified into serogroups, serotypes and subtypes on the basis 
of antigenic differences in their capsular polysaccharides and in class 2/3 and class 1 outer 
membrane proteins (OMP's), respectively. Meningococci were serogrouped by means of 
Ouchterlony gel diffusion with the use of rabbit antisera (produced at the Reference 
Laboratory) to the capsular polysaccharides of the serogroups (309). Serotyping and 
subtyping were performed by means of a whole cell ELISA (207) (3). 
Clinical hematology and chemistry: Laboratory studies including a complete blood count 
and serum chemistry analysis were routinely performed on admission. Blood samples for 
analysis of hematologic characteristics were collected in a microtainer containing 
EDTA(K,). Blood samples for clinical chemistry were collected into sterilized siliconized 
vacutainer glass tubes (Becton Dickinson, Meylan Cedex, France) and allowed to clot at 
room temperature. Samples were centrifuged at 1600 g for 10 minutes at 4 'C. 
Characteristics of coagulation and fibrinolysis: All assays were performed with 
commercially available reagents and methods. Blood samples for analysis of coagulation 
and fibrinolysis assays was collected in trisodium citrate 0.109 M (anticoagulant to blood 
1:9 vol/vol). Clotting assays were used for the determination of the activated partial 
thromboplastin time (APTT). Factor V (F V) was determined with a one stage assay using 
factor V deficient plasma and fibrinogen according to the Clauss method (69) 
(Behringwerke AG, Marburg, Germany). A semi-quantification of FOP in plasma was 
performed by latex agglutination (Diagnostica Stago, Asnieres-sur-Seine, France). 
2.3 Statistical analysis 
Results are expressed as means ± SO unless stated otherwise. Comparison of various 
variables between groups of patients were tested with the Mann-Whitney test. Frequencies 
of various findings between groups were compared by the Fisher'S Exact Test. Peason's 
(r) or spearman (r,) correlation coefficient were used to evaluate the relation between 
specific variables. Multiple regression analysis was performed to evaluate factors which 
might affect the difference in variables between survivors and non-survivors. Logistic 
regression analysis with backward elimination was performed to develop a prognostic 
score for mortality based on variables obtained on admission (7). Two-tailed P values ~ .05 
were considered statistically significant. 
3 RESULTS 
3.1 Patient characteristics 
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Seventy-five patients with meningococcal septic shock were evaluated. Forty-two were 
males and 33 were females. The children had a median age of 3.2 years (range 3 weeks 
-17.9 years). Twenty-four (32%) children were less than 2 years, 35 (47%) between 2 and 
10 years, 16 (21%) were older than 10 years. Forty-nine of the children participated in the 
clinical trial to study the efficacy of HA-1A human monoclonal antibody (23 HA-1A and 26 
placebo recipients). The PRISM score at admission in the PICU ranged from 0 to 38 
(median 11). Twelve patients were directly admitted to our hospital, and 63 were referred 
by other hospitals. None of the patients received antibiotic treatment before or during 
transport to the first institution. Hospitalization occurred within 12 hours after the onset of 
petechiae in 95% of the patients. In 10 (13%) patients petechiae developed during 
hospitalization. The transferral time from the first institution to the PICU of Sophia 
Children's Hospital was less than 12 hours in 55 of the 63 transferred patients. The duration 
(mean ± SD) of symptoms and the interval between the appearance of petechiae and 
admission to the Sophia Children's Hospital were 19.2 ± 7.3 and 7.1 ± 5.8 hours 
respectively. 
A lumbar puncture was performed in 53 cases at the time of admission. Meningitis was 
documented in 33 (62%) cases. A positive CSF culture was obtained in 9 patients. All 75 
patients needed inotropic and vasopressor support. Forty-four of the 75 (59%) patients 
needed mechanical ventilation. 
3.2 Bacteriological findings 
Cultures of blood, CSF or skin biopsies grew N. meningitidis in 75 children. A total of 71 
strains of N. meningilidis were available for typing. Four other isolates were not sent to the 
Reference Laboratory. The distribution of the serogroups and serotypes/subtypes of N. 
meningitidis are depicted in Table 1. Fifty-eight of 71 strains (82%) were serogroup Band 
13 (18%) were serogroup C. The most common phenotype of N. meningitidis in the present 
study was B:4:P1.4 (27%). The age distribution differed among the various serogroups. 
The mean age of children affected with serogroup C meningococci was significantly higher 
than in those with serogroup B (4.6 ± 4.6 years vs. 7.7 ± 5.3 years: P = .04). 
3.3 Outcome 
Survivors vs non-survivors: The mortality was 21 % (95% confidence interval [CIJ: 12% -
32%). We did not observe a difference in mortality rate between HA-1A and placebo 
recipients (5 [22%J of 23 vs. 7 [27%J of 26; P = .75). Fourteen children died as a 
consequence of irreversible septic shock. Two patients died as a result of central nervous 
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Table 1. Distribution of serogroups, serotypesand -subtypes in 71 patientswilh septic shock due to Neisseria 
meningitidis 
Serogroup 
B C 
58 (82%) 13 (18%) 
serotype 
2a 2 ( 3%) 7 ( 10%) 
4 38 (54%) 3 ( 4%) 
Other 6( 8%) 1 ( 1%) 
Non-typeable 12(17%) 2 ( 3%) 
subtype 
P1.4 24 (34%) 3 ( 4%) 
P1.15 5 ( 7%) o ( 0%) 
Other 16 (23%) 7 ( 10%) 
Non-typeable 13 ( 18%) 3 ( 4%) 
The number of patients with a specific serograup, serotype or subtype is indicated followed by the percentage of the 
tolal number of patients between parentheses. 
system complications. Fifty percent of the deaths occurred within the first 24 hours and 
nearly 90 % occurred within 48 hours. The median (range) duration from the onset of 
symptoms until death was 40 hours (11-143 hours). The demographic and clinical 
characteristics of the 59 survivors and the 16 non-survivors at admission to the PICU are 
shown in Table 2. The mortality rate was higher in children younger than 4 years of age (13 
[33%J of 40 vs. 3 [9%J of 35; P = .02). Patients admitted primarily to the Sophia Children's 
Hospital had a higher mortality rate in comparison with secondary referrals (5 [42%J of 12 
vs. 11 [17%J of 63; P = .12J. The PRISM score of the primary referrals was worse than that 
olthe secondary referrals (14.3 ± 5.2 vs. 11.7 ± 7.9; P = .21). The interval between the onset 
of petechiae and admission to the PICU was shorter in non-survivors. 
Complications and sequelae of survivors: The median hospital stay was 13 days (range 10 
- 207) among the survivors. Twenty-eight of the 59 survivors were mechanically ventilated 
for a median duration of 7 days (range 1 - 24 days). Most survivors recovered without 
sequelae. Two patients had serious neurologic sequelae. Dermatologic or orthopedic 
sequelae requiring skingrafts or amputations occurred in 9 olthe 59 survivors. Two patients 
required hemofiltration because of renal failure, one patient developed osteomyelitis. 
Seizures occurred in 7 patients. 
3.4 Laboratory findings 
Demographic and laboratory features of survivors and non-survivors are depicted in 
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Table 2. Characteristics of 75 children with meningococcal septic shock on admission at the PICU. 
survivors nonsurvivors p-value 
characteristic n (n = 59) (n = 16) 
Age (y) 75 5.8 ± 5.0 3.6 ± 3.7 NS 
Sex (% male) 75 33 (56) 9 (56) NS 
Transferred 75 52 (88) 11 (69) NS 
Interval (h) from 
- onset symptoms 
to admission PICU 72 19.5±7.1 18.0 ± 8.3 NS 
- appearance of petechiae 
to admission PICU 73 7.6 ± 5.9 5.5 ± 5.1 .06 
PRISM score 75 10.1±7.1 18.6±5.1 <.001 
Hematology 
Hb 75 6.6 ± 0.9 6.1 ± 1.2 NS 
WBC (x10'/L) 75 14.5 ± 10.0 9.0 ± 9.6 .02 
pla!ele!s (x10'/L) 74 110±51 63 ± 37 .001 
Chemistry 
sodium (mmoI/L) 75 135 ± 5 137 ± 4 NS 
potassium (mmoI/L) 75 3.4 ± 0.6 4.1 ± 0.7 <.001 
calcium (mmollL) 70 1.92 ± 0.24 1.83 ± 0.26 NS 
glucose (mmoIlL) 65 6.6 ± 2.9 4.6 ± 2.8 .02 
lactate (mmollL) 70 5.1 ± 3.3 7.3±4.1 .005 
creatinine (fJmoUL) 70 87 ± 55 118±67 NS 
CRP (mg/L) 66 135 ± 69 80±53 .006 
albumen (giL) 67 33 ± 6 34 ± 10 NS 
Acid Base balance 
pH 75 7.37 ± 0.08 7.27± 0.12 .003 
BE (mmoI/L) 74 -6.2 ± 3.9 -11.4±4.4 <.001 
bicarbonate (mmoI/L) 75 17.4 ± 3.5 13.9±3.1 .001 
Plus-minus value are mean ± SO. Values in parentheses are percentages. Abbreviations: n, number of 
observations; PICU, Pediatric Intensive Care Unit; Hb, Hemoglobin; wac, white blood cell; CRP, C-
reactive protein; BE, base excess; NS, not significant. 
Tables 2 and 3. Occasionally laboratory data were missing, but this never occurred in more 
than 11 patients for a given characteristic. 
Initially, 16 (21 %) patients had a peripheral white blood cell (WBC) count lower than 5 x 10'1 
L. Platelet counts were below 50 x 10'IL in 13 of 74 (18%) patients. The acid-base status 
and the arterial serum lactate levels showed striking abnormalities that were more severe 
in non-survivors. Serum glucose levels were significantly lower in the non-survivors but 
hypoglycemia « 2.5 mmollL) was observed in 7 children. Hypokalemia « 3.5 mmollL) was 
observed in 52%. Serum potassium levels were highly correlated with the arterial pH (r, = 
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Table 3. Coagulation and fibrinolysis characteristics in 75 patients with meningococcal septic shock 
reference n 
characteristic range 
Coagulation 
APTT (sec) 28-40 66 
Factor V (%) 70-140 64 
Fibrinogen (giL) 1.8-3.5 67 
Fibrinolysis 
FOP (mglL) <5 65 
sUlVivors 
(n = 59) 
54 (29->200) 
40 ± 21 
2.6 «0.4-5.8) 
50 «5->300) 
nonsurvivors 
(n = 16) 
104 (53-200) 
21 ± 14 
1.1 «0.4-5.4) 
110 (35->300) 
p-value 
<_001 
.002 
.001 
.003 
Data are expressed as median (range) specified otherwise. 'mean ± standard deviation. Abbreviations: n, number of 
observations; APTT, activated partial thromboplastin time; FOP, fibrin/fibrinogen degradation products. 
-.46, P < .001)_ Analysis of covariance showed that serum potassium levels were 
significantly higher in non-survivors in comparison to survivors irrespective of the arterial 
pH (Figure 1). Serum calcium concentrations were measured in 70 cases (93%). 
Hypocalcemia « 2.2 mmol/l) was detected in 62 patients (89%). Ionized calcium levels 
were only available in a limited number of patients and are therefore not shown. Of interest, 
serum calcium levels were lower in patients with seizures in comparison with those without 
seizures (1.69 ± 0.12 mmol/L vs. 1.92 ± 0.03 mmol/l; P = .03). The serum levels of CRP 
were significantly lower in non-survivors in comparison with survivors and correlated 
strongly with the time interval between the onset of symptoms and petechiae and the 
moment of blood sampling (r = .62, P < .001 and r = .54, P < .001, respectively). 
Coagulation studies were performed in most patients (Table 3). Fibrinogen levels were less 
than or equal to 1.5 giL in 17 of 67 (25%) patients. DIC could be determined in 60 patients. 
DIG occurred significantly more often in non-survivors than in survivors (12 [92%J of 13 vs. 
23 [49%J of 47; P = .005). 
3.5 Prognostic analysis 
Most variables listed in Tables 2 and 3 documented at the time of admission were 
associated with a poor prognosis. Factors that appeared to discriminate according to the 
univariate analysis were considered for inclusion in a prognostic scoring system. Logistic 
regression analysis identified four independent variables to predict the likelihood of 
survival. These were the serum level of GRP and potassium, the base-excess, and the 
platelet count. Two of these variables were significantly associated with the duration of 
petechiae (base excess: r = .32, P = .007; GRP: r = .54, P < .001). However, logistic 
regression analysis including the duration of petechiae did not improve the predictive value 
of the new prognostic scoring system, the Rotterdam score. The mathematical expression 
168 
• o 
100 -
" 
.L 80 
~ 
-a 60-
'5 
& 40 
.~ 
~ _ 20 
0. 
Chapter 4.3 
2.0 .I--~-~--~-~-~ 
6.8 7.0 7.2 7.4 7.6 7.8 
o +-~=~--.~--~---., 
-5.0 -2.5 0 2.5 5.0 
Arlerial pH Rollerdam scow 
Figure 1. Relation between initial serum concentrations Figure 2. Probability of death according to the 
of potassium and arterial pH in 75 children with Rotterdam score that predicts the outcome of 
meningococcal septic shock. Dashed and solid lines patients with meningococcal septic shock based 
indicate the regression Hnes through the values for on four laboratory variables (C-reactive protein, 
survivors (0) and non-survivors (e) respectively. Slopes serum potassium, base excess, and platelet 
between the regression lines of survivors and non- count). 
survivors did not significantly deviate from parallelism. 
of the probability of PICU death in this study was as follows: 
Probability (PIGU death) = eX / (1+eX) 
in which the Rotterdam score (RS) = 1.01 + 1,21 x Potassium (mmol/l) - 0.29 x Base 
Excess (mmol/l) - 0.024 x Platelets (10'/l) - 3.75 x log (CRP [mg/l]). Figure 2 gives the 
graphical presentation of the model. This new prognostic score was compared with five 
other scoring systems. Each scoring system was applied to our patients. Our score had the 
highest predictive value for death and survival (Table 4). The newly developed Rotterdam 
prognostic score was highly correlated with the PRISM-score (r = .58, P < .001). 
4 DISCUSSION 
The clinical picture of septic shock and purpura is induced by meningococci (occasionally 
other bacteria) and by their products (lipopolysaccharides) and mediated by a multitude of 
inflammatory mediators. The inflammatory response may develop into irreversible 
circulatory collapse, renal failure, adult respiratory distress syndrome and death. 
In the present study we show that meningococcal septic shock is associated with a 
mortality rate of 21 % and serious sequella in 17% of the survivors. A higher mortality was 
observed in patients directly admitted to the Sophia Children'S Hospital in comparison with 
secondary referrals. This was probably due to patient selection, since extremely ill patients 
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Table 4. Outcome prediction in patients with meningococcal septic shock based on different prognostic 
scoring systems. 
Score Number of Predictive value for Accuracy 
patients survival death 
Niklasson (250) 53 88% 25% 45% 
Leclerc (205) 63 93% 61% 84% 
CRP (206) 66 91% 39% 66% 
Giraud (131) 67 90% 47% 78% 
PRISM (274) 75 88% 72% 85% 
Rotterdam 65 90% 71% 86% 
The Rotterdam score predicts the outcome of patients with meningococcal septic shock based on four 
laboratory features (C-reactive protein, serum potassium, base excess, and platelet count). 
died before referral could be organized. The clinical condition of secondary referred 
patients was relatively better as can be inferred from the lower PRISM-score. In contrast, 
Tesoro et al. observed that patients transferred from another hospital had a higher mortality 
(328). In our study, the mortality rate was also higher among children below 4 years of age 
in comparison with older children. The lower plasma levels of the naturally occurring 
circulating anticoagulants protein C and S in children younger than 4 years of age may 
contribute to the worse outcome in this group (279). Long-term morbidity was observed in 
17% of the survivors and was caused by deforming amputation or large areas of soft tissue 
destruction secondary to the coagulopathy and by neurological sequelae. A similar 
percentage was observed by Madden et al. (222, 245). 
Meningococcal disease in the Netherlands has gradually increased from 1.1 cases per 
100,000 in 1982 to 4.3 cases per 100,000 in 1993. Strain B:4:P1.4 was most frequently 
isolated in our patients. This strain was not found before 1980 but became the most 
prevalent strain in 1990 (21% of all isolates) (304). 
Striking differences were observed in clinical and laboratory characteristics between 
survivors and non-survivors. The shorter interval between the appearance of petechiae 
and admission and the lower level of CRP in non-survivors suggest a shorter disease 
course. These data indicate that non-survivors deteriorate more quickly because they 
accumulate more native LPS per time span, trigger all mediator systems more intensively 
or because they have a higher responsiveness to LPS or proinflammatory cytokines (195). 
Complex abnormalities were observed in electrolytes and acid-base status. Metabolic 
acidosis and increased arterial serum lactate levels are the inevitable consequence of poor 
end-organ perfusion leading to anaerobic glycolysis. The serum sodium level was usually 
normal. Interestingly, we found hypokalemia rather than hyperkalemia in patients with 
septic shock. Hypokalemia was more severe in survivors than in non-survivors even when 
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adjusted for the degree of acidosis which would normally be expected to result in a shift of 
potassium from the intracellular space. Hypokalemia may be caused by the release of 
catecholamines leading to an increased intracellular shift of potassium into skeletal muscle 
(188). The relatively higher serum potassium levels in non-survivors may be caused by 
metabolic derangements (188), the more severe renal impairment, or rhabdomyolysis. In 
addition, hypocalcaemia was also seen in a large number of patients as observed by others 
(50, 225, 299). Interestingly, patients that had seizures during their initial disease course 
had lower serum calcium levels than the other children. Hypotension, acidosis and 
electrolyte abnormalities may playa major role in the deterioration of myocardial function 
and may predispose to arrhythmias and cardiac arrest. 
Scoring systems for disease severity or a prognostic score have been useful in the 
assessment of care requirement, efficacy of therapy and prognosis. Previously, several 
scoring systems were developed for patients with acute meningococcal infections or septic 
shock and purpura. Most of these systems include the presence or absence of meningeal 
irritability or an elevated CSF WBC count (93,120,185,214,250,316). The assessment 
of neck stiffness, however, is unreliable in severely ill patients. Tesoro et al. concluded that 
absence of meningeal involvement is not an important predictor of mortality (328). A CSF 
WBC count is not always available since a lumbar puncture is usually not performed due 
to the unstable clinical condition on presentation. Other scoring systems require variables 
such as the erythrocyte sedimentation rate, and skin/rectal temperature difference 
determination that are not always available (316, 331). We therefore developed a simple 
score for patients with meningococcal septic shock which only requires objective variables 
available at any emergency room or PICU soon after admission. Logistic regression 
analysis revealed four laboratory features including low potassium levels, a negative base 
excess, a low platelet count and a low CRP level which were all significantly associated with 
fatal outcome. Base excess and potassium levels both reflect the degree of metabolic 
abnormalities. Low platelet counts are highly predictive for the presence of DIC. CRP level 
reflect the duration of illness since this level correlates positively with the duration of 
petechiae and other symptoms of patients with septic shock and purpura (195). The 
mortality risk predictor developed by us only needs simple laboratory features which are 
routinely performed. The prognostic value was higher than in previously developed scoring 
systems. However, since we validated this new score for patients with meningococcal 
septic shock on the same group of patients used to develop this score, a slight overestimate 
of the utility of the score in predicting mortality may have occurred. 
This score will enable accurate mortality risk prediction for individuals or provide a relative 
scale for severity of illness. This score can also be used to evaluate the effects of future 
therapeutic interventions and to assess the evolution of disease in the first 24 hours. 
Beneficial effects of HA-1A on the outcome of children in the present study with 
meningococcal septic shock were not shown. This observation is in accordance with a 
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recent study that did not find a reduction in the 14-day mortality rate in patients with gram-
negative bacteremia and septic shock (236). 
We conclude that meningococcal septic shock in children is associated with a mortality of 
21% (95% C112% - 32%). The mortality was even higher in children below 4 years of age. 
About 17% olthe survivors had serious sequelae such as skin necrosis requiring skingrafts 
or amputation, osteomyelitis, neurologic sequelae. Logistic regression analysis identified 
four laboratory features which were used in a prognostic score to predict outcome. The 
predictive value for death and survival were 71 % and 90% respectively. The overall 
outcome was predicted correctly in 86% of the cases. 
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1. THE PROBLEM OF SEPSIS IN CHILDREN 
The physiological changes that constitute the process of sepsis are induced by microbial 
agents during bloodstream infection or by Ihe toxic products of pathogens that are released 
from sites of focal infection. This process involves changes generated by the immune 
system in which hormones, cytokines and enzymes are involved. Many host and microbial 
factors may unfavorably influence this complex immune-response. There are several 
differences between the host response of young children and adults with (meningococcal) 
sepsis. One of the major factors responsible for these differences is the immaturity of the 
immune system in young infants. Issues related to this topic are reviewed in Chapter 1.2. 
The severity of meningococcal disease ranges from sepsis to sepsis syndrome and finally 
septic shock. Septic shock with purpura is a rapidly evolving clinical picture characterized 
by sepsis (tachycardia, tachypnea, fever), shock (hypotension or signs of end-organ 
failure) and a spectrum of coagulation disorders (ranging from petechiae, purpura to 
ecchymoses). It is mainly (80 %) caused by N. meningi/idis (group A, B or C). The disease 
is also called meningococcal sepsis or severe meningococcal disease (SMD). In The 
Netherlands the incidence of SMD is 3.5 per 100.000 inhabitants. Approximately 60 
persons die yearly due to SMD. Two-third of these are below the age of 15 years. The 
growing interest in infections caused by meningococci has resulted in a large number of 
research projects in this field during the last decade. The application of molecular and 
immunological methods in animal experimental and human studies of meningococcal 
sepsis has contributed to our understanding of the disease. Recent progress in the 
understanding of the pathophysiology of meningococcal sepsis in children is discussed in 
Chapter 1.3 
2. ENDOTOXIN AND INFLAMMATORY MEDIATORS 
2.1 endotoxin clearance 
Characteristic features of meningococcal sepsis are the specific nature of the endotoxin 
and the very high concentrations in plasma during the acute phase. It is not yet fully 
understood how endotoxin is cleared from the circulation. Certain specific and non-specific 
endotoxin binding proteins are involved in the clearance as discussed in Chapter 1.3. 
Lipopolysaccharide binding protein (LBP) is a specific endotoxin binding protein and acts 
as an acute phase protein. LBP forms a complex with lipopolysaccharides (LPS). 
Subsequently this complex is attached to the CD14-receptor of cells of the immune system 
such as monocytes. These cells are then activated and start to synthesize mediators such 
as TNF-o: and IL-1f1. Binding ofLPS to LBP leads to an amplification of the biological effect 
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of LPS. 
In addition, during meningococcal sepsis neulrophils are destroyed and their content 
degranulates. One of Ihe released proteins is bactericidal permeability increasing protein 
(BPI). BPI is also capable to bind LPS. However, binding to BPI leads in contrast to binding 
with LBP to neutralization of the biological effects of LPS. A recombinant form of BPI has 
been lested in a phase I trial in patients with meningococcal sepsis and recently a phase 
III trial in children was started. The natural course of these plasma proteins in children with 
septic shock still needs to be elucidated. 
We studied experimental meningococcal sepsis in young (3 weeks) and old (4 months) 
pigs and the possible age-related differences in endotoxin levels and cytokine profiles after 
a standardized challenge of low and high dose of crude meningococcal endotoxin. This 
study is described in Chapter 2.1. We assessed endotoxin levels, as well as the balance 
between pro- and counter-inflammatory cytokines (TNF-a. IL-6, and IL-10 levels) in the 4 
hours following an one-hour infusion of endotoxin. The clinical picture and the mortality 
were similar in all groups. In young animals the median of the maximal endotoxin levels was 
4.4 times higher than in the older animals, whereas endotoxin was cleared at a lower rate 
compared to the older pigs. Despite higher levels of endotoxin in young pigs, the levels of 
TNF-a, IL-6, and IL-10 were similar or even slightly higher in the older animals. Age related 
differences therefore seem to playa role in the endotoxin binding and clearance. 
HDL and lipoproteins are non-specific endogenous LPS-binding proteins. Binding of LPS 
to these proteins leads to neutralization, at least in the presence of a normal liver function. 
In adults with sepsis it has been shown that levels of these proteins are much lower than 
in control subjects. In children with meningococcal sepsis the course of these plasma 
lipoprotein levels has not been studied, but probably shows a comparable picture: a relative 
deficiency of these proteins. Therefore lipoproteins and HDL have a potential therapeutical 
value. As a consequence a phase II study using reconstituted HDL in children with 
meningococcal sepsis has been initiated. 
2.2 cytokines 
Once activated, monocytes, macrophages and endothelial cells start to produce cytokines, 
which playa crucial role in the immune response as discussed in Chapters 1.2 and 1.3. In 
a limited number of patients (n=17) with sepsis or septic shock with purpura, we analyzed 
the levels of these cytokines (TNF-a, IL-1-1> and IL-6) and correlated these values with 
routine laboratory values. This study is described in Chapter 2.2. All cytokine levels were 
significantly increased, but only IL-6 levels had a good predictive value for severity of 
disease. 11-6 has previously been shown to be a reliable indicator for severity of disease and 
outcome in other pediatric and adult patients with sepsis. From the laboratory parameters 
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(fibrinogen, CRP, and lactate), only arterial laclate was posilively correlated to outcome 
and severity of disease. 
In a subsequent sludy, described in Chapter 3.3, we eslimated the levels of TNF-a, IL-6, 
IL-B, IL-10, and Ihe soluble TNF receptors p55 and p75 in 30 palients with septic shock and 
purpura. All cytokine levels were higher in non-survivors. However, when these levels 
were corrected for the lime between the moment the petechiae were first noticed and the 
moment of blood sampling, these differences disappeared. Another interesting finding was 
that both levels of pro-inflammatory (TNF-a, IL-6, IL-B) as well as counter-inflammatory 
cytokines (lL-10 and s-TNF-R) were significantly increased in non-survivors. It is not yet 
clear whether Ihis represents a situalion of excess-produclion of pro-inflammatory 
cytokines, or an insufficient produclion of counler-inflammatory cytokines. Perhaps 
sequenlial analysis of Ihe immune status during the disease e.g. using whole blood culture 
systems looking at cytokine profiles and leucocyte aclivalion markers after a standardized 
slimulus, can provide an answer to this queslion. 
In the same group of 4B palients, we measured plasma levels of IL-12 and IFN-y. 
Interleukin 12 (lL-12), a recently described cytokine composed of two different polypeptide 
subunits (p40 and p35), which plays a role in the host defense against microbial infections 
and has been shown to induce the produclion of interferon (IFN)-y. Levels of IFN-y are 
increased in experimental as well as clinical sepsis. We hypothesized that IL-12 and IFN-
y playa role in the pathogenesis of seplic shock and purpura (Chapter 2.3). The median 
plasma IL-12 p40 level on admission was related to outcome, severity of disease and the 
levels of other cytokines even when corrected for time of petechiae, while IL-12 p70 
(complete cytokine) levels were only increased in 9 palients (19%). Patients with 
detectable IL-12 p70 levels had higher IL-12 p40 levels than those without detectable IL-
12 p70 levels. Twelve (29 %) of the patients had detectable levels of IFN-y. No relation with 
outcome could be detected. In those 12 palients, other cytokine levels, among which IL-
12 p70, although not significantly, were increased. However, this was not true for the IL-
12 p40 levels. In our patients a posilive correlalion was found between IL-10 and IL-12, 
which was in contrast to findings in sepsis in baboons where a negalive correia lion was 
found. In vitro, IL-10 is a slrong inhibitor of LPS-dependent IL-12 produclion. We propose 
that the synthesis of pro- and counter-inflammatory cytokines is so strong and conlinuously 
stimulated in palients wilh meningococcal sepsis, that counter-regulatory mechanisms are 
insufficient to suppress excessive production. 
3. COAGULATION DISORDERS 
3.1 link between coagulation and inflammation 
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Inflammation and coagulation can not be considered as two separate processes, since 
there are several links making them part of the host response during not only infectious, but 
also traumatic, hypoxic and hypovolemic incidents. The endothelium represents the 
interface between inflammation and coagulation: it is a surface where coagulation is 
activated, but under cytokine stimulation it provides a site of attachment for inflammatory 
effector cells. During inflammation coagulation is initiated through activation of factor XII 
and tissue factor mainly by TNF-o:, IL-1-B, and IL-6. Activation of factor XII leads to the 
production of bradykinin, kallikrein, factor Xla and plasmin, all forming part of the contact 
system. These factors are related to the complement system through one regulating 
protein: C1-esterase inhibitor. The formation of thrombin following the activation of the 
coagulation cascades is an essential issue in the development of hemostasis. Thrombin 
stimulates fibrin formation and leads to platelet aggregation and degranulation by which a 
number of vasoactive mediators are released. In addition, thrombin affects a series of 
endothelial functions and stimulates cells involved in inflammation. Thrombomodulin (TM) 
is a high affinity endothelial receptor for thrombin. The thrombin-TM complex activates 
protein C. However, TNF-o: downregulates the expression of thrombomodulin in this way 
interacting with protein C. Activated protein C complexes with a co-factor protein S. Protein 
S is bound in plasma to C4 binding protein (C4bp), which is a complement system 
regulating protein. This is another indication of the interaclion between coagulation and 
complement system. Therefore, in the study of the host defense during a severe infection, 
the involvement of the coagulation pathway has to be taken into account. 
3.2 protein C 
Protein C inactivates factors Va and Villa, and, at the same time stimulating the fibrinolytic 
pathway, by inactivating plasminogen activator inhibitor (PAI-1), an acute phase protein 
from which the production is promoted by cytokines such as TNF-o:. 
Since the initial report in 1991 of decreased levels of protein C levels in meningococcal 
disease, we became interested in the protein C system in our patients. In a study with the 
University Hospital of Lille, France, we analyzed protein C and S levels in 40 children with 
septic shock with purpura (Chapter 3.1). Protein C levels (both antigen and activity) were 
strongly decreased and the decrease was related to the presence of DIC and outcome. For 
this reason protein C supplementation should be evaluated in children with severe septic 
shock and purpura. 
3.3 relation with age 
Many studies have reported coagulation parameters in patients with meningococcal 
sepsis. Most of these studies encompassed small numbers of patients, with a 
179 
Chapter 5 
heterogenous population (mild and severe cases), different age groups (children and 
adults), or analyzed a limited number of parameters. We prospectively measured in a large 
number (79) of children with septic shock and purpura several parameters of coagulation 
and fibrinolysis on admission and after 24 and 72 hours (Chapter 3.2). The results were 
consistent with a heavily activated coagulation system, inhibition of natural anticoagulants 
such as antithrombin and protein C, depletion of coagulation factors, and a strong inhibition 
of the fibrinolytic system mainly by the presence in plasma of very high concentrations of 
PAl-i. After classifying the patient group with respect to the median age (3.1 years), it 
became clear that the severity of coagulation disorders (presence of DIC, depletion of 
coagulation factors and inhibitors) was more intense in the younger age group. However, 
the differences between the two age groups with respect to cytokines were not significant. 
Therefore, one may hypothesize that these age related differences in coagulation 
parameters are partly responsible for the difference in mortality between younger and older 
patients. 
3.4 relation PAl, cytokines and protein C 
Since PAI-1levels were clearly increased and PAI-1 behaves as an acute phase protein, 
we became interested in the relation between PAI-1 and cytokines such as TNF-a 
(Chapter 3.3). There was a significant correlation between PAI-1 and TNF-a. To our 
surprise we found that this relation was different for survivors and non-survivors. With the 
same level ofTNF-a the PAI-1levels were 1.9 higher in the non-survivors. The same was 
true for other cytokines. This indicates that the individual PAI-1 production is directly related 
to outcome. In this study PAI-1 antigen was measured and not PAI-1 activity. New studies 
should direct attention to measure PAI-1 activity, since this may not be similar to PAI-1 
antigen level. One of the possible explanations for the extreme low protein C levels in our 
patients, reported in Chapter 3.1 and 3.2, is the fact that activated protein C forms a 
complex with PAI-1 and in this way is consumed. Since protein C is important in the 
regulation of coagulation and fibrinolysis, it is worthwhile assessing the therapeutic value 
of restoring these extreme low levels of protein C to normal, or even supra normal values. 
In 1997 a phase II dose finding study has started with reconstituted protein C. Aim of this 
trial, which is coordinated by the Department of Pediatrics of the Sophia Children's 
Hospital, is to establish an appropriate dosing regimen and to study the course of these 
PAI-1/protein C complexes as well as activated protein C and soluble protein C receptors. 
3.5 PAl polymorphism 
The significantly increased levels of PAI-1 in non-survivors from SMD raised the question, 
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whether a polymorphic immune response was involved in the outcome of these patients. 
When studying the literature we indeed found a description of a common functional 
polymorphism in the PAI-1 gene. A single base pair insertion (5G) I deletion (4G) 
polymorphism 675 base pairs upstream from the start of transcription is functionally 
important in the regulation of the expression of the PAI-1 gene. Subjects homozygous for 
the 4G allele have higher basal and inducible levels of PAI-1 than those with 1 or 2 copies 
of the 5G allele. A reduced fibrinolytic capacity due to increased plasma levels of PAI-1 may 
have pathogenetic importance in myocardial infarction, particularly in young patients with 
hypertriglyceridemia or with diabetes. We postulated that children possessing the high 
responding 4G14G genotype would produce higher levels of PAI-1, develop more severe 
coagulopathy, and be at greater risk of death during meningococcal sepsis (Chapter 3.4). 
The relationship between oulcome, PAI-1 levels and genotype were investigated in a 
Rotterdam cohort of 37 children with sepsis and a london cohort of 138 children with sepsis 
or meningitis. PAI-1levels were measured by ELISA and the 4G/5G PAI-1 polymorphism 
detected by peR and hybridization. Plasma levels on admission correlated with 
presentation (sepsis or meningitis) and outcome. The median PAI-11evel in fatal cases was 
6.6 fold higher than in survivors. Patients possessing the 4G/4G genotype had significantly 
higher PAI-1 levels than those with the 4G/5G or 5G/5G genotype and had a 2 fold 
increased risk of death for the 2 cohorts combined. This re-emphasizes the important role 
of fibrinolysis in the pathophysiology of meningococcal sepsis. 
It is becoming more and more obvious that the role of genetic factors determining 
susceptibility and severity of disease are of crucial importance. In cardiovascular disease 
genetically determined polymorph isms in the genes for factor V, factor VII, 
homocysteinemia, and PAI-1 play an equally important role as conventional risk factors like 
smoking and hypertension. The genetic constitution probably plays an equally important 
role in the pathogenesis of infectious disease as environmental and microbial factors. At 
least 2 clinically relevant polymorph isms have been reported in meningococcal sepsis: 
TNF-a polymorphism (an association between a polymorphic variation in the TNF-a gene 
promotor region, leading to a higher TNF-a production, and death) and PAI-1 
polymorphism. These two are strongly related to outcome, but are probably not the only 
determinants for outcome. A better understanding of the influence of genetic factors will 
enable us to explain why in one individual a bacteremia leads only to a non-fatal meningitis 
and in another to a possibly fatal sepsis, and to explain the variability in severity of disease 
between individuals. 
3.6 other therapeutic options 
Since the inhibition of flbrinolysis is a hallmark of meningococcal disease, it would be 
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logical from a therapeutical point of view to consider administration of endogenous 
plasminogen activators like tissue type plasminogen activator (t-PA). Recently, a number 
of case reports on this issue have been published. However, the development of cerebral 
bleeding is a considerable risk in patients in whom t-PA is administered. The dose of this 
drug needs to be titrated individually since the ratio of PAI-1/t-PA is high on admission, but 
in many cases already normalized at 24 hours. Another recently developed drug is an 
endogenous regulator of the coagulation called tissue factor pathway inhibitor, which is a 
regulator of the extrinsic pathway. Not much is known about the natural course of this 
protein during meningococcal sepsis. Therefore serum levels of this protein should be 
studied in patients before therapeutic use may be considered. 
Prostacyclin has been used in individual patients to inhibit platelet aggregation and 
produce peripheral vasodilatation. However, it has not been tested in prospective 
randomized clinical trials, nor has the importance of the platelet (adherence, aggregation, 
platelet activating factor, serotonin etc) been evaluated in this disease. 
4. EXPERIMENTAL AND CLINICAL ASPECTS OF CIRCULATORY FAILURE 
4.1 capillary leakage 
The enormous capillary leakage early in meningococcal disease is an important 
pathophysiological and clinical finding in patients with meningococcal sepsis. This feature, 
caused by increased vascular permeability and necessitating high amounts of volume 
resuscitation, is related to the extent of activation of the complement system. To assess the 
relation between capillary leakage and inflammatory mediators, blood samples were taken 
on admission, and 24 and 72 hours after admission in 52 children with meningococcal 
sepsis. Parameters related to cytokine production, neutrophil degranulation, complement 
activation and complement regulation were determined. The degree of capillary leakage 
was derived from the amount of plasma infused (Chapter 4.1). Levels of IL-6, IL-8, C3b/c, 
C3-CRP complexes and C4bp on admission adjusted for the duration of skin lesions, were 
significantly different between survivors and non-survivors. A substantial part of the 
complement activation was through the classical route, probably by CRP. Mortality was 
independently related to levels of C3b/c and C3-CRP complexes. In agreement herewith, 
levels of complement activation products correlated well with the PRISM score or capillary 
leakage. Therefore, excessive complement activation is associated with a poor outcome 
and a more severe disease state. Further studies should reveal whether complement 
activation may be a target for therapeutical intervention, e.g. with C1-inhibitor. 
Since the capillary leakage is such an important clinical feature, it would be of great value 
to possess a tool useful in the clinical situation to assess vascular permeability. Indirect 
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quantification is obtained from the amount of plasma infused, total body water 
measurements like bioimpedance, or the measurement of extravascular lungwater. Efforts 
should be directed into either improvement of these techniques or development of new 
ones like micro-dialysis or infrared spectroscopy. 
4.2 circulatory failure 
Not all hemodynamic disturbances can be easily studied in humans. Because of our 
observation that major differences exist in the outcome of young « 3 years) and older 
patients, we decided to develop an experimental model for meningococcal sepsis in young 
(8 kg) and older (40 kg) pigs. We studied (Chapter4.2) the possible age related differences 
in global hemodynamic and regional blood flow responses to different dosages (1 and 10 
~g/kg body weight) of crude meningococcal endotoxin in younger and older piglets. 
Animals were chronically instrumented and studied in the awake state after a period (5-7 
d) of adaptation. The response to plasma infusion (30 mllkg in 30 minutes) was evaluated 
after infusion of placebo and endotoxin. The clinical picture was similar in all groups and the 
mortality was 018 in young, low dose group; 3/8 in young, high dose; 1/8 in old, low dose; 
and 4/9 in old, high dose. Major findings were that cardiac index (CI) decreased in the 
young animals after endotoxin infusion, while it was well preserved in the older animals. 
This difference was probably related to a different vascular response: in the older animals 
the systemic vascular resistance (SVRI) decreased 20%, while in the younger ones there 
was no change in resistance. Conductance to the kidneys, intestines and spleen 
decreased significantly more in the younger animals, while the increase in conductance 
and flow to the liver was higher in the older animals. Subsequent volume loading resulted 
only partly in a recovery of the hemodynamic parameters, but failed to improve oxygen 
delivery. Our study shows that this "pediatric" experimental meningococcal sepsis model 
in piglets, a model consisting of a chronically instrumented piglet of 8 kg, can be used to 
study the pathophysiology and the effects of vaccines and anti-inflammatory agents 
against meningococcal sepsis. Administration of a crude meningococcal endotoxin 
preparation was potent in a low dosage and could be used to analyze the effects of 
endotoxin. However, it is possible, that many of the circulatory changes may be contributed 
to the rapid increase in pulmonary vascular resistance (PVRI), which is less extreme in 
humans. This is likely to be caused by the fact that the endotoxin is infused in one hour and 
reaches levels, which in the human situation are only approached after several hours. 
Moreover, this study had an observation period of about 6 hours, which means that the 
prolonged or delayed effects of host response to endotoxin like coagulation disturbances, 
could have been overlooked. This problem might be overcome by gradually infusing the 
endotoxin over time starting at a very low dose and extending the observation period to 24 
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h. A new study with this design is under preparation. 
Clinical assessment of the hemodynamic situation of the patient is usually done using 
clinical parameters as well as simple to measure hemodynamic variables like heart rate, 
arterial and central venous blood pressure. Our hemodynamic study in pigs showed that 
the central venous pressure is of limited value. It is not routine clinical practice in pediatric 
patients to insert pulmonary artery catheters and use parameters like cardiac output and 
vascular resistance, despite the use of various inotropic drugs in high dosages. To be more 
adequately informed about the hemodynamic condition of the patient and to tune the 
medication, we should either encourage the use of a pulmonary artery catheter, or improve 
less invasive techniques like echo doppler cardiography, or thermo-dilution with a 
thermistor at the arterial site instead of the pulmonary site. 
4.3 prognostic score 
It is often difficult on arrival to assess the clinical condition immediately of a child with 
meningococcal sepsis. We evaluated a group of 75 patients for their clinical and laboratory 
parameters and analyzed these parameters statistically to produce a mortality prediction 
score consisting of simple laboratory parameters, this study is described in Chapter 4.3. 
Logistic regression analysis identified four laboratory parameters, which were 
independently associated with mortality: serum potassium, CRP, platelet number and base 
deficit. Predictive value for death and survival was 71 % and 90 %, respectively. The 
outcome was predicted correctly in 86 % of the patients, which is higher than rates 
previously predicted for scoring systems. Our score was developed on the basis of a 
retrospective analysis and is currently validated in a prospective way together with the 
group of St Mary's Hospital in London. 
5. ENDOCRINOLOGICAL ASPECTS 
From a therapeutical point of view it still is not clear whether a patient with a meningococcal 
sepsis is optimally stressed or is nearly exhausted. Especially with respect to the adrenal 
function and the post-mortem findings of adrenal bleeding (described by Waterhouse and 
Friederichsen). The few studies evaluating the adrenal function showed conflicting results. 
More efforts should be directed to provide a better understanding of the adrenal function of 
the individual patient. When the patient has survived the first 48 hours, the mortality 
depends not any longer on the original severity of the disease, but more on the supportive 
treatment or possible complications. In this respect it is important, that adequate attention 
is given to the provision of optimal nutritional support. 
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6. LONG TERM OUTCOME 
There are only limited data on the long-term follow up of pediatric patients after meningitis 
or sepsis. Especially in meningococcal sepsis it is generally assumed that when a patient 
survives the acute phase, there is good chance for complete recovery, besides the necrotic 
sequella. However, this has never been evaluated in an adequate number of patients. 
Studies aiming at the psycho-social and medical long term outcome of children after a 
meningococcal sepsis should therefore, be seriously considered. 
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1. Het probleem sepsis op de kinderleeftijd 
De fysiologische veranderingen welke plaatsvinden tijdens het doormaken van een sepsis 
worden ge"induceerd door micro-organismen op het moment dat deze zich in de bloedbaan 
bevinden, of door de toxische producten van deze pathogen en die vrijkomen vanuit 
plaatsen met een focale infectie. Dit sepsis proces omvat veranderingen ingezet door het 
immuunsysteem, waarbij diverse hormonen, cytokines en enzymen betrokken zijn. Vele 
gast- en microbiele factoren kunnen deze complexe afweerreactie ongunstig be·invloeden. 
Er zijn diverse verschillen tussen de gastheerrespons van een jong kind en die van een 
volwassene met een (meningococcen) sepsis). Een van de belangrijke factoren 
verantwoordelijk voor deze verschillen is de onrijpheid van het afweersysteem bij jonge 
kinderen. Een aantal van deze leeflijdsspecifieke factoren wordt besproken in Hoofdstuk 
1.2. 
De ernst van meningococcenziekte kan varieren van een meningitis met bacteriemie, via 
sepsis, sepsis syndroom tot een septische shock. Een fulminante meningococcensepsis, 
of zoals het formeel genoemd wordt een septische shock met purpura, is een zich zeer snel 
ontwikkelend klinisch beeld gekarakteriseerd door een sepsis (tachycardie, tachypneu, 
koorts), shock (hypotensie, of aanwijzingen van orgaan falen) en een spectrum van 
stollingsstoornissen (petechiae, purpura en ecchymosen). 
Het wordt vooral (> 80%) veroorzaakt door de N. Meningitidis (groep A, B of C). In 
Nederland is de incidentie van ernstige meningococcenziekte (SMD) ca 3.5 per 100.000 
inwoners. Ongeveer 60 personen overlijden jaarlijks aan een SMD, waarvan zeker !:weel 
derde kinderen onder de 15 jaar zijn. De toenemende interesse in meningococcen-
infecties he eft gedurende het laatste decennium geresulteerd in een groot aantal 
onderzoeksprojecten op dit gebied . De toepassing van moleculaire en immunologische 
method en bij dier-experimentele en humane studies van meningococcensepsis he eft 
geleid tot een beter beg rip van deze ziekte. Recente vorderingen op het gebied van de 
pathofysiologie van meningococcensepsis bij kinderen worden besproken in Hoofdstuk 
1.3. 
2. Endotoxine en onlslekings-medialoren 
2.1 Endoloxine klaring 
Karakteristieke kenmerken van meningococcen sepsis zijn de bijzondere aard van het 
endotoxine en de zeer hoge concentraties ervan in plasma gedurende de acute fase van 
de ziekte. Het is nog niet volledig begrepen hoe endotoxine verwijderd wordt uit de 
circulatie. Bepaalde specifieke en niet-specifieke endotoxine bindende eiwitten zijn 
betrokken bij deze klaring, zoals besproken in Hoofdsluk 1.3. Lipopolysaccharide binding 
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protein (LBP) is een specifiek endotoxine bindend eiwit, welke zich gedraagt als een acuut 
fase eiwit. LBP vormt een complex met lipopolysaccharide (LPS). Vervolgens wordt dit 
complex gebonden aan de CD14-receptor van imuuncellen zoals monocyten. Deze cellen 
worden dan geactiveerd en gaan mediatoren synthetiseren waaronder TNFa en IL-1B. 
Binding van LPS aan LBP leidt op die manier tot een versterking van het biologische effect 
van LPS. 
Tevens worden gedurende sepsis neutrofiele granulocyten afgebroken, waarvan de 
inhoud vervolgens vrijkomt. Een van de uit de granulae vrijkomende eiwitten is het 
bactericidal permeability increasing protein (BPI). BPI is ook in staat om LPS te binden, 
maar in tegenstelling tot LBP leidt binding met BPI tot neutralisatie van de biologische 
effecten van LPS. Een recombinante vorm van dit BPI is onderzocht in een fase 1 studie 
bij kinderen met een meningococcen sepsis en recent is een fase 3 studie gestart. Het 
natuurlijke beloop van deze plasma eiwitten bij kinderen met sepsis is nog niet goed 
vastgelegd. 
Wij bestudeerden in een experimentele meningococcen sepsis bij jonge (3 weken) en oude 
(4 maanden) biggen de mogelijke leeftijds gerelateerde verschillen in endotoxine 
concentraties alsmede de cytokine profielen na een gestandaardiseerde test met een lage 
en hoge dose ring van ruw meningococcen endotoxine. Deze stu die is beschreven in 
Hoofdstuk 2.1. Wij onderzochten de endotoxine concentraties, alsmede de balans tussen 
de pro- en anti-inflammatoire cytokines (TNFa, IL-6 en IL-10 concentraties) in de 4 uren 
volgend op een 1 uurs infusie van endotoxine. Het klinisch beeld en de mortaliteit waren 
overeenkomstig in aile groepen. Bij de jongere dieren was de mediaan van de maxima Ie 
endotoxine concentratie 4.4 x hoger dan die van de oudere dieren, terwijl de endotoxine 
langzamer geklaard werd dan bij de oudere biggen. Ondanks hogere endotoxine 
concentraties in serum bij de jonge biggen, waren ervergelijkbare of zelfs enigszins hogere 
concentraties van TNFa , IL-6 en IL-10 in serum bij de oudere biggen. Leeftijds 
gerelateerde verschillen spelen klaarblijkelijk een rol in de endotoxine binding en klaring. 
High density lipoproteines (HDL) en andere lipoproteines zijn niet-specifieke endogene 
LPS-bindende eiwitten. Binding van LPS aan deze eiwitten leidt tot neutralisatie, aithans bij 
een normale leverfunctie. Bij volwassenen met sepsis is aangetoond dat de plasma 
concentraties van deze eiwitten in de acute fase veellager zijn dan bij controle personen. 
Bij kinderen met meningococcen sepsis is het verloop van deze plasma lipoproteine 
concentraties nog niet bestudeerd, maar zal mogelijk een vergelijkbaar beeld vertonen als 
bij volwassenen: een relatief tekort in de acute fase. Daarom hebben lipoproteines en HDL 
een therapeutische betekenis. Als gevolg daarvan is errecenteen fase 2studie gestart met 
een humaan geconcentreerd HDL preparaat bij kinderen met een meningococcen sepsis. 
2.2 Cytokines 
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Eenmaal geactiveerd, zullen monocyten, macrofagen en endotheelcellen cytokines gaan 
produceren, die een zeer belangrijke rol spelen in de immuunrespons zoals reeds 
besproken in Hoofdsluk 1.2 en 1.3. In een beperkt aantal patienten (n=17) met sepsis of 
septische shock met purpura, analyseerden wij de plasma oncentraties van deze cytokines 
(TN Fa ,IL-1B en IL-6) en correleerden deze waarden met de resultaten van routinematig 
bepaalde laboratorium parameters. Deze studie is beschreven in Hoofdsluk 2.2. Aile 
cytokine concentraties waren duidelijk verhoogd, maar aileen de IL-6 concentraties 
hadden een goede predictieve waarde voor de ernst van de ziekte. IL-6 was eerder al 
aangetoond een betrouwbare indicator voor de ernst van de ziekte en mortaliteit te zijn bij 
pediatrische en volwassen patienten met sepsis. Van de laboratorium parameters 
(fibrinogeen, C-reactive protein en lactaat) was aileen het arteriele lactaat positief 
gecorreleerd aan mortaliteit en ernst van de ziekte. 
In een vervolg studie, beschreven in Hoofdsluk 3.3, bepaalden wij de concentraties van 
TN Fa , IL-6, IL-8, IL-10 en de oplosbare TNF receptoren p55 en p75 in 38 patienten met 
septische shock en purpura. Aile cytokine concentraties waren hoger in de niet-overlevers. 
Echter wanneer de concentraties gecorrigeerd werden voer de tijd tussen het moment 
waarop de petechiae voor het eerst ondekt werden en de tijd van bloedafname, waren de 
verschillen verdwenen. Een andere interessante bevinding was dat zowel de concentraties 
van de pro-inflammatoire (TNFa , IL-6, IL-8) als die van de anti-inflammatoire cytokines 
(lL-10 en s-TNF-R) significant verhoogd waren in de niet-overlevers. Het is niet geheel 
duidelijk of er hier nu sprake is van een overproductie van pro-inflammatoire cytokines, dan 
wei van een te lage productie van anti-inflammatoire cy1okines. Mogelijk dat 
opeenvolgende analyses van de immuun staus gedurende de ziekte, b. v door volbloed 
kweek systemen, waarbij gekeken wordt naar cy10kine profielen en leukocyten activatie 
markers na een standaard stimulus, een antwoord op deze vraag kunnen verschaffen. 
In een groep van 48 patiiinten, werden plasma concentraties van IL-12 en interferony 
(IFNy) bepaald. IL-12, een recentelijk voor het eerst beschreven cytokine bestaande uit 2 
verschillende polypeptide subunits (p40 en p35), speelt een rol in de gastheeerrespons 
tegen microbiele infecties en waarvan is aangetoond dat het de produktie van IFNy 
induceert. Plasma concentraties van IFNy zijn verhoogd in zowel experimentele als 
klinische sepsis. Wij veronderstelden dat IL-12 en IFNy een rol zouden spelen in de 
pathogenese van septische shock en purpura (Hoofdsluk 2.3). De mediane plasma IL-12 
concentratie bij opname was gerelateerd aan mortaliteit, ernst van de ziekte en de 
concentraties van andere cytokines, zelfs wanneer deze gecorrigeerd waren voor de duur 
van de petechiae, terwijl de IL-12 p70 (het complete cytokine) con centra ties slechts 
verhoogd waren in 9 patienten (19%). Daarentegen hadden patienten met aantoonbare IL-
12 p70 concentraties hogere IL-12 p40 plasma waardes dan die zonder aantoonbare IL-12 
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p70 concentraties. Twaalf patienten (29%) hadden aantoonbare concentraties IFNy , 
zonder dat er een relatie met mortaliteit kon worden vastgesteld. Bij deze 12 patiiinten 
waren de andere cytokine concentraties, waaronder IL-12 p70, ook verhoogd. Echter dit 
was niet het geval voor IL-12 p40. Bij onze patienten kon een positieve correlatie 
aangetoond worden tussen IL-10 en IL-12. Dit was in tegenstelling met de bevindingen bij 
de sepsis in bavianen, waar een negatieve correlatie gevonden werd. In vitro is IL-10 een 
sterke inhibitor van de LPS-afhankelijke IL-12 productie. Wij veronderstellen dat de 
synthese van pro- en anti-inflammatoire cytokines zo sterk en continu gestimuleerd is in 
patienten met een meningococcensepsis, dat de anti-inflammatoire mechanismen tekort 
schieten om deze overproductie te compenseren. 
3 Stollingsstoornissen 
3.1 Verband tussen stolling en ontsteklng 
Ontsteking en stolling kunnen niet als 2 aparte processen gezien worden daar er 
verschillende schakels zijn die hen gezamenlijk onderdeel maken van de gastheerrespons 
niet aileen tijdens een ernstige infectie, en ook na trauma, hypoxie en hypovolemie. Het 
endotheel kan beschouwd worden als een contactplaats tussen ontsteking en stolling: het 
is een oppervlak waar stolling geactiveerd wordt, maar na cytokine stimulatie ontstaat er 
een hechtingsplaats voor ontstekingscellen. Gedurende ontsteking wordt de stolling 
geinitieerd via activering van factor XII en weefselfactor door TNFo: , IL-1B en IL-6. 
Activering van factor XII leidt tot de productie van bradykinine, kallikreine, factor Xla en 
plasmine, welke allen onderdeel zijn van het contactsysteem. Deze factoren zijn 
gerelateerd aan het complementsysteem door een gemeenschappelijk regeleiwit: C1-
esterase inhibitor. De vorming van trombine als gevolg van de active ring van 
stollingscascades is een essentieel onderdeel van de hemostase. Trombine stimuleert de 
vorming van fibrine en leidt tot plaatjes-aggregatie en degranulatie waardoor een aantal 
vasoactieve mediatoren vrijkomen. Bovendien be'invloedt trombine een aantal 
endotheelfuncties en stimuleert cellen betrokken bij de ontstekingsreactie. Trombomoduline 
is een endotheelreceptor voor trombine. Het trombine-trombomoduline complex activeert 
proteine C, een belangrijke inhibitor van de stollingscascade. Echter, TNFo: downreguleert 
de expressie van trombomoduline en beInvloedt op die manier proteIne C. Geactiveerd 
proteIne C complexeert met een co-factor prote"ine S. ProteIne S is in plasma gebonden 
aan C4 binding proteIne (C4bp), wat een regulatie eiwit is van het complement systeem. 
Dit is weer een voorbeeld van de interacties die er bestaan tussen stolling en het 
complement systeem. Daarom is het noodzakelijk dat in de stu die van de gastheerrespons 
gedurende een ernstige infectie, het stollingssysteem mede betrokken word!. 
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3.2 Prote'ine C 
Prote'ine C inactiveert de factoren Va en Villa. en stimuleert op hetzelfde moment de 
fibrinolyse. door plasminogeen activator inhibitor 1 (PAI-1) te inactiveren. PAI-1 is een 
acuut fase eiwit waarvan de productie gestimuleerd wordt door cytokines zoals TNFa . 
Sedert de eerste vermelding in de literatuur in 1991 van de sterk verlaagde plasma 
concentraties van prote'ine C. zijn wij ge'interesseerd geraakt in deze materie. In een studie 
gezamenlijk met het Universiteitsziekenhuis van Lille in Frankrijk. analyseerden wij de 
protei'ne C en S concenlraties van 40 kinderen met septische shock en purpura 
(Hoofdstuk 3.1). Prole'ine C niveau's (zowel antigeen als activileil) waren sterk 
verminderd en het niveau was gerelaleerd aan de aanwezigheid van diffuse inlravasale 
slolling (DIC) en mortalilei!. Om die reden werd als conclusie gelrokken dal prole'ine C 
suppletie overwogen zou moeten worden bij kinderen met seplische shock en purpura. 
3.3 Relatie met leeftijd 
Er zijn meerdere studies geweesl die slollingsparameters gerapporteerd hebben van 
palienlen mel een meningococcensepsis. De meeste van deze studies omvalten kleine 
aanlallen patienten. met een heterogene populatie (milde en ernstige gevallen). 
verschillende leeftijdsgroepen. of analyseerden een beperkt aanlal parameters. Wij 
onderzochten prospectief bij een groot aantal (79) kinderen met septische shock en 
purpura diverse parameters van stolling en fibrinolyse. bij opname. en na 24 uur en 72 uur. 
(Hoofdstuk 3.2). De resultaten vertoonden een beeld overeenkomend met een sterk 
geactiveerd stollingssysteem. een inhibitie van natuurlijke anticoagulanten (prote'ine C. 
antilrombine). een tekort aan stollingsfactoren. en sterke inhibitie van het fibrinolytisch 
systeem vooral door de aanwezigheid in serum van zeer hoge concentraties PAI-1. Na 
stratificalie van de patienten naar de mediane leeftijd (3.1 jaar). werd het duidelijk dat de 
ernst van de stollingsafwijkingen (aanwezigheid van DIC. tekort van stollingsfactoren en 
inhibitors) ernstiger was in de jonge leeftijdsgroep. Echter. de verschillen tussen de 2 
leeftijdsgroepen met belrekking tot cytokines waren niet significan!. Daarom 
veronderstelden wij dat deze leeftijd gerelateerde verschillen in coagulopathie ten dele 
verantwoordelijk zijn voor het verschil in mortaliteit tussen jongere en oudere patienten. 
3.4 Relatie PAl, cytokines en prote'ine C 
Omdat de PAI-1 concentraties zo duidelijk verhoogd waren en PAI-1 zich gedraagt als een 
acuut fase eiwil, raakten wij ge'interesseerd in de relatie tussen PAI-1 en cytokines als 
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TNFa (Hoofds!uk 3.3). Erbleek een significante relatie te bestaan tussen PAI-1 en TNFa. 
Tot onze verassing constateerden wij dat deze relatie verschillend was voor de overlevers 
en de niet-overlevers. Bij een zellde concentratie aan TNFa was de concentratie van PAI-
1,1.9x hoger in de niet-overlevers. Het zellde was het geval voor de relatie met de andere 
cytokines. Dit betekent dat de individuele PAI-1 productie direct gerelateerd is aan 
mortaliteit. Bij deze studie is het PAI-1 antigeen bepaald en niet de activiteit. Bij nieuwe 
studies moet aandacht gericht worden op het be palen van de activiteit daar dit niet perse 
hetzellde hoeft te zijn. Een van de mogelijke verklaringen van de extreem verlaagde 
concentraties proteIne C gerapporteerd in Hoofds!uk 3.1 en 3.2, is het feit dat geactiveerd 
prote'ine C een complex vormt met PAI-1 en op die manier verbruikt wordt. Aangezien 
prote'ine C belangrijk is in de regulatie van stolling en fibrinolyse, is het van be lang de 
therapeutische waarde te analyseren van het herstel van deze extreem lage concentraties 
tot normale of zelfs supra-normale waarden. In maart 1997 is er een fase 2 dosis 
evaluerende studie gestart met geconcentreerd proteIne C. Doel van deze studie, die 
gecoordineerd wordt door de afdeling Kindergeneeskunde van het Sophia 
Kinderziekenhuis, is een zinvolle dosering te vinden en het verloop te bestuderen van PAI-
1/prote'ine C complexen, het geactiveerde proteIne C en de recent ontdekte oplosbare 
prote'ine C receptoren. 
3.5 PAI-1 polymorfisme 
De significant verhoogde concentraties PAI-1 m.n in de niet-overlevers, brachten de vraag 
op of er mogelijk een polymorfe immuunrespons betrokken zou kunnen zijn bij de 
mortaliteit van deze patienten. Bij het bestuderen van de literatuur, vonden wij inderdaad 
een beschrijving van een functioneel polymorfisme in het PAI-1 gen. Een enkele base paar 
insertie (5G) I deletie (4G) polymorfisme 675 base paar stroomopwaarts van de start van 
de transcriptie is functioneel van betekenis in de regulatie van de expressie van het PAI-
1 gen. Personen homozygoot voor het 4G allel hebben een hogere bas ale en te induceren 
PAI-1 concentratie dan personen met 1 of 2 kopieen van het 5 G alIBI. Een verminderde 
fibrinolytische capaciteit door een verhoogde plasma concentratie van PAI-1 kan van 
pathogenetisch be lang zijn bij myocard infarct, m.n bij jonge patienten met 
hypertriglyceridemie of met diabetes. Wij veronderstelden dat kinderen met het hoog 
responderende 4G/4G genotype meer PAI-1 zouden produceren, een ernstiger 
coagulopathie zouden ontwikkelen, en een groter risico op een slechte afloop zouden 
hebben bij het doormaken van een meningococcensepsis (Hoofdstuk 3.4). De relatie 
tussen mortaliteit, PAI-1 concentraties en genotype werd onderzocht in een cohort van 37 
Rotterdamse kinderen met sepsis en een cohort van 138 Londense kinderen met sepsis 
of meningitis. PAI-1 concentraties werden bepaald met een ELISA methode en het 4G/5G 
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PAI-1 polymorfisme met een polymerase ketting reactie (peR) en hybridisatie. Plasma 
concentraties bij opname correleerden met het klinisch beeld (sepsis of meningitis) en 
mortalitei!. De mediane PAI-1 concentratie in de fatale gevallen was 6.6x hoger dan bij de 
overlevers. Patienten die in het bezit waren van het 4G/4G genotype had den significant 
hogere PAI-1 concentraties dan die met het 4G/5G of 5G/5G genotype en hadden een 2x 
zo grote kans om te overlijden. Dit benadrukt opnieuw het be lang van fibrinolyse in de 
pathofysiologie van meningococcensepsis. 
Het wordt meer en meer duidelijk dat genetische factoren een belangrijke rol spelen in het 
bepalen van de gevoeligheid voor en ernst van ziekten. In hart- en vaatziekten spelen 
genetisch bepaalde polymorfismen in b.v. het gen voor factor V, factor VII, 
homocysteinemie en PAI-1 een even belangrijke rol als klassieke risico factoren als roken 
en hypertensie. Voor de pathogenese van een infectieziekte is de genetische constitutie 
zeker zo belangrijk als de omgeving- of microbiele factoren. Zeker 2 relevante 
polymorfismen zijn nu gerapporteerd in meningococcensepsis: TN Fa polymorfisme (een 
associatie tussen een polymorfe variant in het TN Fa promotor gen, welke tot een hog ere 
TNFa productie en hogere mortaliteit aanleiding geeft) en het PAI-1 polymorfisme. Deze 
2 zijn sterk gerelateerd aan mortaliteit, maar zijn waarschijnlijk niet de enige bepalende 
factoren. Een beter beg rip van de invloed van genetische factoren zal het ons mogelijk 
maken te verklaren waarom bij het ene individu een bacteriemie aanleiding geeft tot een 
niet fatale meningitis en in een ander geval er een mogelijk fatale sepsis ontstaat, en 
waarom er zo'n variatie in ernst van de ziekte bestaat tussen de verschillende individuen. 
3.6 Andere therapeutische opties 
Daar de remming van de fibrinolyse zo'n belangrijk kenmerk is van de meningococcen-
sepsis, zou het vanuit therapeutisch perspectief logisch zijn toediening van endogene 
plasminogeen activaloren zoals weefsel type plasminogeen activator (t-PA) te overwegen. 
Recentelijk zijn er een aantal case reporten m.b.!. deze therapie gepubliceerd. Echter, de 
mogelijkheid van hersenbloedingen vorml een belangrijk risico bij patienten aan wie l-PA 
wordt loegediend. De dosering van dit medicijn moet individueel getitreerd worden daar de 
verhouding PAI-1/t-PA hoog is bij opname, maar in vele gevallen genormaliseerd is na 24 
uur. Een ander recent ontwikkeld medicijn is ook een endogene regulator van de 
stollingscascade, nl de weefsel factor pathway inhibitor. Niet veel is er bekend over dit eiwit 
tijdens meningococcensepsis. Daarom dienen de plasma concentraties bij palienten eerst 
onderzocht te worden alvorens hel therapeutisch gebruik overwogen kan worden. 
Prostacycline wordt gebruikt in individuele paliiinten om de plaatjes aggregatie te 
verminderen en perifere vasodilatatie te produceren. Echter, prostacycline is nog niet in 
prospectieve gerandomiseerde klinische trials onderzochl, noch is hel belang van de 
194 
Chapter 5 
bloedplaatjes Op zich (adherentie, aggregatie, platelet activating factor, serotonine) 
geevalueerd bij deze ziekte. 
4 Experimentele en klinische aspecten van circulatoir falen 
4.1 Capillair lek 
Het enorme capillair lek vroeg in de ziekte is een belangrijk pathofysiologisch en klinische 
bevinding bij patienten met een meningococcensepsis. Dit verschijnsel veroorzaakt door 
een verhoogde permeabiliteit van de vaatwand en welke grote hoeveelheden volume 
resuscitatie noodzaakt, is gerelateerd aan activatie van het complement systeem. Om de 
relatie tussen capillair lek en ontstekings-mediatoren te analyseren, werd bloed 
afgenomen bij opname, en 24 en 72 uur na opname bij 52 kinderen met meningococcen 
sepsis. Parameters gerelateerd aan cytokine productie, granulocyten degranulatie, 
complement activatie en complement regulatie werden bepaald. De mate van capillair lek 
werd bepaald aan de hand van de hoeveelheid ge'infundeerd plasma (Hoofdstuk 4.1). 
Plasma concentraties van IL-6, IL-8, C3b/c, C3-CRP complexen en C4bp bij opname 
gecorrigeerd voor de duur van de huidlesies, waren significant verschillend tussen 
overlevers en niet-overlevers. Een belangrijk deel van de complement activatie was 
ontstaan door de klassieke route, vermoedelijk door CRP. De mortaliteit was onafhankelijk 
gerelateerd aan de concentraties van C3b/c en C3-CRP complexen. De concentraties van 
de complement activatie producten correleerden uitstekend met de PRISM score en met 
de capillaire lek. Dus excessieve complement activatie is geassocieerd met een hoge 
mortaliteit en een meer ernstige ziekte. Aanvullende stu die moet aantonen of complement 
activatie een doel moet zijn voor therapeutische benadering, b.v met C1-esterase inhibitor. 
Daar het capillaire lek zo'n belangrijk klinisch verschijnsel is, zou het van groot belang zijn 
in de klinische situatie te kunnen beschikken over een meetinstrument om de vaat 
permeabiliteit te kunnen kwantificeren. Indirecte kwantificering wordt verkregen vanuit de 
hoeveelheid ge'infundeerd plasma, totaal lichaamswater metingen, of de meting van 
extravasculair longwater. Richting zal er gegeven moeten worden aan het onderzoek om 
deze technieken te verbeteren, dan wei nieuwe te ontwikkelen zoals micro-dialyse dan wei 
infrarood spectroscopie. 
4.2 Circulatoir falen 
Niet aile hemodynamische verstoringen kunnen makkelijk bestudeerd worden bij de mens. 
Mede omdat wij observeerden dat de mortaliteit van jonge « 3 jaar) en oudere kinderen 
zoveel van elkaar verschilden, hebben wij daarom besloten een experimenteel 
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meningococcen sepsis model in jonge (3 weken) en oude (4 maanden) op te gaan zetten. 
In dit model bestudeerden wij (Hoofdstuk 4.2) de mogelijke leeftijd gerelateerde 
verschillen in totale hemodynamische en regionale bloed flow veranderingen na 
verschillende doseringen van ruw meningococcen endotoxine in jonge en oude biggen. De 
dieren waren chranisch ge'jnstrumenteerd en werden bestudeerd in wakkere toestand na 
een periode van ca 5-7 dagen adaptatie. De respons op plasma infusie (30 mllkg in 30 
minuten) werd geevalueerd zowel na een placebo als na de endotoxine infusie. Het klinisch 
beeld was overeenkomstig in aile graepen en de mortaliteit was 0/8 in de jonge, lage dosis 
groep; 3/8 in de jonge, hoge dose ring graep; 1/8 in de oude, lage dose ring graep; en 4/9 
in de oude, hoge dosering graep. De belangrijkste bevindingen waren dat de cardiac index 
(CI) verminderde in de jonge dieren na de endotoxine infusie, terwijl deze redelijk stabiel 
bleef in de oudere dieren. Dit verschil was waarschijnlijk gerelateerd aan een verschillende 
vasculaire res pons: in de oudere dieren daalde de systemische vaatweerstand (SVRI) met 
ca 20 %, terwijl in de jongere dieren er geen verandering in weerstand was. Conductantie 
naar de nieren, darmen en milt nam duidelijk meer at bij de jongere dieren terwijl de 
toename in conductantie en flow naar de lever duidelijk meer was bij de oudere dieren. De 
na de endotoxine volgende volume belasting resulteerde maar ten dele in een verbetering 
van de hemodynamische parameters, maar had geen toename van het O,-transport naar 
de weefsels ten gevolg. Onze studie toont aan dat dit "pediatrisch" experimenteel 
meningococcen sepsis model in biggen, een model bestaande uit een chranisch 
ge'instrumenteerde big van 8 kg, gebruikt kan worden om de pathofysiologie te bestuderen, 
alsmede de effecten van vaccins en anti-inflammatoire therapie te evalueren. Toediening 
van een ruw meningococcen endotoxine preparaat was potent in een lage dose ring en 
hiermee kan het effect van endotoxine bestudeerd worden. Echter, het is mogelijk dat veel 
van de circulatoire veranderingen toegerekend moeten worden aan de snelle stijging in 
pulmonale vaatweerstand (PVRI) die bij de mens minder extreem is. Mogelijk heel! dit te 
maken met het feit dat de endotoxine ge'jnfundeerd wordt in 1 uur en dan niveau's bereikt 
die bij de mens pas na uren bereikt zal worden. Tevens was er bij deze stu die sprake van 
een observatie periode van "slechts" 6 uur, wat betekent dat late effecten van respons op 
endotoxine zoals stollingsstoornissen gemist kunnen worden. Dit prableem kan verholpen 
worden door het endotoxine langzamer te infunderen, met een zeer lage start dosis en de 
observatie periode uit te breiden tot 24 uur. Een nieuwe studie met deze opzet is in 
voorbereiding. 
Klinische evaluatie van de hemodynamische conditie van de patient vindt meestal plaats 
gebruikmakend van klinische parameters en eenvoudig te meten hemodynamische 
variabelen zoals hartfrequentie, arteriele en centraal veneuze drukken. Onze 
hemodynamische studie in biggen toonde aan dat de centraal veneuze druk van beperkte 
waarde is. Het is geen klinische routine in pediatrische patienten pulmonaal katheters te 
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plaatsen en parameters als cardiac output en vaatweerstanden te gebruiken. Om 
adequater ge"informeerd te zijn omtrent de hemodynamische conditie van de patient en de 
medicatie beter af te stell en, moeten we of het gebruik van de pulmonaal katheter 
stimuleren, of minder invasieve technieken verbeteren als echo Doppler cardiografie, of 
thermodilutie met een thermistor op een arteriele locatie i.p.v. pulmonaal. 
4.3 Prognostische score 
Het is vaak moeilijk om onmiddellijk bij opname de klinische conditie en mogelijke uitkomst 
van een kind met een meningococcen sepsis in te schaUen. Met die achtergrand 
evalueerden wij van een graep van 75 patienten de klinische en laboratorium parameters 
en analyseerden wij deze parameters statistisch om een mortaliteitspredictie score te 
bepalen bestaande uit simpele laboratorium parameters, deze studie wordt beschreven in 
Hoofds!uk 4.3. Logistische regressie analyse identificeerde 4 laboratorium parameters, 
welke onafhankelijk geassocieerd bleken te zijn met mortaliteit: serum kalium, eRP, aantal 
plaatjes en base deficit. De predictieve waarde voor dood en overleving was 71 % en 90 
% respectievelijk. De uitkomst werd correct voorspeld in 86 % van de patienten, wat hoger 
is dan de uitkomsten van een aantal bestaande scoring systemen. Onze score werd 
bepaald op basis van een retraspectieve stu die en wordt op dit moment gevalideerd in een 
praspectieve, landelijke registratie studie en tevens met de onderzoeksgroep uit het St 
Mary Ziekenhuis in Londen. 
5 Endocrinologische aspec!en 
Mede vanuit een therapeutisch oogpunt is het nog niet geheel duidelijk of een patient met 
een meningococcen sepsis optimaal gestresst is of nagenoeg uitgeput is. Met name met 
betrekking tot de bijnierfunctie en de post-mortem bevindingen van bijnierbloedingen (voor 
het eerst beschreven door Waterhouse en Friederichsen). De enkele studies die de 
bijnierfunctie in de acute fase evalueren tonen confiicterende resultaten. Meer aandacht 
moet er besteed worden aan een beter beg rip van de bijnierfunctie van de individuele 
patient. Als de patient de eerste 48 uur overleeft heeft, hangt de mortaliteit niet meer af van 
de oorsprankelijke ernst van de ziekte, maar meer van de ondersteunende therapie of 
mogelijke complicaties. Wat dat betreft is het belangrijk dat er aandacht wordt besteed aan 
een adequate voeding. 
6 Lange !ermijn ui!koms! 
Er zijn slechts weinig gegevens omtrent de lange termijn uitkomsten van pediatrische 
patienten na een meningitis of sepsis. Met name bij de meningococcen sepsis wordt in het 
197 
Chapter 5 
algemeen aangenomen dat als een patient de acute lase overleeft, er een goede kans is 
op volledig herstel, behoudens eventuele huidlesies. Echter, dit is nooi! geevalueerd in een 
adequaat aantal patienten. Studies gericht op de psycho-socia Ie en medische lange 
termijn uilkomst van kinderen na een meningococcen sepsis moeten daarom serieus 
overwogen worden. 
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